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„Das Große kommt nicht allein durch Impuls zustande,  
sondern ist eine Aneinanderkettung kleiner Dinge,  
die zu einem Ganzen vereint worden sind.“ 
Vincent van Gogh (1853-1890) 
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1 General introduction 
1.1 The building plan and function of the retina 
The mammalian retina represents one of the most complex tissues of the human 
body. This piece of tissue, embedded in the eyecup, equips us with the most 
important sense: vision. The complexity of the retina is represented by its unique 
cellular structure bearing more than 55 different cell types which are each highly 
specialized (Masland 2001).  
 
Figure 1 Gross anatomy of the eyeball and detailed cross-section of the human retina. (A) 
The retina is lining the posterior segment of the eyeball. (B) Stained cross-section through the human 
retina with schematic cell types for better illustration. Orange: Müller cells; grey: Ganglion cells; blue: 
bipolar cells; light green: rods; green: cones; brown: retinal pigment epithelial cells; RPE, retinal 
pigment epithelium; PhR, photoreceptor layer; ONL, outer nuclear layer; OPL, outer plexiform layer; 
INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer. The white scale bar 
represents 100 μm. (Eyeball modified from Campbell et al. 2010); cross section modified from 
http://www.oculist.net/downaton502/prof/ebook/duanes/pages/v8/v8c013.html). 
In detail, the retina is a polarized tissue, organized in layers of different cell types, 
with a thickness ranging up to 200 μm (Klinke et al. 2003). Light has to pass through 
all retinal layers in order to reach the light-sensitive cells of the retina, the 
photoreceptors. The human retina contains approximately 110 million rod- and  
6 million cone-photoreceptors (Klinke et al. 2003), ensuring adaptation to day- and 
night conditions. Cone-photoreceptors are specialized in day- and color vision and 
enriched in the macular, whereas rod photoreceptors enable us to see during weak 
light conditions, located predominantly in peripheral areas of the retina.  
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The photoreceptor layer (Fig. 1, PhR) is embedded in the retinal pigment epithelium 
(RPE) which phagocytoses old photoreceptor discs, recycles the light sensitive 
pigment rhodopsin and provides nutrients for photoreceptors. The nuclei of 
photoreceptors are tightly stacked in the outer nuclear layer (ONL) and connected to 
the outer segments (OS) by the connecting cilium, which transports proteins from the 
golgi apparatus towards the OS layer. Absorption of photons by rhodopsin induces 
the isomerization of 11-cis-retinal to all-trans-retinal and triggers the 
phototransduction cascade, involving hyperpolarization of the photoreceptor 
membrane. Nuclei of bipolar and horizontal cells constitute the inner nuclear layer 
(INL), their synapses are connected to photoreceptors in the outer plexiform layer 
(OPL). The photoreceptor signal is forwarded to ganglion cells in the ganglion cell 
layer (GCL) via synapses in the inner plexiform layer (IPL). Amacrine cells in the INL 
modulate signal transduction between bipolar cells and ganglion cells, whose 
bundled axons are forming the optic nerve, the retina’s connection to the brain 
(Klinke et al. 2003). Müller glia cells span the entire retina, exerting supportive 
functions for retinal neurons and signal procession (Bringmann et al. 2006). 
1.2 Inherited diseases of the retina and apoptosis 
Hereditary eye diseases are a major cause for blindness worldwide. The polarized 
nature of the retina and the composition of highly specialized cell types represent 
high susceptibility to genetic defects. To date, the Retnet (Retinal Information 
Network) database counts 249 genes related to retinal disease. The most prevalent 
monogenic disorder is Retinitis Pigmentosa (RP) with more than 50 different genes 
described (https://sph.uth.tmc.edu/RetNet/disease.htm). Besides RP, Age-related 
Macular Degeneration (AMD) represents a major cause of vision loss in the 
industrialized world. Unlike monogenic disorders, AMD is classified as a complex 
genetic disease. Multiple environmental factors and various genetic variants increase 
the risk for AMD development and contribute to the pathogenesis of retinal 
degeneration (Jager et al. 2008; Yuhong Chen 2010; Swaroop et al. 2007).  
Due to poor availability of human retinal tissue, numerous animal models of retinal 
dystrophies have been generated to gain insight into the pathology of degenerative 
diseases. Although a multitude of diverse factors initiate retinal dystrophies, cell 
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death represents the common sink in disease progression (Stone et al. 1999). 
Several studies, investigating the pathology of inherited retinal degeneration in rodent 
models, observe photoreceptor death. The most prominent apoptotic events occur in 
the nuclear layers of the retina, independent of the underlying genetic defect  
(W. Fan et al. 2010; Essner 1979; Sano et al. 2006; Tso et al. 1994; Chang & Hao 
1993). Likewise, Retinoschisin-deficient (Rs1h-/Y) mice develop massive photo-
receptor degeneration very early in postnatal development, accompanied by splitting 
(schisis) of retinal layers (Weber 2002). In human dystrophic postmortem retinas 
obtained from AMD patients, profound cell death in regions of atrophy indicates a 
similar role of apoptosis for AMD pathology as seen in the rodent degeneration 
models (Dunaief et al. 2002). 
On the molecular level, apoptosis is a strict series of cellular signaling events, leading 
to autonomous cell death. Entry into apoptosis is triggered by receptor-induced 
(extrinsic) or intracellular (intrinsic) signaling pathways. In the extrinsic route, 
transmembrane death-receptors like tumor necrosis factor receptor 1 (TNFR1) or 
CD95 (alias FAS) are activated by their specific ligands (Ashkenazi & Dixit 1998), 
resulting in the formation of a death-induced signaling complex (DISC), which 
includes caspases 8 and 10 (Ashkenazi & Dixit 1998; Chaigne-Delalande et al. 
2008). Intrinsic apoptosis is initiated in mitochondria by cellular stressors like DNA 
damage, ultraviolet light or deprivation of trophic factors (Lo et al. 2011; Brenner & 
Mak 2009). Subsequent release of cytochrome c initiates the formation of the 
apoptosome, involving initiator caspase 9 (Brenner & Mak 2009). Both pathways 
activate effector caspases 3, 6 and 7 as downstrean targets (Lavrik 2010). Molecular 
and histological studies of dystrophic retinas suggest that both types of apoptosis are 
involved in photoreceptor death (Mohlin et al. 2011; Lohr et al. 2006; Rohrer et al. 
2004; Gehrig et al. 2007; Ebert et al. 2009). 
1.3 Microglia biology 
As unique hematopoetic cell types, macrophages constitute distinct resident 
populations in diverse tissues, to which they can adapt phenotypically and 
morphologically (Gordon & Taylor 2005). The phenotypic heterogeneity reflects the 
importance of macrophages in the maintenance of diverse tissues, a task that is 
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performed by microglia in the central nervous system (CNS). Based on observations 
in the brain, Rio-Hortega was the first to hypothesize, that microglia are mobile, 
macrophage-like cells, being an active part in all inflammatory and necrotic nerve 
tissues (Rio-Hortega 1939). Hickey and Kimura could confirm Rio-Hortega’s 
hypothesis and showed that microglia are bone-marrow (BM) derived, immune 
competent cells (Hickey & Kimura 1988). Nowadays we know that microglia perform 
essential tasks in the healthy and  diseased CNS that can be both detrimental and 
beneficial (Hanisch & Kettenmann 2007).  
1.3.1 The origin of microglia 
Primitive yolk sac macrophages establish the CNS population of microglia during 
embryonic development prior to blood brain barrier (BBB) formation (Ginhoux et al. 
2010). Although the developmental origin of brain and retinal microglia have been 
clarified, it is still an open question, how renewal of the adult microglia population is 
performed. The BBB and respectively the blood retinal barrier (BRB) isolates the 
CNS and the retina from the periphery. It acts as a selective filter for the influx of 
molecules like energy substrates (Liebner et al. 2011), simultaneously restricting the 
intrusion of neurotoxic molecules and blood-derived leukocytes, which could harm 
the fragile neuronal tissue (Streit 2002). It is questioned whether under homeostatic 
conditions, blood-derived microglial precursors can cross the BBB/BRB in order to 
renew the population or if the population is maintained by in situ proliferation. Several 
studies performed in BM-chimeric mice, report donor-derived hematopoetic precursor 
invasion into the retina and CNS (H. Xu et al. 2007; Kezic & McMenamin 2008; 
Soulet & Rivest 2008; Mildner et al. 2007). In contradiction, engraftment of blood-
derived cells were not, or only to a minor extent, observed in parabiont animal 
studies (Ginhoux et al. 2010; Ajami et al. 2007), arguing that irradiation during BM-
chimera generation might impair BBB permeability and allow artificial blood-cell 
migration into the CNS (Mildner et al. 2007; Ginhoux et al. 2010). Notably, parabiont 
animals possess a co-joined blood circulation system, generating blood-chimeras 
without irradiation, which presents a closer physiological system (Ajami et al. 2007). 
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1.3.2 Physiological functions of retinal microglia 
Pioneering studies in the developing mouse retina have revealed the presence of 
microglia, distributed in an array of cells throughout distinct regions (Hume 1983). 
The concept of ‘resting’ microglia arose from static observations in neuronal tissue, 
describing immobile microglial cells with long, branched protrusions (Hume 1983; 
Perry et al. 1985; Perry & Gordon 1988). In fact, novel in vivo imaging techniques 
revealed that the long microglial processes are highly dynamic subcellular structures, 
which continually survey the integrity of the surrounding environment  
(Nimmerjahn et al. 2005). In the healthy retina, microglia are distributed throughout 
the plexiform layers, frequently found at the margin to adjacent nuclear layers  
(Ebert et al. 2009; Karlstetter et al. 2010b; Eter et al. 2008). Microglial surveillance in 
the healthy retina is crucial for the maintenance of tissue homeostasis by performing 
tasks like clearance of cellular debris and apoptotic neurons (e.g. dying 
photoreceptors), secretion of trophic factors and monitoring synapse function  
(Streit 2002; Hanisch & Kettenmann 2007; Takahashi 2005; Wake et al. 2009). 
Neurons produce suppressive ligands like CD200 or CX3CL1 to stimulate essential 
maintenance tasks in microglia, yet avoiding neurotoxic immune activation. 
Constitutive ligand-induced receptor signaling via the CD200/CD200R- and 
CX3CL1/CX3CR1-axis, provides suppressive signals for microglia, preventing 
harmful activation during tissue homeostasis (Broderick et al. 2002; Hoek 2000; 
Carter & Dick 2004; Cardona et al. 2006). Simulatenously CD200 and CX3CL1 
stimulate microglial migration and protrusion movements, to control the surveillance 
frequency and vigilance in healthy tissue (Carter & Dick 2004).  
1.3.3 Mechanisms of pro-inflammatory microglial activation 
The CNS has evolved a tightly controlled innate immune system, to protect fragile 
neuronal tissue from harmful adaptive immune reactions in response to damage and 
infection. Apart from the essential role in the healthy retina (see above), classical 
microglial activation is the result of any kind of subtle tissue damage  
(Hanisch & Kettenmann 2007). Perturbances in cell-cell communication with neurons 
and/or triggers from damaged cells, result in microglial activation. Initiation of 
microglial activation is associated with the release or presentation of soluble factors 
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from apoptotic cells, so called damage-associated molecular patterns (DAMPs). 
DAMPs are recognized by innate immune receptors on the microglial surface. In this 
respect, apoptotic neurons realease high-mobility group protein 1 (HMGB1) which 
raises a pro-inflammatory response in microglia (Gao et al. 2011) via toll-like receptor 
4 (TLR4) and toll-like receptor 9 (TLR-9) signaling (Park 2003). In parallel, the P2Y12 
receptor mediates microglial activation by binding ATP sequestered from impaired 
cells (Haynes et al. 2006; Davalos et al. 2005). Both signaling events cause 
downstream nuclear translocation of nuclear factor ‚kappa-light-chain-enhancer’ of 
activated B-cells (NFkB), triggering transcription of pro-inflammatory target gene 
clusters (Lotze & Tracey 2005; Brambilla et al. 2003).  
 
Figure 2 Morphological transition of microglia during the progression of retinal degene-
ration. Under homeostatic conditions (left), resting microglia build long and branched protrusions and 
carry out tissue surveillance and maintenance tasks. Perturbance of tissue homeostasis leads to 
alerted microglia (middle) with less branched protrusions and larger cell bodies. Ongoing apoptotic 
events during retinal degeneration directs to neurotoxic (‘classical’) activation of microglia (right), 
characterized by an amoeboid and bloated cell shape. The progression of retinal degeneration is 
shown as color gradient. Microglial cell shapes were excised from microphotographs of wholemount 
preparations from wt Mac Green mouse retinas (resting microglia) (Sasmono 2002) and Rs1h-/Y x Mac 
Green retinas (alerted and activated microglia). Pictures photographed by Stefanie Ebert. The white 
scale bar represents 50 µm. 
As a consequence of pro-inflammatory activation, ramified microglia morphologically 
transform into an amoeboid shape and migrate towards the lesion spot (Fig. 2 & 3). 
Activated microglia express increased levels of chemokine (C-C) motif ligand 2 
(CCL2), a modulator of microglial migration and proliferation (Hinojosa et al. 2011), 
building a chemoattractant gradient at the lesion spot to attract further cells and 
shield the adjacent tissue environment from neurotoxic substances (Ambrosini & 
Aloisi 2004). Activated microglia sequester effector cytokines like interleukin-6 (IL-6) 
and interleukin-1β (IL-1β) leading to paracrine activation of migrating microglia  
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(Krady et al. 2008; Ferreira et al. 2010). Clearance of damaged cells involves release 
of nitric oxide (NO) and reactive oxygen species (ROS) from microglia, followed by 
phagocytosis of cellular debris (Langmann 2007). During the resolution of 
inflammation, tissue homeostasis is reconstituted to prevent secondary damage of 
healthy surrounding tissue. As part of this, microglia exit the inflammatory program 
based on intrinsic feed-back regulators, that are induced during activation  
(J. Yang et al. 2005; Karlstetter et al. 2010a).  
1.3.4 Microglial activation in retinal degeneration 
Retinal degenerative diseases mostly affect broad areas of the retina and create a 
major imbalance of tissue homeostasis, perpetuating neuronal inflammation. 
Irrespective of the causative genetic defect and the subsequent pathomechanism, 
studies from retinal degeneration models report the early occurrence of amoeboid, 
activated microglia, predominantely in regions of photoreceptor loss, the ONL 
(Thanos 1991; Essner 1979; Zeiss 2004; Gehrig et al. 2007; Combadière et al. 2007; 
Ebert et al. 2009). In accordance with this, dystrophic retinas from human AMD and 
RP patients (Gupta et al. 2003; Penfold et al. 1985) reveal the appearance of 
activated microglia in the ONL, bearing engulfed fragments from apoptotic 
photoreceptors (Gupta et al. 2003). Laser-induced damage in mouse retinas shows 
an immediate microglial reaction, involving activation and migration to the lesion spot 
in vivo (Eter et al. 2008; J. E. Lee et al. 2008). Resting microglia in the proximity of 
the lesion site, start directed remodelling of their protrusions within minutes after 
laser-damage (J. E. Lee et al. 2008). One hour after damage, activated microglia 
accumulate at the damage site (Eter et al. 2008). Due to the rapid progression of 
degeneration, the Rs1h-/Y mouse model (Fig. 3) allows staging of microglial activation 
in respect to degenerative processes at high resolution. Migration of activated 
microglia into the INL of very young Rs1h-/Y retinas can be observed even before the 
occurence of signs of apoptosis (Ebert et al. 2009; Gehrig et al. 2007). In detail, time-
dependent assessment of the global Rs1h-/Y retinal transcriptome has identified 
immune-/microglia-related transcript expression from postnatal day 12 (P12) 
onwards, prior to the rise of cell-death related transcripts, suggesting early  
microglial activation as a key event preceding/triggering photoreceptor death  
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(Gehrig et al. 2007; Langmann 2007). A similar expression profile was observed in 
the Rd mouse model. Microglial activation markers were expressed from P8 onwards 
peaking at P14, whereas the climax of apoptosis was seen towards P16  
(Zeng et al. 2005). In addition to resident microglia, ongoing damage of the retina 
allows the recruitment of peripheral macrophages. In the retinal microenvironment, 
recruited macrophages transform phenotypically into microglia-like cells and actively 
contribute to the inflammatory processes (Kaneko et al. 2008). 
To sum up, early microglial activation represents a mutual phenotype in retinal 
dystrophies and a starting point for loss of retinal neurons and impairment of 
physiological properties.  
 
Figure 3 Location and morphology of microglia in the healthy and degenerating retina. 
Cross-sections of EGFP+  microglia (A) in the wt Mac Green murine retina (P18). Ramified microglia 
are localized in the plexiform layers in the healthy retina. During severe retinal degeneration, microglia 
migrate to the INL (B) in the Rs1h-/Y x Mac Green retina (P18) and are transformed into amoeboid, 
bloated microglial cells. Notably, the degenerated retinal layers are thinner compared to the healthy 
wt-retina. The white scale bar represents 50 µm. Pictures modified from (Karlstetter et al. 2010b).  
GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform 
layer; ONL, outer nuclear layer. 
1.3.5 Microglial phenotypes in retinal degeneration 
Microglia are facing a multitude of stimuli which appear during imbalance of tissue 
homeostasis. Depending on the extent and progression of degeneration, microglia 
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are exposed to various molecules of different quantity, quality at different time points 
of disease. Due to the plasticity of myeloid cells, microglia possess a tremen- 
dous heterogeneity, allowing them to respond accurately to the stimuli landscape  
(Lawson et al. 1990).  
Integration of macrophage biology can also serve as a guide for the classification of 
microglia activation phenotypes. Macrophage phenotypes are roughly  
classified into ‘classically’ (M1) and ‘alternatively’ (M2) activated macrophages 
(Ransohoff & Perry 2009). In response to profound TLR4 stimulation, microglia 
trigger a ‘classical’ activation program, associated with pro-inflammatory cytokine 
expression and NO-production (Michelucci et al. 2009), generating a toxic 
environment for photoreceptors (Dirscherl et al. 2010). In contrast, the cytokines 
interleukine-10 (IL-10) and interleukine-4 (IL-4) induce neuroprotective ‘alternative’ 
activation, characterized by the markers arginase 1 (ARG1) and triggering receptor 
expressed on myeloid cells-2 (TREM2) (Takahashi 2005). Alternatively activated 
microglia show an enhanced phagocytic capacity (Michelucci et al. 2009). A study 
investigating microglial activation in a spinal chord injury model reports the co-
existence of M1-like and M2-like microglia. Notably at the site of injury, M2-microglia 
are overrun by an extensive and persistent M1-population resulting in impaired tissue 
regeneration (Kigerl et al. 2009). The same study reports M2-like microglia to be 
beneficial for axonal regeneration, whereas M1 microglia have the opposite effect  
(Kigerl et al. 2009). Likewise, retina-invading M2-primed macrophages increase 
photoreceptor survival and slow down the course of retinal degeneration  
(Sasahara et al. 2008). Genome-wide expression profiling of the Rs1h-deficient 
mouse retina has also revealed co-expression of classical and alternative marker 
genes suggesting the same concept of co-existing microglia phenotypes in retinal 
degeneration (Gehrig et al. 2007).  
1.4 Strategies for modulation of microglial phenotypes 
Pro-inflammatory microglial activation is a common theme in the development of 
retinal dystrophies, yet distinct populations of activated microglia may exert 
neuroprotective features on retinal cells. This suggests that reprogramming of 
microglia could be a potential approach for broad therapeutic intervention in retinal 
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diseases. Several modulation strategies have been described involving endogenous 
mechanisms, natural compounds, dietary supplements or immune-modulating 
substances that are already in clinical use. 
1.4.1 Endogenous microglial factors 
Microglia and macrophages have evolved endogenous mechanisms to prevent 
excessive over-activation and to ensure reversion to the ‘resting’ state after clearance 
of insult. As one example, the small RNAs miRNA-124 and miRNA-147 have been 
described to act suppressively on microglia/macrophage activation in vitro and in vivo 
(Liu et al. 2009; Ponomarev et al. 2010). Furthermore, whey acidic domain proteins 
(WAPs) represent a family of secreted innate immune peptides bearing several 
unique immuno-modulatory features in one molecule (Bingle & Vyakarnam 2008). 
The best studied whey acidic protein, secretory leukocyte protease inhibitor (SLPI) is 
expressed in multiple tissues including activated microglia (Dirscherl et al. 2010; 
Mueller et al. 2008). SLPI has a tripartite function with anti-bacterial, anti-
inflammatory and protease-inhibitory potential (Bingle & Vyakarnam 2008). SLPI is 
secreted during microglial activation and exerts its anti-inflammatory function by 
inhibiting NFkB-binding to promoters of pro-inflammatory target genes (Taggart et al. 
2005; F. Y. Jin et al. 1997). Thus, over-expression of SLPI prevents pro-inflammatory 
activation of myeloid cells (Zhu et al. 1999).  
1.4.2 Natural compounds  
Herbal plants and their natural active compounds serve as traditional medicine since 
ancient times, especially due to their antioxidant and anti-inflammatory features  
(Choi et al. 2011). Most of the plant molecules belong to the chemical class of 
polyphenols and are characterized by good bioavailability, absorption and biosafety 
(Choi et al. 2011). General health benefits have been described for numerous 
compounds including Curcumin, Resveratrol and Luteolin. The latter belongs to the 
most abundant class of polyphenols, the flavonoids (Ross & Kasum 2002). Luteolin is 
enriched in spices and vegetables like parsley, celery or sage (Seelinger et al. 2008) 
and has high impact on microglial activation due to its anti-oxidant and radical 
scavenging features (Harris et al. 2006). Luteolin directly inhibits intracellular 
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signaling pathways mediated by the transcription factors NFkB and activator protein 1 
(AP-1) (C. Chen et al. 2007), preventing induction of pro-inflammatory IL-6 ex-
pression and sequestration of NO (J. Kim et al. 2006). Luteolin treatment attenuates 
microglial activation and induces a neuroprotective phenotype (Dirscherl et al. 2010; 
H.-Q. Chen et al. 2008).  
Curcumin is derived from the plant Curcuma longa, and has been extensively studied 
due to its pleiotropic anti-oxidant and anti-inflammatory features, known from 
traditional chinese medicine (Jagetia & Aggarwal 2007). Like Luteolin, Curcumin 
antagonizes inflammatory microglial activation involving downregulation of NO- and 
inflammagen-production coupled with increased phagocytic capacity (K. K. Jung et 
al. 2006; C.-Y. Jin et al. 2007a). Curcumin treated activated microglia are 
neuroprotective and can rescue neurons from apoptosis in vitro (S. Yang et al. 2008).  
Docosahexaenoic acid (DHA) is an essential long chain fatty acid and can be 
administered by consumption of fish or commercially available capsules. DHA 
supplementation has beneficial effects on infant neurodevelopment, general mental 
health and neuroinflammatory conditions (Davis-Bruno & Tassinari 2011; Cole et al. 
2010). DHA is highly abundant in the CNS and retina, and serves as a precursor of 
neuroprotectin D1, which is a trophic factor for photoreceptors (Mukherjee et al. 
2007). Treatment of activated microglia with DHA reduces IL-6 production and 
increases the M2-marker genes Il-10- and Arg1. DHA-induced M2 microglia are 
beneficial for survival and differentiation of neuronal progenitor cells (Antonietta 
Ajmone-Cat et al. 2011), and DHA supplementation can inhibit the progression of 
retinal degeneration in mice (Ebert et al. 2009).  
1.4.3 Approved pharmaceuticals and potential new candidates 
Clinically used immuno-suppressing drugs are promising tools for modulation of 
microglia, because biosafety, toxicity and side effects have been evaluated during 
their approval. Recombinant type I interferons are routinely used to treat Multiple 
Sclerosis (MS), a demyelinating autoimmune disorder involving microglial activation 
(Benveniste 1997).  Selective depletion of the complementary interferon-α/β receptor 
(IFNAR) on microglia in a mouse model for MS, reveals a profound worsening of 
disease progression. These findings suggest a major impact of type I interferon 
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signaling on modulation of the microglial phenotype. Notably, type I interferon (IFN-β) 
stimulation of microglia induces a unique phenotype, showing characteristics for both 
M1- and M2- microglial activation without inducing neuronal apoptosis in vitro  
(S. Jin et al. 2007b; Prinz et al. 2008).  
Ligands for mitochondrial translocator protein (18 kD) (TSPO) have been extensively 
studied and used for treatment of anxiety disorders (Rupprecht et al. 2009). 
Increased expression of TSPO has been reported in response to injury and during 
progression of various neurological diseases (Girard et al. 2012). In this context, 
TSPO was found to be predominantely expressed by activated microglia and 
selected TSPO ligands are capable of modulating microglial activation. TSPO ligand 
PK11195 was shown to modulate microglial action by inhibition of pro-inflammatory 
cyclooxygenase-2 (Cox2) expression (Hong et al. 2006). PK11195-treated mice with 
primed inflammation in the hippocampus, reveal a decreased number of microglia in 
the inflamed tissue and less apoptotic neurons, compared to controls  
(Veiga et al. 2007). Due to their pleiotropic effects, IFN-β and TSPO ligands are 
interesting candidates for the modulation of microglial activation. 
1.5 Aim of the thesis 
The aim of this work was to investigate the therapeutic potential of microglial 
modulators and their regulatory potential in respect to neurotoxic microglial activation. 
Microglial activation is a mutual event in all retinal dystrophies and is thought to 
promote the progression of degenerative processes. Thus, attenuation of pro-
inflammatory activation represents a promising approach to mitigate retinal 
degeneration. In one part of this work (Chapter 1), the functional characterization of 
the novel whey acidic protein AMWAP should provide insights into the transcriptional 
regulation of the AMWAP gene during retinal degeneration. Furthermore, it should be 
clarified whether AMWAP has modulatory potential on microglial activation with a 
special focus on anti-inflammatory, neuroprotective features. Another attempt of this 
thesis was to test the therapeutic potential of the plant-derived polyphenolic 
compounds Curcumin (Chapter 2) and Luteolin (Chapter 3). As part of a novel 
screening pipeline, genome-wide transcript profiling was performed, to obtain a 
comprehensive view on transcriptomic changes upon microglial modulation by 
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Luteolin and Curcumin. This approach was aimed to identify novel genes and 
pathways for subsequent functional analyses. 
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2 Results  
2.1 Chapter 1 – AMWAP (Karlstetter et al. 2010a) 
 
 
The novel Activated Microglia/Macrophage WAP Domain Protein, AMWAP, acts as a 
counter-regulator of pro-inflammatory response 
 
Marcus Karlstetter, Yana Walczak, Karin Weigelt,  Stefanie Ebert,  
Jan Van den Brulle, Heinz Schwer, Rudolf Fuchshofer, and Thomas Langmann 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Published in the Journal of Immunology. 2010 Sep 15;185(6):3379-90.  
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Abstract 
Microgliosis is a common phenomenon in neurodegenerative disorders including 
retinal dystrophies. To identify candidate genes involved in microglial activation, we 
used DNA-microarray analysis of retinal microglia from wild-type and retinoschisin-
deficient (Rs1h-/Y) mice, a prototypic model for inherited retinal degeneration. 
Thereby we cloned a novel 76 amino acid protein encoding a microglia/macrophage-
restricted whey acidic protein (WAP) termed activated microglia/macrophage WAP 
domain protein (AMWAP). The gene consists of three exons and is located on mouse 
chromosome 11 in proximity to a chemokine gene cluster. mRNA expression of 
AMWAP was detected in microglia from Rs1h-/Y retinas, brain microglia, and other 
tissue macrophages. AMWAP transcription was rapidly induced in BV-2 microglia 
upon stimulation with multiple TLR ligands and IFN-γ. The TLR-dependent 
expression of AMWAP was dependent on NFkB while its microglia/macrophage-
specific transcription was regulated by PU.1. Functional characterization showed that 
AMWAP over-expression reduced the pro-inflammatory cytokines Il-6 and Il-1β and 
concomitantly increased expression of the alternative activation markers arginase 1 
and Cd206. Conversely, siRNA knock-down of AMWAP lead to higher Il-6, Il-1β, and 
Ccl2 transcript levels while diminishing arginase 1 and Cd206 expression. Moreover, 
AMWAP expressing cells had less migratory capacity and showed increased 
adhesion in a trypsin-protection assay indicating anti-serine protease activity. In 
agreement with findings from other WAP proteins, micromolar concentrations of 
recombinant AMWAP exhibited significant growth inhibitory activity against E. coli,  
P. aeruginosa and B. subtilis. Taken together, we propose that AMWAP is a counter-
regulator of pro-inflammatory microglia/macrophage activation and a potential 
modulator of innate immunity in neurodegeneration. 
Introduction 
Microglial cells, the resident phagocyte population of the nervous system, exert 
several important functions in immune surveillance (Hanisch 2002; Hanisch & 
Kettenmann 2007) and neuronal homeostasis (Streit 2002; Streit 2005). In the 
healthy brain and the retina, ramified microglia serve as highly motile patrolling cells 
constantly surveying their microenvironment (Nimmerjahn et al. 2005). There is an 
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ongoing debate whether resident microglia in the CNS and the retina are replenished 
by in situ proliferation and/or recruitment of myeloid cells from the bloodstream 
(Soulet & Rivest 2008; Graeber & Streit 2009; Ransohoff & Perry 2009). 
Accumulating evidence now suggests that experimental confounds including 
alterations of the blood-retina barrier could have biased earlier results from bone-
marrow chimeras (Ransohoff 2007). Thus, parabiosis studies demonstrated that 
microglia in the healthy or experimentally damaged brain are poorly replenished from 
the bloodstream (Ajami et al. 2007). Moreover, Mildner et al. (Mildner et al. 2007) 
showed that irradiation is essential for infiltration of circulating microglial precursors 
into the brain in chimerism experiments. 
Microglia communicate with other glial cells and neurons which regulate their 
activation status, their capacity for phagocytosis of cellular debris, and secretion of 
neurotrophic factors (Dick 2003). Key regulatory signals from neurons and glia are 
transmitted to microglia cells through various soluble factors including nucleotides 
(Inoue et al. 2007), the chemokine fractalkine (Ransohoff et al. 2007), transforming 
growth factor beta (Paglinawan et al. 2003), and nerve growth factor  
(De Simone et al. 2007). Control of microglial activation and function is further 
regulated by direct neuron-microglia cross-talk including Cd200/Cd200 receptor 
ligation (Hoek 2000) and complex formation of triggering receptors expressed on 
myeloid cells with different ligands on neurons (Klesney-Tait et al. 2006).  
Activated microglia can elicit both protective and deleterious functions. In the early 
phase of neurodegeneration, microglia evoke potent tissue remodeling programs 
(Streit 2005) and initiate repair mechanisms such as glial scar formation  
(Muzio et al. 2007). However, excessive or prolonged microglial activation in the CNS 
and the retina can lead to chronic inflammation with severe pathological side effects 
often resulting in irreversible neuronal loss (Hanisch 2002; Langmann 2007; Schuetz 
& Thanos 2004). In eye research, various animal models have demonstrated that 
microglial activation is tightly associated with and mostly precedes retinal 
degeneration and photoreceptor apoptosis (Zeng et al. 2005; Zeiss 2004; Gehrig et 
al. 2007). Functional and phenotypic characterization of microglia populations in the 
diseased retina could be of high relevance to reveal signaling events that trigger their 
activation. However, like other tissue macrophages (Hume 2008), activated microglia 
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comprise a continuum of diverse functional phenotypes with a broad spectrum of 
activation markers (Schwartz et al. 2006). 
Our laboratory has employed large-scale transcriptional phenotyping to identify 
characteristic gene signatures of LPS and chondroitin sulphate proteoglycan-
disaccharide (CSPG-DS) stimulated BV-2 microglia as clearly polarized cell 
populations (Ebert et al. 2008). Moreover, we have profiled primary retinal microglia 
from wild-type and retinoschisin-deficient (Rs1h-/Y) mice (Weigelt et al. 2007), 
a prototypic model for rapid retinal apoptosis and degeneration (Weber 2002). In 
contrast to LPS and CSPG-DS treated microglia, expression profiles of retinal Rs1h-/Y 
microglia indicated overlapping transcript clusters reminiscent of both pro- and anti-
inflammatory macrophage activation (Weigelt et al. 2007; Ebert et al. 2009; 
Langmann et al. 2009). Finally, several transcripts previously not linked to microglial 
activation have been identified in these genome-wide expression studies, including 
high levels of the adaptor protein STAP-1 (Stoecker et al. 2009) and the 
uncharacterized whey acidic protein (WAP) motif bearing protein AMWAP. 
WAP domain proteins have originally been described as low molecular weight 
proteins with ‘defensin-like’ properties involved in immune homeostasis  
(Bingle & Vyakarnam 2008). Their counter-regulatory role on inflammatory mediators 
is mainly ascribed to the anti-protease and anti-microbial activities of the WAP 
domain (Hiemstra et al. 1996; Ranganathan et al. 1999; Williams et al. 2006). This 
40-50 amino acid motif contains eight conserved cysteins which form four defined 
disulfide bonds. Secretory leukocyte protease inhibitor (SLPI) and elafin are the best 
studied WAP proteins in humans and mice (Moreau et al. 2008). SLPI is 
constitutively produced at many mucosal surfaces and is also produced by lung 
epithelial cells, neutrophils, and macrophages (Doumas et al. 2005). SLPI expression 
in macrophages is induced by bacterial endotoxin leading to the suppression of NO 
and TNF secretion (J. Yang et al. 2005). Elafin is mainly present in epithelia of the 
skin, oral cavity, vagina and lung to fulfill distinct anti-microbial and immuno-
modulatory functions (Molhuizen & Schalkwijk 1995).  
In this study, we identified a novel microglia/macrophage-restricted WAP domain 
protein, AMWAP, in activated primary retinal microglia. AMWAP expression is rapidly 
induced by ligands for TLRs2/4/9 and IFN-γ in the BV-2 cell line. AMWAP  
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over-expression reduces pro-inflammatory cytokine expression and concurrently 
induces markers for alternative macrophage activation. We therefore propose that 
AMWAP is a novel modulator of microglial activation in neurodegenerative disorders. 
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Materials and Methods 
Animals 
Retinoschisin knockout (Rs1h-/Y) mice have been described previously (Weber 2002) 
and C57BL/6 mice were purchased from Charles River Laboratories. Mice were kept 
in an air-conditioned barrier environment at constant temperature of 20-22°C on a 
12-h light-dark schedule, and had free access to food and water. The health of the 
animals was regularly monitored, and all procedures were approved by the University 
of Regensburg animal rights committee and complied with the German Law on 
Animal Protection and the Institute for Laboratory Animal Research Guide for the 
Care and Use of Laboratory Animals, 1999. 
Isolation and culture of primary cells 
Retinal microglia were isolated and cultured as described earlier (Weigelt et al. 
2007). Briefly, retinal tissue from wild-type and Rs1h-/Y mice at postnatal days 14 and 
18 was isolated from eye bulbs and purified from contaminating vitreous body and 
retinal pigment epithelium/choriocapillaris. Pools of 4-6 retinas each were cut into 
small pieces and incubated for 40 min at 37°C in 1 ml of PBS with 1 mg/ml 
collagenase type I (Sigma), 0.3 mg/ml DNase I (Roche) and 0.2 mg/ml hyaluronidase 
(Sigma). The cell suspension was filtered through a 70 µm cell strainer  
(Becton Dickinson). Cells were washed twice with 10 ml DMEM/10% FCS and finally 
subjected to Ficoll density gradient centrifugation for 20 min at 2000 rpm  
(690 x g, without brake) in a Heraeus centrifuge for the isolation of mononuclear 
cells. The interphase was carefully removed and washed with 10 ml DMEM/FCS. The 
cells were cultured for 11 days in 75 cm2 flasks containing DMEM/10% FCS 
supplemented with 50 ng/ml recombinant human M-CSF (R&D Systems) and phase 
contrast micrographs were taken with a Nikon Eclipse TE2000-S microscope. 
Brain microglia were isolated from the brains of 4 weeks old wild type mice. Each 
brain was dissected, cut into small pieces in 520 µl PBS, and incubated for 40 min at 
37°C with vigorous shaking (800 rpm) containing the same dissolving solution 
described above. The single cell suspension was filtered through a 70 µm cell 
strainer (Becton Dickinson), washed twice with 10 ml DMEM/10% FCS followed by 
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centrifugation at 1600 rpm for 5 min at room temperature. The pellet was 
resuspended in 10 ml DMEM/10% FCS supplemented with 50 ng/ml recombinant 
human M-CSF (R&D Systems) and cultured in 75 cm2 cell culture flasks. Non 
adherent cells were removed after four days by washing with culture medium. After 
11 days of culture 100 ng/ml LPS was added where indicated and total RNA was 
isolated after 24 h of stimulation. 
Bone marrow macrophages were isolated from bone marrow of adult wild-type 
animals. Femur and tibia were dissected from the surrounding muscle tissue  
and both ends were cut. Bone marrow was flushed with 2 ml DMEM/10% FCS with a 
27 G syringe and cell clumps were separated by pipetting. The cell suspension  
was centrifuged for 10 min at 1200 rpm at room temperature. The supernatant was 
discarded and the pellet was dissolved in 2 ml Red Blood Cell lysis buffer (Sigma) 
and incubated for 7 min at room temperature. Then incubation was stopped with 5 ml 
DMEM/10% FCS followed by centrifugation. The cell pellet was resuspended in 10 ml 
DMEM/10% FCS supplemented with 50 ng/ml recombinant M-CSF (R&D Systems). 
Cell culture medium was removed at days 4 and 8. After 10 days in culture, bone 
marrow macrophages were stimulated with 100 ng/ml LPS where indicated and total 
RNA was isolated after 24 h. 
Dissected spleen tissue of adult wild-type animals was disintegrated by scissors in 
520 µl PBS, passed through a wire mesh and washed with 10 ml DMEM/10% FCS. 
Cells were filtered through a 40 µm cell strainer and processed as described above 
for bone marrow macrophage isolation. 
Immature bone marrow dendritic cells were isolated as described previously  
(Lutz et al. 1999). For maturation, dendritic cells were collected after 10 days, and 
resuspended in culture medium containing 100 U/ml rmGM-CSF and 1 µg/ml LPS. 
Total RNA was collected after 24 h of maturation. 
Cell lines and reagents 
RAW264.7 cells were received from the American Type Culture Collection 
(Manassas, VA, USA) and BV-2 cells were kindly provided by Professor Ralph Lucius 
(Clinic of Neurology, Christian Albrechts University, Kiel, Germany). RAW264.7 
macrophages were kept in DMEM supplemented with 10% FCS, 100 U/ml penicillin 
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and 100 µg/ml streptomycin. BV-2 cells were cultured in RPMI/5% FCS 
supplemented with 2mM L-Glutamine and 195 nM β-mercaptoethanol. Culture  
and treatment of tamoxifen-inducible PUER cells has been described elsewhere  
(Weigelt et al. 2009). Lipopolysaccharide (LPS), interferon-g (IFN-γ), and 
cycloheximide (CHX) were purchased from Sigma. PAM3CSK4 was purchased from 
Invitrogen. The phosphorothioate CpG oligonucleotide (5'-tccatgacgttcctgatgct-3') and 
control oligonucleotide (5'-tccatgaggttcctgatgct-3') were synthesized by Metabion 
(Martinsried, Germany). Caffeic acid phenethyl ester (CAPE) was purchased from 
Tocris Bioscience (Ellisville, MO, USA). For activation experiments, cells were 
exposed to LPS, IFN-γ, CpG oligonucleotides, or PAM3CSK4 in various doses for 
different time points. For inhibition of NFkB and protein synthesis, BV-2 cells were 
pre-treated with 15 µg/ml CAPE for 2 h or 5 µg/ml CHX for 1h, respectively. Cells 
were then washed with culture medium prior to stimulation with 50 ng/ml LPS,  
1 µg/ml CpG oligonucleotides, or 1 µg/ml PAM3CSK4 for 4 h. 
RNA isolation, Reverse Transcription and 5’-RLM-RACE 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen). Purity and integrity of 
the RNA was assessed on the Agilent 2100 bioanalyzer with the RNA 6000 Nano 
LabChip® reagent kit (Agilent Technologies). The RNA was quantified 
spectrophotometrically and stored at -80°C. cDNAs were generated using the 
RevertAid™ H Minus First Strand cDNA Synthesis Kit (Fermentas). 
To identify and clone full-length AMWAP transcripts, 5’RNA ligase mediated RACE-
PCR was carried out using RNA from RAW264.7 cells activated with 100ng/ml LPS 
and the Ambion FirstChoice® RLM-RACE Kit according to the manufacturer´s 
instructions. AMWAP-specific reverse primers were designed on the incomplete 
database entry Mm.24097. The first 5'-RLM-RACE PCR was carried out with the 
AMWAP-specific reverse primer 5'-GGG CAG GAT CCA TCT CCT-3' and the  
5'-RACE outer primer 5'-GCT GAT GGC GAT GAA TGA ACA CTG-3'. The nested  
5'-RLM-RACE PCR was conducted with the AMWAP-specific reverse primer  
5'-TTT GCA GAC ATG ACC ACA GC-3' and the inner 5' RACE primer 5'-CGC GGA 
TCC GAA CAC TGC GTT TGC TGG CTT TGA TG-3'. PCR products were analyzed 
on 2% agarose gels and individual bands were extracted, cloned into the pCR2.1 
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Topo TA vector (Invitrogen) and sequenced. The full-length AMWAP sequence  
was submitted to Genbank under accession number FJ007372 
(http://www.ncbi.nlm.nih.gov/Genbank). 
Quantitative real-time RT-PCR 
Relative transcript levels were assessed by amplifications of 50 ng cDNA in a 
7900HT real-time PCR detection system (Invitrogen Life Technologies). The 20 µl 
reaction volumes contained 1x TaqMan Gene Expression Master Mix (Invitrogen Life 
Technologies), 200 nM primers (Supplementary table 1) and 0.25 µl dual-labelled 
probe (Roche Universal Probe Library). The PCR reaction parameters were as 
follows: 2-min 50 °C hold, 30-min 60 °C hold, and 5-min 95 °C hold, followed by 45 
cycles of 20-s 94 °C melt and 1-min 60 °C anneal/extension. The results were 
analyzed using the ΔΔCt method for relative quantification (Mauerer et al. 2009). 
Chromatin immunoprecipitation (ChIP) 
ChIP experiments of RAW264.7 cells coupled to Affymetrix Promoter Arrays have 
been described elsewhere (44). For ChIP-PCR with microglia, 10 million BV-2 cells 
were treated with 1% formaldehyde for 15 min and lyzed with SDS, Empigen and  
NP-40 (supplemented with 1 mM PMSF, 1 µg/ml aprotinin and 1 µg/ml pepstatin A). 
The nuclear pellet was homogenized by sonication twice at 30% amplitude for 10 s. 
Immunoprecipitation was performed on the lysate with 2.5 µg of anti-PU.1 antibody 
(Santa Cruz Biotechnology) anti-di-acetylated (K9 and K14) histone H3  
(Upstate Biotechnology), anti-p300 clone RW128 (Upstate Biotechnology), anti-CBP 
(Upstate Biotechnology), or anti-IgG antibody (Santa Cruz Biotechnology). After 
washing and elution steps, cross-links were reversed at 65°C overnight. The 
immunoprecipitated DNA was purified using the QIAquick PCR purification kit 
(Qiagen) and analyzed by PCR using the forward primer 5’-CCC CTC GAG CTG 
GAA AAA GGA ACC TGG TG-3′ and the reverse primer 5′-CCC AAG CTT TCA TCC 
CCA CAG TGA TCA AA-3′ specific for the AMWAP proximal promoter region 
−114/+68. 
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Over-expression of AMWAP in BV-2 cells 
The full-length coding sequence of mouse AMWAP was RT-PCR amplified from 
RAW264.7 RNA with primer pair forward 5’-CCC AGC TTC CCA ACA TGA AGA 
CAG CCA CA-3’ and reverse 5’-CCC CTC GAG TAA AAG ACA GGA GTT TTG CAG 
AC-3’. PCR products were sequenced and cloned into the HindIII/XhoI site of a 
pCEP1.4 vector in-frame with a C-terminal rhodopsin (Rho)-1D4 tag  
(Stoehr et al. 2004) to generate pAMWAP-1D4. A fusion protein of milk fat globule 
protein 8 with a C-terminal rhodopsin (Rho)-1D4 tag (pMFG-1D4) was cloned as 
positive control. The AMWAP-GFP-fusion protein (pAMWAP-GFP) was created by 
cloning the AMWAP open reading frame into the pcDNA/CT-GFP-TOPO vector using 
RT-PCR with primer pair forward 5’-CCC GGT ACC CCA ACA TGA AGA CAG CCA 
CA-3’ and reverse 5’-CCC GAT ATC TAA AGA CAG GAG TTT TGC AGA C-3’, 
containing restriction sites for KpnI and EcoRV, respectively. BV-2 cells were 
transfected with 2µg of endotoxin-free plasmid using transIT-LT1 transfection reagent 
(Mirus Bio) following the manufacturer’s recommendations. Stable BV-2 cell 
transformants expressing GFP or AMWAP-GFP were created by neomycin selection. 
Successful expression of GFP and AMWAP-GFP was monitored by GFP 
fluorescence. 
siRNA knock-down of AMWAP in BV-2 cells 
Target sequences for murine AMWAP were based on the longest transcript obtained 
from the 5’ RLM-RACE-PCR (Accession Nr. FJ007372.1). siRNAs were designed 
with the Ambion siRNA target finder and synthesized with the siRNA construction kit 
(Ambion, Austin, TX, USA). AMWAP siRNA was synthesized using sense primer  
5’-AAA GGA TCC ATC TCC TGA GCA CCT GTC TC-3’ and antisense primer  
5'-AAT GCT CAG GAG ATG GAT CCT CCT GTC TC-3'. BV-2 cells were transfected 
with 33 nM AWMAP siRNA or scrambled siRNA (Ambion) using lipofectamine 2000 
(Invitrogen). Twenty four hours after transfection, cells were stimulated with 5 ng/ml 
LPS for 24 h before isolation of total RNA. 
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Western blotting 
Cells were grown in 10 cm dishes and lysed in 1 ml boiling lysis buffer  
(PBS, 1% SDS). Equal amounts of protein samples were separated with NuPAGE 
Bis-Tris 4-12% gels (Invitrogen) and subsequently transferred to a Hybond ECL 
membrane (Amersham Biosciences). For determination of protein size, PageRulerTM 
prestained protein standard (Fermentas) was used. The membranes were blocked in 
5% milk powder in PBS and probed with either anti-Rhodopsin-1D4 mouse 
monoclonal antibody (1:10000) (a generous gift of Robert S. Molday, Department of 
Biochemistry and Molecular Biology, Centre for Macular Research, University of 
British Columbia, Vancouver, Canada) or anti-His-Penta mouse monoclonal antibody 
(Qiagen, 1:10000). A HRP-conjugated secondary antibody against mouse Ig  
(Cell signaling Technology) and the ECL Plus system (Amersham Biosciences) were 
used for detection. 
Immunocytochemistry 
BV-2 cells were plated overnight on coverslips, fixed with 4% paraformaldehyde for 
10 min at 37°C, permeabilized with 0.2% Triton X-100, blocked with 5% non-fat milk 
in 0.2% Triton X-100, and stained with anti-GFP-antibody (Abcam). Nuclei were 
stained with DAPI for 10 min (0.1 µg/ml in PBS, 4’6-diamidino-2-phenylindol, 
Molecular Probes). Coverslips were mounted on glass slides and visualized with an 
Axioskop 2 fluorescence microscope equipped with an Eclipse digital analyzer  
(Carl Zeiss). 
Wound healing and transwell migration assays 
Stably pAMWAP-GFP and pGFP expressing BV-2 cells were grown in 6-well plates 
as 80% confluent monolayers and were wounded with a sterile pipette tip. Cell 
migration into the open scar was documented with microphotographs at time points  
0 h and 24 h after wounding. As an independent method, the Costar Transwell 
System (8 µm pore size polycarbonate membrane) was used to evaluate cell 
migration. BV-2 cells (1 × 106 cells in 1.5 ml serum-free medium) were added to the 
upper well, and 2.6 ml serum-free medium was added to the lower chamber. 50 
ng/ml LPS or ethanol as solvent control were added to the lower chamber medium. 
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At the end of the 24 h incubation, cells on the top of the membrane were removed by 
swiping with a damp cotton swab, and cells that had migrated to the lower surface 
were fixed in methanol for 15 minutes at room temperature and stained with 1% 
crystal violet. The migration activity was quantified by counting the migrated cells on 
the lower surface of the membrane using light microscopy. 
Trypsin protease protection assay 
Stably AMWAP-GFP and GFP-expressing BV-2 cells were cultured in 24-well plates 
overnight until 80% confluence was reached. The culture medium was removed and 
0.25% trypsin in PBS was added to the cells for the indicated time points. Complete 
medium containing 10% FCS was added to the cells to stop trypsin activity. The cells 
were washed three times and stained with 0.2% crystal violet in PBS for 10 min. After 
additional washing steps, cell-associated crystal violet was extracted with 10% acetic 
acid and the optical density was assessed on a microplate reader at 600 nm.  
OD values were normalized to untreated control cells. 
Ccl2 luciferase reporter assay 
The murine Ccl2 promoter (-988/+113) was PCR amplified from genomic DNA using 
the primers forward 5’-CCC CTC GAG CAT GCT ACA GAA AGC CCA AAA-3’ and 
reverse 5’-CCC AGA TCT GGC CCA GAA GCA TGA CAG-3’. The PCR product was 
cut with restriction enzymes XhoI and BglII and cloned into the pGL4.10 vector 
(Promega). BV-2 cells were co-transfected with the luciferase construct and a pTK-
Hyg vector (Clontech, CA, USA) for selection of stable clones with Hygromycin B 
(PAA). BV-2 cells stably expressing the Ccl2 luciferase reporter were transiently 
transfected with 2 µg of pAMWAP-GFP or pGFP vectors. Transfected cells were 
harvested after 24 h and luciferase activity was determined with the Luciferase assay 
system (Promega) on a FLUOstar Optima plate reader (BMG Labtech). 
Bacterial expression and purification of recombinant AMWAP 
The AMWAP cDNA sequence was codon-optimized and de novo synthesized for 
recombinant expression in E. coli (Sloning Biotechnology), resulting in an increased 
codon adaption index from 0.7 to 0.91 (Fig. S1) (46). Signal-sequence lacking and 
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codon-optimized AMWAP was PCR amplified from pSlo1.0-AMPWAP with forward 
primer 5’-CCC CAT ATG ACC TAT GTG GTG TCC TGT CC-3’ and reverse primer 
5’-CCC AAG CTT AAA CAC CGG GGT TTT GC-3’. The PCR product was inser- 
ted with NdeI and HindIII into the pET21a(+) vector (Novagen) in-frame with an  
N-terminal His-tag sequence. 
E. coli BL21α-DE3 cells transformed with pAMWAP-His were grown in 500 ml of  
LB-medium until an OD600 of 0.7 was reached. Isopropyl-β-D-thiogalactoside was 
added to a final concentration of 1 mM and culture was continued at 37°C for 4 h. 
Cells were harvested, the cell pellet was resuspended in 7 ml lysis buffer  
(300 mM NaCl, 50 mM sodium phosphate, pH 8.0) containing 7 mg lysozyme, and 
the sample was incubated for 30 min at 4°C. Thereafter, the cell suspension was 
sonicated and stirred on ice with 5 µg/ml DNase I for 15 min. The crude lysate was 
centrifuged at 10,000 x g for 30 min at 4°C and the supernatant was loaded onto 
Protino Ni-TED Columns (Macherey-Nagel). Three fractions were eluted in buffer 
containing 250 mM imidazole and concentrated in Amicon Ultra-4 Ultracel 5kDa 
tubes (Millipore) by centrifugation. The protein was dialysed four times against PBS, 
the concentration of each fraction was determined by Bradford assay and purified 
recombinant protein was stored at -80°C. 
Antimicrobial assay 
The bacterial strains E.coli (ATCC25922), P. aeruginosa (ATCC27853) and  
B. subtilis (ATCC6633) were grown in LB medium at 37°C to an OD600 of 1.0. 
Bacteria were then diluted in MT-LB medium (16 mM disodium hydrogen phosphate, 
5 mM sodium dihydrogen phosphate, 150 mM sodium chloride and 1% LB medium) 
to a concentration of 1 x 104 colony forming units/ml. 50µl of bacterial suspensions 
were incubated with PBS as control or 10 µM, 20 µM, or 30 µM AMWAP-His protein 
for 2 h at 37°C. Subsequently, appropriate serial dilutions were plated on LB agar 
plates, incubated over night at 37°C and colony-forming units were determined. 
Statistical analyses 
The Student’s t test or Mann-Whitney-U test were used for the comparison of 
experimental groups as indicated. p<0.05 was considered significant. 
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Microarray datasets used in this study 
The microarray datasets cited in this study are available at the NCBI Gene 
Expression Omnibus as series records GSE5581 (Rs1h-/Y vs. wild-type  
retinas), GSE9011 (PU.1 ChIP-Chip), and GSE13125 (PUER cells) at 
(http://www.ncbi.nlm.nih.gov/geo/). 
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Results 
AMWAP is strongly induced in activated retinal microglia 
To identify novel genes involved in the activation of microglia, we have previously 
performed DNA-microarray analysis of isolated retinal microglia from degenerating 
Rs1h-/Y and wild-type retinas (Gehrig et al. 2007; Weigelt et al. 2007; Ebert et al. 
2009). Nine previously uncharacterized transcripts showed a significantly different 
expression pattern in activated Rs1h-/Y versus non-activated wild-type microglia  
(data not shown). Among these, a more than 7-fold induction of a predicted gene with 
the UniGene entry Mm.24097 was detected in activated retinal microglia. Here, we 
confirmed these microarray findings by quantitative real-time RT-PCR assays with 
RNA samples from independently isolated retinal microglia from Rs1h-/Y and  
wild-type mice were performed. AMWAP transcript levels were increased in microglia 
from postnatal day 14 (P14) Rs1h-/Y retinas and were further substantially induced in 
P18 Rs1h-/Y microglia (Fig. 4A). We have previously shown that microglia activation 
starts at P14 in the retina of retinoschisin-deficient mice, a time point where neuronal 
apoptosis and degeneration is not yet evident (Gehrig et al. 2007). 
For a more precise refinement of the temporal expression profile of AMWAP in 
relation to the inflammatory process, mRNA levels were quantified in retinal tissue of 
postnatal stages (P)11, 12, 14, 18, 21, 24, and 28 (Fig. 4B). The highest AMWAP 
expression was noted at P18 and P21 and thereafter declined to intermediate levels 
(Fig. 4B). The AMWAP transcript profile is in good accordance with the time kinetics 
of the known early activation markers lysozyme (Lyzs) (Fig. 4C) and secreted 
phosphoprotein 1 (SPP1, alias osteopontin) (Fig. 4D). This implicates that high 
AMWAP expression is already present at the very early stage of retinal microglial 
activation and declines in the chronic and resultion phase of neuroinflammation. The 
deduced protein sequence contains a whey acidic protein (WAP) domain and 
together with the data on its specific expression pattern, this gene was named 
AMWAP for Activated Microglia/Macrophage WAP Domain Protein. 
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Figure 4 Temporal qRT-PCR expression profile of AMWAP during early retinal microglia 
activation. (A) AMWAP mRNA expression in primary retinal microglia isolated from postnatal day 14 
(P14) and P18 wild-type (wt) and retinoschisin-deficient (Rs1h-/Y) mice. Temporal expression profiles 
of AMWAP (B), lysozyme (C), and secreted phosphoprotein 1 (D) in early postnatal retinas of Rs1h-/Y 
mice compared to age-matched wild-type mice. Data represent means ± SD of two independent 
microglia preparations (A) or the means ± SD of three independent retina preparations analyzed in 
triplicates (B-D), respectively. 
AMWAP is exclusively expressed in activated microglia and macrophages 
We next addressed the question whether AMWAP is also expressed in brain 
microglia and macrophages outside of the CNS. Primary brain microglia, spleen 
macrophages, bone-marrow-derived macrophages, and bone-marrow-derived 
dendritic cells were isolated and stimulated with LPS to induce a pro-inflammatory 
state. AMWAP transcripts were already present in the four different types of 
macrophages but stimulation with LPS further up-regulated AMWAP gene expression 
(Fig. 5). Examination of AMWAP transcript levels in public domain Affymetrix 
microarray data (BioGPS, http://biogps.gnf.org and http://macrophages.com) further 
revealed a macrophage-restricted expression of probeset 1436530_at, which 
specifically and exclusively targets the AMWAP mRNA (Fig. S2). In the BioGPS 
database, high abundance of AMWAP transcripts was detected in microglia, bone-
marrow-derived macrophages, peritoneal macrophages, and osteoclasts, but not in 
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any of the other studied mouse tissues or cell types (Fig. S2). Consistent with our 
qRT-PCR data, these comprehensive expression profiles indicate that AMWAP is a 
microglia/macrophage-specific transcript induced by pro-inflammatory activation. 
 
Figure 5 AMWAP is expressed and LPS-inducible in brain microglia and other tissue 
macrophages. Brain microglia (A), spleen macrophages (B), bone-marrow-derived macrophages (C), 
and bone-marrow-derived dendritic cells (D) were cultured in the absence or presence of 100 ng/ml 
LPS for 24 h. Total RNA was isolated and AMWAP transcript levels were determined by qRT-PCR. 
Data points represent the means ± SD of three independent cell preparations analyzed in triplicates.  
*, p<0.05; Student’s t test. 
Multiple TLR ligands and IFN-γ rapidly trigger AMWAP transcription in microglia 
We next analyzed AMWAP expression and regulation in the BV-2 microglial cell line 
as an independent in vitro model system. AMWAP mRNA was present in BV-2 cells, 
but transcript levels were markedly elevated after pro-inflammatory stimulation with 
TLR ligands and IFN-γ (Fig. 6). Specifically, treatment of BV-2 cells with LPS as 
TLR4 ligand (Fig. 6A, B), CpG oligonucleotides as TLR9 ligand (Fig. 6C, D), 
PAM3SCK4 as TLR2 ligand (Fig. 6E, F), and IFN- γ (Fig. 6G, H) evenly up-regulated 
AMWAP expression in a time- and dose-dependent manner.   
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Figure 6 AMWAP is up-regulated by multiple TLR ligands and IFN-γ in BV-2 microglia in a 
time- and dose-dependent manner. Time-course (A, C, E, G) and dose-response (B, D, F, H) of  
BV-2 cells treated with the indicated concentrations for the given time periods of LPS (A, B), CpG 
oligonucleotides or control GG oligonucleotides (C, D), PAM3SCK4 (E, F), or IFN-γ (G, H). qRT-PCR 
was performed to determine AMWAP levels. Values represent the means ± SD of three independent 
cell cultures analyzed in triplicates. *, p<0.05; **, p<0.01; ***, p<0.001; Student’s t test.  
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The shortest time of treatment (1 h) and the lowest concentration of each compound 
were sufficient to induce significant increases in AMWAP levels. These data suggest 
that AMWAP transcription is very sensitive to pro-inflammatory stimulation of BV-2 
microglial cells. 
We then examined whether AMWAP induction by TLR ligands depends on the 
transcription factor NFkB. BV-2 cells were pre-treated with the specific NFkB inhibitor 
CAPE before exposure to LPS, PAM3SCK4, or CpG oligonucleotides. CAPE 
completely prevented TLR-dependent AMWAP up-regulation in all three stimulatory 
conditions (Fig. 7A), indicating that NFkB is absolutely required for AMWAP 
induction. Next, we pre-treated BV-2 cells with cycloheximide (CHX), a protein 
synthesis inhibitor, to study whether newly synthesized proteins may be involved in 
this process. We found that TLR-dependent expression of AMWAP was diminished 
by CHX pre-treatment (Fig. 7B). 
     
Figure 7 AMWAP up-regulation by TLR ligands requires NFkB and new protein synthesis.  
To block NFkB, BV-2 cells were pre-treated with 15 µg/ml caffeic acid phenethyl ester (CAPE) for 2 h 
and cells were thereafter stimulated with 50 ng/ml LPS, 1 µg/ml CpG oligonucleotides, or 1 µg/ml 
PAM3SCK4 for 4 h (A, C). To block new protein synthesis, BV-2 cells were pre-treated with 5 µg/ml 
cycloheximide (CHX) for 1 h and were thereafter stimulated with 50 ng/ml LPS, 1 µg/ml CpG 
oligonucleotides, or 1 µg/ml PAM3SCK4 for 4 h (B, C). qRT-PCR was performed to determine mRNA 
levels of AMWAP (A, B) and IL-1β as NFkB-dependent control gene (C). Values represent the means 
± SD of three independent cell cultures analyzed in triplicates. *, p<0.05; ***, p<0.001; Student’s t test. 
This suggests that new protein synthesis is necessary and that additional factors may 
be relevant for AMWAP induction by TLR-ligands. As a positive control, the LPS-
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induced expression of Il-1β was critically dependent on NFkB, but required no protein 
synthesis (Fig. 7C). 
Cloning and genomic structure of AMWAP 
The previous database entry of Mm.24097 (Genbank Accession No. BC089618) was 
complete at the 3’-end including the polyA tail, but contained only nine nucleotides 
upstream of the start codon. We therefore performed 5’-RLM-RACE with RNA from 
LPS-stimulated RAW264.7 cells (Fig. 8A). 
  
Figure 8 AMWAP full-length cDNA, genomic structure and protein domains. (A) Distinct  
5’-RLM-RACE-PCR products generated with template cDNA from LPS-activated RAW264.7 cells and 
a reverse primer located in the second exon. Specific bands are indicated by arrows and the asterisk 
denotes a double band. (B) Full-length AMWAP cDNA sequence deposited in Genbank under 
Accession No. FJ007372. The open reading frame and translated amino acids are given in bold 
letters. The potential signal sequence is shaded in light gray and the WAP domain is marked in dark 
grey. The position of the stop codon is indicated by an asterisk and the polyadenylation signal is 
underlined. (C) Genomic organization of the AMWAP gene (top), predicted protein domains  
(middle panel), and eight cysteine-residues forming four putative disulfide bonds (bottom). 
Three major 5’-RLM-RACE-PCR products were amplified and sequencing after 
cloning of the individual products identified four different transcripts with the longest 
variant extending 68 bp further upstream (Fig. 8A). 
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The 526-bp full-length AMWAP cDNA encodes for a 76 amino acid polypeptide. After 
predicted cleavage of the 19 amino acid signal sequence, the mature AMWAP 
polypeptide should consist of a 58 amino acids single WAP motif (Fig. 8B). BLAST 
analysis against DNA databases resulted in the identification of the AMWAP gene on 
mouse chromosome 11, consisting of three exons and two introns (Fig. 8C). The  
N-terminal signal peptide is encoded by exon one, whereas exon two completely 
codes for the C-terminal WAP domain with eight cysteines presumably forming four 
disulfide bonds (Fig. 8C). The four-disulfide core domain and its genomic structure as 
single exon are characteristic features of all WAP proteins (Laslo et al. 2006). 
Microglia/macrophage-specific AMWAP expression depends on PU.1 binding to its 
proximal promoter 
Because of the microglia/macrophage-restricted expression of AMWAP, we sought to 
investigate the relevant cis-regulatory elements. A comparison of mouse and rat 
AMWAP promoter sequences and their closest rodent homologue Expi revealed a 
highly conserved TATA-box, proximal PU.1 sites, a STAT motif and an overlapping 
IRF/PU.1 sequence (Fig. 9A). Our information from 5’ RLM-RACE identified the 
existence of four alternative transcription start sites (Fig. 9A, arrows). Since the 
longest AMWAP transcript includes the TATA-motif and extends 40 bp upstream, a 
nearby PU.1 site could function in the formation of the transcription preinitiation 
complex and thus regulate AMWAP gene activity (Fig. 9A). 
To determine whether PU.1 is directly involved in the macrophage-specific 
expression of the AMWAP gene, recent PU.1-related large scale genomic data from 
our group were used as resource for further analyses. In the first dataset, a genome-
wide discovery of PU.1 target genes in RAW264.7 macrophages was performed 
using chromatin immunoprecipitation coupled to microarrays (ChIP-Chip)  
(Weigelt et al. 2008). In the second dataset, PU.1-/- progenitors and PUER cells with 
restored PU.1 activity were analyzed with exon-specific microarrays to identify PU.1 
regulated genes (Weigelt et al. 2009). Results from the ChIP-Chip experiments 
revealed that the proximal AMWAP promoter strongly bound macrophage PU.1 in 
vivo, indicated by the specific enrichment of probes in the immediate upstream region 
(Fig. 9B, black bars). In full agreement with these data, restored PU.1 activity in 
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PUER cells and differentiation along the macrophage lineage caused a significant 
increase of AMWAP transcript levels, as shown by specific hybridization signals to all 
three AMWAP exons (Fig. 9B, red bars).  
 
Figure 9 PU.1 regulates the macrophage/microglia-specific expression of AMWAP.  
(A) Alignment of proximal promoter sequences of rodent AMWAP and Expi. Predicted transcription 
factor binding matrices are shaded. Arrows indicate transcription start sites experimentally verified by  
5’-RLM-RACE. (B) Genomic structure of the AMWAP gene and log2 enrichment/expression values of 
tiled probes spanning the promoter and all three exons. Significant probes of PU.1 vs. IgG ChIP-Chip 
analysis of RAW264.7 cells are shown in black and differentially expressed probes in exon array 
analyses of 24 h OHT-treated PUER cells versus untreated PUER cells are depicted in red.  
(C) Chromatin immunoprecipitation analysis of PU.1 and co-activator binding to the AMWAP promoter. 
Agarose gel analysis of AMWAP-specific PCR products generated from BV-2 DNA after chromatin 
immunoprecipitation with anti-PU.1, anti-Cbp, anti-p300, anti-AcH3, or anti-IgG-control antibodies. 
Input DNA was used as positive control in the PCR reaction. (D) Time kinetics of AMWAP transcript 
expression before and after OHT treatment of PUER cells to induce macrophage differentiation. Error 
bars indicate the standard deviation of the mean from two independent experiments performed in 
duplicates. 
To recapitulate the findings from PU.1 ChIP-Chip experiments with RAW264.7 
macrophages also in microglial cells, ChIP-PCR assays were performed with BV-2 
microglia. The proximal −114/+68 AMWAP promoter region harbouring the 
conserved PU.1 site was specifically enriched in PU.1-precipitated DNA compared to 
the IgG control (Fig. 9C, upper panel). Moreover, ChIP-PCR products were obtained 
with precipitated DNA from antibodies directed against the transcriptional co-
activators p300 and Cbp (Fig. 9C, lower panel), factors known to be involved in 
chromatin relaxation via histone acetyltransferase activity and RNA polymerase II 
recruitment to transcription start sites. The −114/+68 AMWAP promoter DNA was 
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also enriched in anti-AcH3 antibody precipitated DNA (Fig. 9C, lower panel), 
indicating open chromatin and active AMWAP gene expression in BV-2 cells.  
We then aimed to validate the microarray findings of increased AMWAP mRNA 
expression in differentiated PUER cells by real-time qRT-PCR. In this tuneable 
system the PU.1-estrogen receptor binding domain fusion protein PUER is 
conditionally activated in myeloid progenitors upon addition of 4-hydroxy-tamoxifen 
(OHT), leading to rapid cell cycle arrest and differentiation into macrophages  
(Weigelt et al. 2009; Laslo et al. 2006). Quantitative RT-PCR analysis of independent 
RNAs from a time series of OHT-treated PUER cells showed very low AMWAP 
mRNA levels in PU.1-/- progenitors and a steep increase of AMWAP transcripts in 
OHT-differentiated cells (Fig. 9D). These data strongly support the hypothesis that 
AMWAP expression in macrophages as well as in microglia is critically dependent on 
PU.1 binding to its proximal promoter region. 
AMWAP reduces pro-inflammatory gene expression and triggers alternative 
activation markers in microglia 
To further investigate the immunological functions of AMWAP in microglia cells, the 
full-length open reading frame was over-expressed in BV-2 cells. A C-terminally  
1D4-rhodopsin-epitope-tagged variant of AMWAP was transiently expressed in BV-2 
cells. The rhodopsin epitope is not endogenously expressed in BV-2 cells, as shown 
by the absence of a Western blot band using a monoclonal anti-1D4 antibody  
(Fig. 10A). A specific band of 10 kDa was detected in cells transfected with the 
pAMWAP-1D4 construct, demonstrating successful over-expression of AMWAP in 
BV-2 cells (Fig. 10A). A milk fat globule protein-1D4 fusion protein was used as 
positive control and produced the expected band size of 15 kDa (Fig. 10A). To verify 
these findings and to visualize AMWAP within cells, BV-2 transformants expressing 
AMWAP-GFP or only GFP as control were generated. GFP-immunofluorescence 
confirmed that recombinant AMWAP was expressed in BV-2 cells (Fig. 10B). 
AMWAP-GFP was localized in perinuclear structures and in some cells in dome-
shaped structures with a polarity that resembled the Golgi apparatus (Fig. 10B, 
arrows in left panel). In constrast, GFP alone was broadly expressed in the 
cytoplasmic region (Fig. 10B, right panel). This finding is consistent with proteins that 
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are processed through the endoplasmic reticulum and Golgi for extracellular 
transport.  
Because AMWAP transcription was regulated by pro-inflammatory activation and the 
related WAP protein SLPI modifies inflammatory responses (Nakamura et al. 2003; 
Taggart et al. 2005), the effect of AMWAP on macrophage/microglia activation 
marker expression was studied. The immune-regulatory potential of AMWAP was 
addressed under basal and LPS-treated conditions. Enhanced AMWAP-GFP 
expression in non-stimulated and LPS-treated BV-2 cells reduced transcripts for Il1-β, 
Il-6, and Ccl2, three typical markers for pro-inflammatory activation of macrophages 
(Fig. 10C-E). In the same cells, the alternative macrophage activation markers 
arginase 1 and Cd206 were substantially increased (Fig. 10F-G). These effects were 
not due to different growth conditions of the cells or varying transfection efficiencies 
(data not shown). To investigate if AMWAP is also a direct suppressor of pro-
inflammatory gene transcription, we determined its effect on Ccl2 promoter activity. 
A stable BV-2 cell line was generated with a luciferase reporter under the control of 
the murine Ccl2 promoter region. In these cells, transient co-transfection of AMWAP 
strongly decreased Ccl2 promoter activity compared to mock transfected cells  
(Fig. 10H).  
We next studied the role of physiological AMWAP levels in the modulation of 
microglial activation. Knock-down experiments with specific AMWAP siRNA or control 
siRNA were performed and marker transcripts were determined in transiently 
transfected BV-2 cells. A 30 % knock-down of AMWAP expression was achieved in 
both the basal and LPS-activated state (Fig. 11A). AMWAP silencing resulted in 
significantly de-repressed transcript levels of Il1-β, Il-6, and Ccl2 (Fig. 11B-D) and 
markedly reduced arginase 1 and Cd206 expression (Fig. 11E, F). These data 
suggest that AMWAP acts as negative regulator of pro-inflammatory gene expression 
and may support alternative activation of microglial cells. 
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Figure 10 AMWAP over-expression reduces pro-inflammatory gene expression and up-
regulates alternative activation markers in BV-2 microglia. (A) BV-2 cells were transiently 
transfected with an AMWAP-Rhodopsin 1D4 tag fusion protein, empty 1D4 mock vector, or a milk fat 
globule (MFG)-1D4 control protein, respectively. Cells were then analyzed by Western blot with anti-
1D4-antibody. (B) BV-2 cells were transiently transfected with an AMWAP-GFP fusion protein or GFP 
vector alone. Intracellular GFP was detected by immunofluorescence microscopy. Dome-shaped Golgi 
regions are indicated by arrows. (C-G) qRT-PCR analysis of Il-6-, Il-1β- and Ccl2-transcripts as  
pro-inflammatory markers (C-E) and arginase 1 and Cd206 levels as alternative activation markers  
(F, G) in AMWAP-GFP versus GFP over-expressing BV-2 cells under basal and LPS-stimulated 
conditions. (H) Luciferase assays of BV-2 microglia containing a stable Ccl2-promoter-luciferase-
construct. BV-2 cells stably expressing the Ccl2 reporter were transiently transfected with either 
AMWAP-GFP or GFP control vector. 24 h after transfection luciferase acitvity was determined. Bar 
graphs represent means ± SD of three independent cell cultures analyzed in triplicates. *, p<0.05; 
**, p<0.01; Student’s t test. 
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Figure 11 AMWAP knock-down leads to increased pro-inflammatory gene expression and 
impairs expression of alternative activation markers in BV-2 microglia. BV-2 cells were 
transiently transfected with 33 nM of each AMWAP-specific siRNA or non-targeting (scrambled) siRNA 
for 24 h. Thereafter, cells were left untreated or were further stimulated with 5 ng/ml LPS for 24 h. 
mRNA levels for AMWAP (A), Il1-β (B), Il6 (C), Ccl2 (D), arginase 1 (E), and Cd206 (F) were 
determined by qRT-PCR. Bar graphs represent means ± SD of three independent cell cultures 
analyzed in triplicates. *, p<0.05; **, p<0.01; ***, p<0.001; Student’s t test. 
AMWAP blocks microglial migration and acts as serine-protease inhibitor 
To assess whether AMWAP influences the motility of microglia as a functional 
parameter, in vitro wound-healing assays and transwell migration experiments were 
performed. A cell-free zone was created in confluent monolayers of stably transfected 
BV-2 cells by scraping cells off with a pipette tip. The repopulation of the cell-free 
zone was then monitored by microscopy. In GFP control cells, migration into the 
wounded area was completed after 24 h (Fig. 12A, left panels). In contrast, AMWAP-
GFP expressing cells showed a clearly reduced capacity to repopulate the cleared 
area, indicating diminished migratory potential (Fig. 12A, right panels).  
To rule out the possibility that the reduced microglial migration in the scratch assays 
was due to different proliferation rates of stably transfected BV-2 cells, we tested their 
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LPS-induced chemotactic migration in transwell chambers. In this system, stable 
AMWAP over-expression reduced the LPS-induced transwell migration of BV-2 cells 
to 50% compared to GFP expressing cells (Fig. 12B). In contrast, transient siRNA 
knock-down of AMWAP significantly promoted chemotactic migration of BV-2 
microglial cells compared to cells transfected with non-targeting control siRNA  
(Fig. 12C). These findings implicate that modulation of AMWAP expression levels in 
microglia directly influences their migration capacity. 
 
Figure 12 AMWAP attenuates microglial migration and exerts anti-serine protease activity.  
(A) Wound-healing assay in BV-2 microglia stably expressing AMWAP-GFP or GFP as control. 
AMWAP-GFP and GFP expressing BV-2 microglia were grown to comparable cell density, wounded 
with a pipette tip and microphotographs from wounded areas were taken immediately and after 24 
hours. (B) Relative LPS-induced transwell chamber migration of stably transfected AMWAP-GFP 
versus GFP expressing BV-2 microglia. (C) BV-2 microglia were transiently transfected with AMWAP-
specific siRNA or non-targeting (scrambled) siRNA for 24 h. Thereafter, the lower wells of transwell 
chambers were treated with LPS for further 24 h and the absolute numbers of migrating cells were 
counted. (D) Trypsin protease protection assay. Stable AMWAP-GFP and GFP expressing BV-2 
microglia were treated with 0.25% trypsin for the indicated time points. Residing attached cells were 
stained with crystal violet, washed with PBS and photomicrographs were taken. (E) Quantitative 
analysis of anti-protease activity in AMWAP-GFP and GFP expressing BV-2 microglia. Optical 
densities were normalized to untreated cells. Bars represent the percentage of adherent cells after 
different time points of trypsin incubation. Data are expressed as mean ± SD of duplicate 
measurements from three independent biological replicates. *, p<0.05; **, p<0.01; ***p<0.001; 
Student’s t test.  
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Since SLPI and other WAP proteins are potent serine protease inhibitors  
(Weldon et al. 2007), we investigated a similar function of AMWAP in a trypsin-
protection assay. In this test system, the adhesive capacity of cells is monitored in 
the presence of trypsin in a time course (Nukumi et al. 2007). The rate of adherent 
cells after trypsinization for 5 min was significantly higher in AMWAP-expressing 
cultures than GFP control cells (Fig. 12D, E). This difference persisted at all time 
points analyzed up to 25 min trypsin incubation, indicating that AMWAP confers 
protease resistance and increases microglial adhesion. In agreement with the wound-
healing assays, the transwell chemotaxis tests and the Ccl2 expression data, these 
results indicate an immuno-modulatory role of AMWAP by limiting microglial 
migration. 
Recombinant AMWAP has anti-bacterial activity 
As anti-bacterial activity is a major feature of WAP domain proteins, we studied the 
effect of recombinant AMWAP on different bacterial strains. Initially, we only achieved 
low recombinant expression of AMWAP in E. coli (data not shown). Therefore, 
codon-optimized AMWAP (Fig. S1) was synthesized, expressed in E.coli, and 
purified via an N-terminal His-tag sequence by affinity chromatography. Western blot 
analysis of the recombinant protein via an anti-His antibody detected a single specific 
band at the expected molecular mass of ~10 kDa (Fig. 13A). To study the anti-
bacterial potential of AMWAP, the target bacteria E. coli (ATCC25922, Gram-
negative rod), P. aeruginosa (ATCC27853, Gram-negative rod), and B. subtilis 
(ATCC6633, Gram-positive rod) were incubated in the presence of recombinant 
AMWAP for 2 h. After overnight growth on plates, colony forming units were counted 
to assess the number of viable bacteria. AMWAP showed a relatively weak  
(IC50 of 30 µM) but significant bactericidal activity against E. coli (Fig. 13B). Growth of 
P. aeruginosa (Fig. 13C) and B. subtilis (Fig. 13D) was significantly inhibited at lower 
micromolar concentrations (IC50 of 16 µM). Thus, the anti-bacterial potential of 
AMWAP increased dose-dependently and reached similar IC50 values as those  
of other WAP motif proteins including SLPI (Hiemstra et al. 1996) and elafin 
(Simpson et al. 1999). 
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Figure 13 Expression, purification and anti-microbial activity of recombinant AMWAP.  
(A) Schematic presentation of the pET21a-AMWAP expression construct. Codon-optimized AMWAP 
cDNA sequence lacking the signal peptide was cloned into pET21a(+) vector in frame with a His-tag. 
Expression in E. coli BL21(DE3) was induced by 1 mM isopropyl-β-D-thiogalactoside and AMWAP-His 
was purified from the soluble fraction of the bacterial lysate using Ni-TED columns. Purified 
recombinant AMWAP-His was separated by SDS-PAGE and detected with Anti-His antibody.  
(B-D) Growth inhibitory activity of different concentrations of recombinant AMWAP-His on E. coli (B), 
P. aeruginosa (C) and B. subtilis (D). Log-phase bacterial cultures were incubated with the indicated 
concentrations of AMWAP-His in MT-LB medium for 2h at 37°C. Bacteria were then plated over-night 
and the number of colony-forming-units was determined by counting colonies. Cells incubated with 
PBS were set as 100%. Data are expressed as mean ± SD of duplicate measurements from three 
independent biological replicates. ***p<0.001; Mann-Whitney-U test. 
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Discussion 
This study is part of an ongoing effort to characterize known and novel transcripts 
involved in the activation and regulation of microglia during retinal degeneration. We 
identified the novel mouse protein AMWAP and investigated its specific expression 
and function in activated microglia and macrophages. AMWAP attenuates pro-
inflammatory cytokine and chemokine expression, while promoting expression of 
alternative activation markers. AMWAP also regulates microglial migration and 
chemotaxis and it directly exerts anti-bacterial activity. 
Although initially identified in early activated microglia from retinoschisin-deficient 
retinas, induced AMWAP transcript levels were also detected in activated microglia 
stimulated with multiple TLR ligands including LPS, CpG oligonucleotides, 
PAM3SCK4 as well as IFN-γ. Up-regulation of AMWAP by these pro-inflammatory 
stimuli was critically dependent on NFkB but also involves new protein synthesis. 
AMWAP mRNA expression was highly enriched in microglia and other tissue 
macrophages, but transcripts were absent in all other mouse tissues studied so far. 
These findings on TLR-dependent and microglia/macrophage-restricted expression 
correlate well with the major influence of NFkB and PU.1 in the transcriptional control 
of the AMWAP gene. PU.1 is a key transcription factor in myeloid cells, with high 
expression levels in activated retinal microglia (Weigelt et al. 2007; Walton et al. 
2000). Although the precise mechanisms underlying the activation-dependent 
induction of AMWAP are not fully understood, we postulate that PU.1 plays a critical 
role in AMWAP expression by direct binding to the proximal promoter. 
Immune-related genes including cytokines and chemokines, as well as their 
receptors are often organized in chromosomal clusters or miniclusters (Rowell et al. 
2008; Colobran et al. 2007; Zlotnik et al. 2006). In agreement with this concept, the 
murine AMWAP gene is located in close proximity to a cluster of the chemokine 
genes Ccl3, Ccl4, Ccl5, Ccl6, and Ccl9. On the other side, the AMWAP gene is 
flanked by the WAP protein extracellular peptidase inhibitor precursor (Expi), which 
shares 83% sequence homology possibly suggesting a gene duplication event. Our 
ChIP-Chip and ChIP-PCR assays have revealed that the AMWAP promoter, but not 
the Expi region are bound by PU.1 and the co-activators Cbp and p300. These 
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findings are consistent with microglia/macrophage-restricted expression of AMWAP 
and the ubiquitous expression of Expi (D. Jung et al. 2004). Likely, the different 
expression patterns and regulation of both genes coincides with different cellular 
functions. In line with this, Expi was identified as a protein over-expressed in non-
metastatic mammary cancer cells (Dear et al. 1989; Dear et al. 1988) and ectopic 
expression of Expi resulted in induced apoptosis of mammary epithelial cells (D. Jung 
et al. 2004). 
Together with SLPI (Mueller et al. 2008), the best studied WAP protein so far, 
AMWAP is the only other WAP family member expressed and regulated in microglia. 
SLPI transcript levels were markedly increased in experimental autoimmune 
encephalomyelitis and a role for SLPI in the promotion of tissue repair was discussed 
(Mueller et al. 2008). SLPI can be secreted by activated macrophages and acts as a 
suppressor of LPS response (F. Y. Jin et al. 1997). The inhibition of LPS-induced NO 
and TNF production in macrophage cell lines by SLPI is independent of its anti-
protease function (J. Yang et al. 2005). Intracellular SLPI also competes with NFkB 
for binding sites in the promoters of pro-inflammatory cytokines (Taggart 2002) and 
blocks LPS-induced IκBα-degradation (Rubartelli & Lotze 2007). Both mechanisms 
may also be relevant for AMWAP function. Support for the hypothesis that AMWAP 
similar to SLPI interferes with NFkB signaling comes from our finding that Ccl2 
promoter activity was directly repressed by AMWAP. 
Two major questions relate to why and how AMWAP expression is induced during 
microglia activation in retinal degeneration. Since no obvious infection is present in 
the gene mutation-based model of retinoschisin-deficient retinas, we speculate that 
AMWAP is induced by damage-associated-molecular-patterns (DAMPs) (Oppenheim 
& D. Yang 2005) and/or alarmins (Scheibner et al. 2006). Our data on the rapid 
induction of AMWAP in early retinal degeneration and the TLR-dependent up-
regulation in BV-2 cells support the assumption that AMWAP may respond very 
sensitive to DAMPs. Innate immune cells are often recruited to injured areas by 
matrix degradation products (Klune et al. 2008) or actively secreted alarmin 
molecules like HMGB1 (Odaka et al. 2003), consequently initiating tissue remodeling 
and repair. Related to this, a secreted and a non-secreted intracellular form of SLPI 
were both induced in mouse macrophages after exposure to apoptotic cells 
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(Sheehan et al. 2007), indicating that SLPI may promote clearance of dying cells in 
the absence of inflammation. AMWAP may have a similar “alarmin-like” function in 
the degenerating retina and thereby may limit microglial activation. 
A hallmark of retinal degeneration in the retinoschisin-deficient mouse model is the 
rapid migration of activated microglia into the photoreceptor and ganglion cell layer 
(Ebert et al. 2009). Ccl2, an important chemoattractant is strongly expressed in  
Rs1h-/Y retinas (Gehrig et al. 2007) and we demonstrated that AMWAP over-
expression down-regulated Ccl2 transcripts in microglia. Furthermore, AMWAP 
diminished BV-2 cell migration and inhibited the serine protease trypsin. Recent data 
indicated that Ccl2 is proteolytically activated by the serine protease plasmin and that 
plasmin-deficient mice were resistant to excitotoxic neurodegeneration (Shai 2002). 
Thus, in addition to its effect on Ccl2 gene expression, AMWAP may impair Ccl2-
mediated migration of microglia by limiting proteolytic processing of Ccl2. 
Our study also suggests that recombinant AMWAP has a potent anti-microbial 
activity. Most bactericidal proteins have a cationic surface that bind negatively 
charged phospholipids and thereby disturb the integrity of bacterial membranes 
(Hagiwara et al. 2003). Although AMWAP has a lower predicted positive charge than 
SLPI and elafin (Moreau et al. 2008), we detected significant antimicrobial activity 
against E. coli, P. aeruginosa and B. subtilis at micromolar concentrations. The 
domain signature of AMWAP is related to the anti-microbial single-WAP-domain 
proteins SWAM1 and SWAM2 (Hagiwara et al. 2003). We therefore speculate that 
local positive charges on the 3D protein surface of AMWAP could be important for 
antibacterial activity (Zasloff 2002). 
Although the precise mechanisms remain to be determined, the data described in 
this study suggest that AMWAP induction by neuronal degeneration and 
inflammatory signals is an important counter-regulatory response in microglial and 
macrophage activation. Moreover, AMWAP seems to actively support alternative 
activation of microglia and macrophages. AMWAP could be a potential candidate for 
modulating the homeostasis of microglia and thereby limit neurotoxicity and apoptotic 
degeneration. AMWAP-deficient mice will be a valuable tool to further characterize 
the in vivo role of this novel WAP protein in microglia and macrophage function.  
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Abstract 
Background 
Microglial cells are important effectors of the neuronal innate immune system with a 
major role in chronic neurodegenerative diseases. Curcumin, a major component of 
tumeric, alleviates pro-inflammatory activities of these cells by inhibiting nuclear 
factor kappa B (NFkB) signaling. To study the immuno-modulatory effects of 
Curcumin on a transcriptomic level, DNA-microarray analyses were performed with 
resting and LPS-challenged microglial cells after short-term treatment with Curcumin. 
Methods 
Resting and LPS-activated BV-2 cells were stimulated with Curcumin and genome-
wide mRNA expression patterns were determined using DNA-microarrays. Selected 
qRT-PCR analyses were performed to confirm newly identified Curcumin-regulated 
genes. The migration potential of microglial cells was determined with wound healing 
assays and transwell migration assays. Microglial neurotoxicity was estimated by 
morphological analyses and quantification of caspase 3/7 levels in 661W 
photoreceptors cultured in the presence of microglia-conditioned medium. 
Results 
Curcumin treatment markedly changed the microglial transcriptome with 49 
differentially expressed transcripts in a combined analysis of resting and activated 
microglial cells. Curcumin effectively triggered anti-inflammatory signals as shown by 
induced expression of Interleukin 4 and Peroxisome proliferator activated receptor α. 
Several novel Curcumin-induced genes including Netrin G1, Delta-like 1, Platelet 
endothelial cell adhesion molecule 1, and Plasma cell endoplasmic reticulum protein 
1, have been previously associated with adhesion and cell migration. Consequently, 
Curcumin treatment significantly inhibited basal and activation-induced migration of 
BV-2 microglia. Curcumin also potently blocked gene expression related to pro-
inflammatory activation of resting cells including Toll-like receptor 2 and 
Prostaglandin-endoperoxide synthase 2. Moreover, transcription of NO synthase 2 
and Signal transducer and activator of transcription 1 was reduced in LPS-triggered 
microglia. These transcriptional changes in Curcumin-treated LPS-primed microglia 
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also lead to decreased neurotoxicity with reduced apoptosis of 661W photoreceptor 
cultures. 
Conclusions 
Collectively, our results suggest that Curcumin is a potent modulator of the microglial 
transcriptome. Curcumin attenuates microglial migration and triggers a phenotype 
with anti-inflammatory and neuroprotective properties. Thus, Curcumin could be a 
nutraceutical compound to develop immuno-modulatory and neuroprotective 
therapies for the treatment of various neurodegenerative disorders. 
Background 
Microglial cells are resident macrophages of the nervous system with pivotal roles in 
innate immune regulation and neuronal homeostasis (Hanisch & Kettenmann 2007; 
Streit 2002). They are cells of the mononuclear phagocyte lineage but their unique 
localization within the nervous system and their morphological features clearly 
distinguish them from other macrophage populations (Giulian et al. 1995). Ramified 
microglial cells actively scan their environment with their long protrusions (Davalos et 
al. 2005; Nimmerjahn et al. 2005) and continuous inhibitory signals from neurons 
prevent microglial toxicity (Broderick et al. 2002; Cardona et al. 2006). Disconnection 
of the microglia-neuron cross-talk (Dick 2003), local danger signals such as released 
ATP (Haynes et al. 2006), or neurotransmitter gradients (Ransohoff & Perry 2009) 
can lead to a functional transformation of microglial populations with a variety of 
effector functions. Consequently, alarmed microglia and reactive microgliosis have 
been identified in a variety of neurodegenerative diseases including Alzheimer’s 
disease (Khoury & Luster 2008), Parkinson’s disease (Orr et al. 2002), amyotrophic 
lateral sclerosis (Sargsyan et al. 2005), multiple sclerosis (Raivich & Banati 2004), 
and inherited photoreceptor dystrophies (Langmann 2007). The concept of a 
microglia-targeted pharmacotherapy to prevent neurodegeneration in the brain and 
the retina is therefore a promising approach under active investigation (Schuetz & 
Thanos 2004; Schwartz 2007). 
There is a growing interest in the identification of natural compounds that limit 
neuroinflammation and simultaneously support neuronal survival (Zhang et al. 2009; 
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Jang & Johnson 2010). Among the naturally occuring immuno-modulators, Curcumin 
((E,E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione), a major con- 
stituent of tumeric, is a herbal medicine used for centuries in India and China 
(Ammon & Wahl 1991). Curcumin has a wide range of pharmacological activities 
including anti-inflammatory, anti-microbial, antioxidant, and anti-tumor effects 
(Maheshwari et al. 2006). Curcumin is a particularly potent immuno-regulatory agent 
that can modulate the activation and function of T-cells, B-cells, neutrophils, natural 
killer cells and macrophages (Jagetia & Aggarwal 2007).  
Curcumin treatment effectively inhibits the activation of microglial cells by diminishing 
the production of nitric oxide (K. K. Jung et al. 2006) and reducing the secretion of 
pro-inflammatory cytokines such as Il1β, Il6 and TNF (C.-Y. Jin et al. 2007a). 
Moreover, Curcumin blocks the LPS-mediated induction of cyclooxygenase-2 (COX2) 
via inhibition of the transcription factors nuclear factor kappa B (NFkB), activator 
protein 1 (AP1), and signal transducers and activators of transcription (STATs)  
(Kang et al. 2004; H. Kim et al. 2003). Recent experiments have also demonstrated 
that Curcumin protects dopaminergic neurons against microglia-mediated 
neurotoxicity (He et al. 2010), limits brain inflammation (S. Yang et al. 2008), and 
rescues retinal cells from stress-induced cell death (Mandal et al. 2009). 
The inhibitory role of Curcumin on pro-inflammatory gene expression in microglia is 
well documented. However, this information is limited to only a few well-studied 
examples including pro-inflammatory cytokines, Nos2 and COX2. In a genome-wide 
search for target genes, we investigated the transcriptomic effects of Curcumin in 
resting and LPS-activated BV-2 microglial cultures using DNA-microarrays. 
Furthermore, we validated the Curcumin-regulated expression of microglial 
transcripts with qRT-PCR and studied the related microglial migration and 
neurotoxicity. 
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Methods 
Reagents 
Curcumin and E.coli 0111:B4 lipopolysaccharide were purchased from Sigma Aldrich 
(Steinheim, Germany). Curcumin was dissolved in DMSO and added in 
concentrations that did not exceed 0.05% of the total volume in any of the cell culture 
experiments. 
Cell culture 
BV-2 microglia-like cells were provided by Professor Ralph Lucius (Clinic of 
Neurology, Christian Albrechts University, Kiel, Germany). BV-2 cells were cultured  
in RPMI/5% FCS supplemented with 2mM L-Glutamine and 195 nM  
β-mercaptoethanol. BV-2 cells were stimulated with 100 ng/ml LPS, 20 µM of 
Curcumin, or DMSO as control for 6 h. These stimulation conditions were adapted 
from previously published experiments (C.-Y. Jin et al. 2007a; Dirscherl et al. 2010). 
MTT assays revealed that 100 ng/ml LPS, 20 µM Curcumin, or a combination of both 
had no cytotoxic effects on BV-2 cells (data not shown). 661W photoreceptor-like 
cells were a gift from Prof. Muayyad Al-Ubaidi (University of Illinois, Chicago, IL) and 
the culture conditions have been described elsewhere (Ebert et al. 2008). 
Scratch assay 
500.000 BV-2 cells were grown in 6-well plates as 80% confluent monolayers and 
were wounded with a sterile 100 µl pipette tip. Thereafter, the cells were stimulated 
with 100 ng/ml LPS, 20 µM of Curcumin, 100 ng/ml LPS + 20 µM of Curcumin, or 
DMSO as solvent control. Migration into the open scar was documented with 
microphotographs at different time points after wounding. The number of migrating 
cells was quantified by counting all cells within a 0.4 mm2 region in the center of each 
scratch. A minimum of 5 individual cultures was used to calculate the mean migratory 
capacity of each cell culture condition. 
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Transwell migration assay 
The Costar Transwell System (8-µm pore size polycarbonate membrane) was used 
to evaluate vertical cell migration. 1 Mio BV-2 cells in 1.5 ml serum-free medium were 
added to the upper well, and 2.6 ml serum-free medium was added to the lower 
chamber. 100 ng/ml LPS, 20 µm Curcumin, 100 ng/ml LPS + 20 µm Curcumin, or 
DMSO as solvent control were added to the lower chamber medium. At the end of a 
24 h incubation period, cells that had migrated to the lower surface were quantified 
by counting the migrated cells on the lower surface of the membrane using 
microscopy. 
661W co-culture in microglia-conditioned medium and apoptosis assay 
To test microglial neurotoxicity, a culture system of 661W photoreceptors with 
microglia conditioned medium was established. 661W cells were incubated for 48 h 
either in their own medium or with culture supernatants from unstimulated, 100 ng/ml 
LPS, 20 µM Curcumin, or 100 ng/ml LPS + 20 µM Curcumin treated microglial cells. 
The 661W cell morphology was assessed by phase contrast microscopy and 
apoptotic cell death was determined with the Caspase-Glo® 3/7 Assay (Promega). 
Cells were lysed and incubated with a luminogenic caspase-3/7 substrate, which 
contains the tetrapeptide sequence DEVD. Luminescence was then generated by 
addition of recombinant luciferase and was proportional to the amount of caspase 
activity present. The luminescent signal was read on a BMG FluoStar Optima plate 
reader (Labtech, Offenburg, Germany). A blank reaction was used to measure 
background luminescence associated with the cell culture system and Caspase-Glo® 
3/7 Reagent. The value for the blank reaction was subtracted from all experimental 
values. Negative control reactions were performed to determine the basal caspase 
activity of 661W cells. Relative luciferase units (RLU) reflect the level of apoptotic cell 
death in the different 661W cell cultures. 
RNA isolation and reverse transcription 
Total RNA was extracted from cultured microglial cells according to the manufactu-
rer's instructions using the RNeasy Protect Mini Kit (Qiagen, Hilden, Germany). Purity 
and integrity of the RNA was assessed on the Agilent 2100 bioanalyzer with the RNA 
6000 Nano LabChip® reagent set (Agilent Technologies,  Böblingen, Germany). 
Results 
 
55 
The RNA was quantified spectrophotometrically and then stored at −80 °C. First-
strand cDNA synthesis was performed with RevertAid™ H Minus First Strand cDNA 
Synthesis Kit (Fermentas, St. Leon-Rot, Germany).  
DNA-microarray analysis 
4x44K microarrays (014868) (Agilent Technologies) were used for hybridization with 
three independent RNAs from non-stimulated BV-2 microglial cells or cultures treated 
for 6 h with 20 µM Curcumin, 100 ng/ml LPS, or 20 µM Curcumin + 100 ng/ml LPS, 
respectively. Briefly, 200 ng of total RNA were labeled with Cy3 using the Agilent 
Quick-Amp Labeling Kit - 1 color according to the manufacturer´s instructions. cRNA 
was purified with the RNeasy Mini Kit (Qiagen) and labeling efficiency was 
determined with a NanoDrop ND-1000 photometer (PeqLab). The arrays were 
incubated with cRNAs in Agilent SureHyb chambers for 17 hours at 65°C while 
rotating. After washing, scanning was done with the Agilent G2565CA Microarray 
Scanner System and the resulting TIFF files were processed with Agilent Feature 
Extraction software (10.7.). Minimum information about a microarray experiment 
(MIAME) criteria were met (Brazma et al. 2001). The microarray dataset of this study 
is publicly available at the National Center for Biotechnology Information Gene 
Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) as series record GSE23639. 
Bioinformatic data analysis 
Integrative analysis of genome-wide expression activities from BV-2 cells was 
performed with the Gene Expression Dynamics Inspector (GEDI), a Matlab 
(Mathworks, Natick, MA) freeware program which uses self-organizing maps (SOMs) 
to translate high-dimensional data into a 2D mosaic (Eichler et al. 2003). Each tile of 
the mosaic represents an individual SOM cluster and is color-coded to represent high 
or low expression of the cluster's genes, thus identifying the underlying pattern. The 
Partek Genomics Suite (Partek Inc.) was used for ANOVA analysis and hierarchical 
clustering of normalized expression values. Differentially regulated transcripts in 
Curcumin-stimulated versus non-treated and Curcumin + LPS versus LPS-treated 
BV-2 cells, respectively, were retrieved with the Genomatix ChipInspector program 
(Genomatix Software GmbH, Munich, Germany), applying the Significance Analysis 
of Microarray (SAM) algorithm using a false-discovery rate of 0.1%. 
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Quantitative real-time RT-PCR 
Amplifications of 50 ng cDNA were performed with an ABI7900HT machine (Applied 
Biosystems) in triplicates in 10 µl reaction mixtures containing 1×TaqMan Universal 
PCR Master Mix (Applied Biosystems), 200nM of primers and 0.25 µl dual-labeled 
probe (Roche Probe Library). The reaction parameters were as follows: 2-min 50 °C 
hold, 30-min 60 °C hold, and 5-min 95 °C hold, followed by 45 cycles of 20-s 94 °C 
melt and 1-min 60 °C anneal/extension. Measurements were performed in triplicate. 
Results were analyzed with an ABI sequence detector software version 2.3 using the 
ΔΔCt method for relative quantitation. A Ct (cycle threshold) <35 was used as cutoff 
for estimating significantly expressed transcripts and cDNA samples with values >35 
were marked with n.e. for not expressed. Ct-values between 35 and 40 were solely 
used for calculation of relative expression differences in treated cells versus control 
cells. Primer sequences and Roche Library Probe numbers are listed in Table 1. 
Table 1 Primer pairs and Roche library probes for real-time qRT-PCR validation 
Gene F-Primer (5'-3') R-Primer (5'-3') Roche Library Probe 
Atp5b ggcacaatgcaggaaagg tcagcaggcacatagatagcc 77 
C3 accttacctcggcaagtttct ttgtagagctgctggtcagg 76 
Ccl2 catccacgtgttggctca gatcatcttgctggtgaatgagt 62 
Dll1 ttcaactgtgagaagaagatggat gccgaggtccacacactt 103 
Egr2 ctacccggtggaagacctc aatgttgatcatgccatctcc 60 
Il4 catcggcattttgaacgag cgagctcactctctgtggtg 2 
Il6 gatggatgctaccaaactggat ccaggtagctatggtactccaga 6 
Nos2 ctttgccacggacgagac tcattgtactctgagggctga 13 
Ntng1 aggggcaagagaccaagg agggatggtgtctatcgtcct 103 
Pecam1 cggtgttcagcgagatcc cgacaggatggaaatcacaa 45 
Perp1 tcatatgccggctcacct atccactggcgtctggagt 110 
Pparα ccgagggctctgtcatca gggcagctgactgaggaa 11 
Ptgs2 gatgctcttccgagctgtg ggattggaacagcaaggattt 45 
Stat1 aaatgtgaaggatcaagtcatgtg catcttgtaattcttctagggtcttga 15 
Tlr2 accgaaacctcagacaaagc cagcgtttgctgaagagga 49 
Statistical analyses 
Statistical analyses were performed on ΔΔCt data using the Mann-Whitney Rank 
Sum test and quantitative expression data are expressed as mean ± SD plotted at a 
logarithmic scale. Gene expression levels in control BV-2 cells were used as 
calibrators. The Student´s t test or Mann-Whitney Rank Sum test were used for the 
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comparison of experimental groups in cell migration assays and apoptosis assays as 
indicated. p<0.05 was considered significant. 
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Results 
Curcumin has a major impact on the microglial transcriptome 
To determine the transcriptional profiles of resting and LPS-activated BV-2 microglial 
cells after treatment with 20 µM Curcumin for 6 h, we performed DNA-microarray 
analyses from three independent stimulations. We first applied the Gene Expression 
Dynamics Inspector (GEDI) on the complete dataset to visualize the global patterns 
of gene expression in the four different conditions, untreated, Curcumin-treated, LPS-
treated, and Curcumin + LPS-treated cells. GEDI uses self-organizing maps to 
capture genome-wide transcriptome activity via ‘gestalt’ recognition  
(Eichler et al. 2003). GEDI facilitates the identification of genome-wide patterns with 
each mosaic tile in the map representing a gene cluster that is expressed at similar 
levels. The four GEDI maps, with blue color indicating low and red color high mRNA 
expression levels, show a dynamic regulation of gene transcription in the cultured 
microglial cells (Fig. 14A). 
  
Figure 14 Curcumin influences global gene expression in resting and LPS-activated BV-2 
microglial cells. (A) Gene Expression Dynamics Inspector (GEDI) analysis of the complete DNA-
microarray dataset from control BV-2 cells or cells treated with 20 µM Curcumin, 100 ng/ml LPS,  
or 20 µM Curcumin + 100 ng/ml LPS for 6 hours. The white rectangles and circles denote the most 
prominent expression changes in corresponding gene clusters. (B) Hierarchical clustering of 
normalized expression levels after one-way ANOVA at p<0.01. Triplicate microarrays were analyzed 
for each condition and the pseudo-color scale indicates high (red) or low (blue) expression levels.  
LPS and Curcumin-related clusters are marked with A and B, respectively.  
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The major difference between Curcumin-treated resting microglial cells and control 
cells was a region with higher expression at the bottom of the map (Fig. 14A,  
white rectangles). In the LPS-treated condition, mimicking a highly activated state, 
elicited a largely converse expression pattern with a pronounced area of weakly 
expressed genes (Fig. 14A, white circles). These data indicate that Curcumin 
stimulates gene expression in resting, non-activated cells but mainly dampens 
activation-associated transcriptional programs in LPS-primed microglia. 
We next calculated hierarchical clusters of each individual microarray dataset after 
filtering for significantly altered gene expression using one way ANOVA at p<0.01. 
This analysis showed a clear separation of the four different conditions with their own 
characteristic gene expression profiles (Fig. 14B). The clustering revealed two 
distinct groups of inversely regulated genes. Group A (Fig. 14B) contains LPS-
induced genes, which are no longer up-regulated in the presence of Curcumin. 
Group B (Fig. 14B) represents genes selectively up-regulated by Curcumin treatment 
of resting microglial cells. Together with the GEDI analysis, these results 
demonstrate that stimulation with Curcumin impacts distinct patterns of gene 
expression in resting and LPS-activated microglial cells, respectively. 
To narrow down the identified global gene clusters to a subset of genes with 
significantly different mRNA expression in the different Curcumin-treated conditions, 
we used the Genomatix ChipInspector tool applying the Significance Analysis of 
Microarray (SAM) algorithm at a false discovery rate of 0.1% and a minimum fold 
change of 2.0 (Weigelt et al. 2009). Thereby, 35 significantly regulated transcripts 
were identified in Curcumin-treated versus resting microglial cells (Table 2) and 30 
differentially expressed genes were detected in Curcumin + LPS versus LPS-
stimulated cells (Table 3). Comparison of the total numer of differentially expressed 
transcripts and considering overlapping gene sets revealed that Curcumin affects 
both resting and LPS-activated BV-2 cells. 
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Table 2 Differentially expressed transcripts after 6 h stimulation of BV-2 cells with  
20µM Curcumin 
Nr ID Symbol Gene Name FC  
UP-REGULATED 
1 80883 Ntng1 Netrin G1 313.0  
2 18613 Pecam1 Platelet/endothelial cell adhesion molecule 1 42.8  
3 13388 Dll1 Delta-like 1 35.5  
4 12824 Col2a1 Collagen, type II, alpha 1 21.6  
5 14103 Fasl Fas ligand (TNF superfamily, member 6) 12.8  
6 12653 Chgb Chromogranin B 11.9  
7 66184 Rps4y2 Ribosomal protein S4, Y-linked 2 9.7  
8 69816 Perp1 RIKEN cDNA 2010001M09 gene 9.7  
9 16992 Lta Lymphotoxin A 9.4  
10 19206 Ptch1 Patched homolog 1 5.9  
11 19013 Ppara Peroxisome proliferator activated receptor alpha 4.6  
12 109685 Hyal3 Hyaluronoglucosaminidase 3 4.5  
13 20997 T Brachyuri 4.2  
14 17246 Mdm2 Transformed mouse 3T3 cell double minute 2 3.1  
15 14102 Fas Fas 2.8  
16 14183 Fgfr2 Fibroblast growth factor receptor 2 2.7  
17 13645 Egf Epidermal growth factor 2.2  
18 14179 Fgf8 Fibroblast growth factor 8 2.1  
19 20655 Sod1 Superoxide dismutase 1 2.1  
20 14526 Gcg Glucagon 2.0  
DOWN-REGULATED 
1 24088 Tlr2 Toll-like receptor 2 -6.9  
2 18505 Pax3 Paired box gene 3 -6.6  
3 14281 Fos FBJ osteosarcoma oncogene -4.4  
4 11622 Ahr Aryl-hydrocarbon receptor -4.1  
5 16835 Ldlr Low density lipoprotein receptor -3.8  
6 13654 Egr2 Early growth response 2 -3.5  
7 68010 Bambi BMP and activin membrane-bound inhibitor -3.3  
8 12048 Bcl2l1 BCL2-like 1 -3.3  
9 19225 Ptgs2 Prostaglandin-endoperoxide synthase 2 -3.0  
10 20296 Ccl2 Chemokine (C-C motif) ligand 2 -2.8  
11 12393 Runx2 Runt related transcription factor 2 -2.8  
12 17311 Kitl Kit ligand -2.4  
13 16869 Lhx1 LIM homeobox protein 1 -2.4  
14 12977 Csf1 Colony stimulating factor 1 -2.4  
15 20528 Slc2a4 Solute carrier family 2, member 4 -2.2  
Significance analysis of triplicate microarrays was performed with a false discovery rate of 0.1%. ID, Entrez Gene ID;  
FC: Fold change. 
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Table 3 Differentially expressed transcripts after 6 h stimulation with 20 µM Curcumin  
+ 100 ng/ml LPS versus 100 ng/ml LPS 
Nr ID Symbol Gene Name FC  
UP-REGULATED 
1 80883 Ntng1 Netrin G1 86.2  
2 18613 Pecam1 Platelet/endothelial cell adhesion molecule 1 11.7  
3 12824 Col2a1 Collagen, type II, alpha 1 9.0  
4 12653 Chgb Chromogranin B 8.1  
5 14103 Fasl Fas ligand (TNF superfamily, member 6) 6.9  
6 19206 Ptch1 Patched homolog 1 6.5  
7 69816 Perp1 RIKEN cDNA 2010001M09 gene 5.4  
8 14526 Gcg Glucagon 5.0  
9 109685 Hyal3 Hyaluronoglucosaminidase 3 4.1  
10 16189 Il4 Interleukin 4 3.8  
11 20655 Sod1 Superoxide dismutase 1 3.5  
12 19013 Ppara Peroxisome proliferator activated receptor alpha 3.1  
13 20997 T Brachyuri 2.6  
14 640627 Gm9789 ENSMUSG00000044227 2.6  
15 16147 Ihh Indian hedgehog homolog 2.6  
16 17246 Mdm2 Transformed mouse 3T3 cell double minute 2 2.5  
17 99439 Duox1 Dual oxidase 1 2.3  
18 257956 Olfr1307 Olfactory receptor 1307 2.3  
19 14179 Fgf8 Fibroblast growth factor 8 2.1  
DOWN-REGULATED 
1 16193 Il6 Interleukin 6 -93.1  
2 18126 Nos2 Nitric oxide synthase 2 -55.7  
3 19225 Ptgs2 Prostaglandin-endoperoxide synthase 2 -17.6  
4 20296 Ccl2 Chemokine (C-C motif) ligand 2 -14.7  
5 12266 C3 Complement C3 -9.1  
6 20846 Stat1 Signal transducers and activator of transcription 1 -7.4  
7 12048 Bcl2l1 BCL2-like 1 -5.4  
8 14281 Fos FBJ osteosarcoma oncogene -4.6  
9 16835 Ldlr Low density lipoprotein receptor -4.1  
10 16992 Lta Lymphotoxin A -3.5  
11 17395 Mmp9 Matrix metallopeptidase 9 -2.2  
Significance analysis of triplicate microarrays was performed with a false discovery rate of 0.1%. ID, Entrez Gene ID;  
FC: Fold change. 
qRT-PCR confirmation of novel Curcumin target genes in microglial cells 
To validate selected differentially expressed genes identified by DNA-microarrays, 
real-time qRT-PCR assays were performed with RNA samples from three Indepen-
dent BV-2 stimulation series. We especially focused ongenes which have not been 
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previously shown to be Curcumin targets. In the first set of experiments, mRNA levels 
of genes highly up-regulated by Curcumin compared to control cells were assessed 
(Fig. 15). Transcripts of Netrin G1 (Ntng1), Platelet endothelial cell adhesion 
molecule 1 (Pecam1), Delta-like 1 (Dll1), Plasma cell endoplasmic reticulum protein 1 
(Perp1), Peroxisome proliferator activated receptor alpha (PPARα), and Interleukin 4 
(Il4) were all significantly increased by stimulation with Curcumin (Fig. 15). 
  
Figure 15 Curcumin induces genes related to adhesion and anti-inflammatory response. 
Real-time qRT-PCR validation of transcripts in BV-2 microglia stimulated with 20 µM Curcumin, 100 
ng/ml LPS, or 20 µM Curcumin + 100 ng/ml LPS for 6 hours. Relative mRNA levels were quantified for 
Netrin G1 (Ntng1), Platelet endothelial call adhesion molecule 1 (Pecam1), Delta-like 1 (Dll1), Plasma 
cell induced endoplasmic reticulum protein 1 (Perp1), Peroxisome proliferator activated receptor α 
(PPARα), and Interleukin 4 (Il4). Expression was normalized to the control gene Atp5b and mRNA 
levels (+/- SD) are graphed relative to control cells. Results are calculated from three independent 
experiments performed in triplicate measurements. * p ≤ 0.05, *** p ≤ 0.001 for Curcumin vs. control, 
Mann-Whitney Rank Sum test. n.e., not expressed. 
Ntng1 showed the strongest expression difference with a change of more than  
1800-fold. Perp1 and PPARα transcripts were not significantly expressed in resting 
microglia and were switched on to intermediate levels after Curcumin treatment  
(Fig. 15). All six transcripts after combined LPS/Curcumin treatment remained 
similarly high as after Curcumin stimulation alone, indicating that the effects of 
Curcumin persist in activated microglial cells.  
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In the next series of qRT-PCR experiments, down-regulated transcripts known to be 
involved in pro-inflammatory activation of microglial cells were analyzed.  
Toll-like receptor 2 (Tlr2), Early growth response 2 (Egr2), Prostaglandin 
endoperoxide synthase 2 (Ptgs2, alias Cox2), and Chemokine (C-C-motif) ligand 2  
(Ccl2, alias Mcp1) showed diminished transcript levels in Curcumin-treated resting 
BV-2 cells (Fig. 16A).  
 
Figure 16 Real-time qRT-PCR validation of transcripts in BV-2 microglia stimulated with 20 
µM Curcumin, 100 ng/ml LPS, or 20 µM Curcumin + 100 ng/ml LPS for 6 hours. Relative mRNA 
levels were quantified for (A) Toll-like receptor 2 (Tlr2), Early growth response 2 (Egr2), Prostaglandin 
endoperoxide synthase 2 (Ptgs2), Chemokine ligand 2 (Ccl2), and (B) Interleukin 6 (Il6), Nitric oxide 
synthase 2 (Nos2, alias iNos), Signal transducer and activator of transcription 1 (Stat1), Complement 
C3 (C3). Expression was normalized to the control gene Atp5b and mRNA levels (+/- SD) are graphed 
relative to control cells. Results are calculated from three independent experiments performed in 
triplicate measurements. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 for Curcumin vs. control, and # p ≤ 0.05, 
## p ≤ 0.01 for Curcumin + LPS vs. LPS, Mann-Whitney Rank Sum test. 
In the activated state, microglial cells also had the tendency to expressed lower 
amounts of these transcript but only Ccl2 levels reached the level of statistical 
significance. When LPS-activated BV-2 cells were incubated in the presence of 
Curcumin, transcription of Interleukin 6 (Il6), nitric oxide synthase 2 (Nos2, alias 
iNos), Signal transducer and activator of transcription 1 (Stat1), and Complement 
factor C3 (C3) were all repressed (Fig. 16B). 
Curcumin has an inhibitory effect on microglial migration 
The induction of several transcripts related to cell motility and adhesion  
(Ntng1, Pecam1, and Perp1) prompted us to study the effect of Curcumin on 
microglial migration. We first cultured BV-2 microglia on plastic dishes until 80% 
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confluence and then created a scratch with a pipette tip. 12 hours after stimulation of 
resting microglia or LPS-activated cells with 20 µM of Curcumin, migration into the 
cell-free scratch area was documented. Representative microscopic images clearly 
showed that Curcumin-treated resting cells as well as activated BV-2 cells exhibit a 
highly reduced migratory potential (Fig. 17A).  
 
Figure 17 Curcumin reduces microglial migration. (A, B) Scratch assays in BV-2 microglia 
treated with solvent control, 20 µM Curcumin, 100 ng/ml LPS, or 20 µM Curcumin + 100 ng/ml LPS for 
12 hours. (A) Micrographs from one representative experiment out of five independent experiments 
are shown. (B) Results of scratch assays are calculated mean values ± SEM from five independent 
experiments. (C) Transwell chamber migration of BV-2 microglial cells treated with solvent control,  
20 µM Curcumin, 100 ng/ml LPS, or 20 µM Curcumin + 100 ng/ml LPS for 24 hours. The absolute 
number of migrating cells was counted in the lower chamber and mean values ± SEM are displayed. p 
≤ 0.05 for Curcumin vs. control, and # p ≤ 0.05 for Curcumin + LPS vs. LPS, Student’s t test. 
The statistical analysis of five independent experiments revealed a significantly 
reduced number of migrating cells when Curcumin was present in the culture medium 
(Fig. 17B). As an independent measure of microglial cell motility and to study the  
long term effects of Curcumin, we performed transwell migration assays over a 
period of 24 hours. Similar as in the scratch assays, the migratory capacity of  
BV-2 cells was not changed by the activation agent LPS alone (Fig. 17C).  
In both, the resting and the activated microglial phenotype, Curcumin caused a 
significant attenuation of microglial migration (Fig. 17C). These results indicate  
that Curcumin-mediated signaling events have functional consequences related to 
microglial motility. 
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Curcumin inhibits LPS-induced microglial neurotoxicity 
To test whether the transcriptomic changes in Curcumin-stimulated cells influence 
microglial neurotoxicity, 661W photoreceptor cells were incubated with conditioned 
medium from BV-2 cells. 661W is a retinoblastoma-derived cell line, which represents 
an established model to study microglial neurotoxicity in the special context of retinal 
degeneration (Dirscherl et al. 2010; Ebert et al. 2008; al-Ubaidi et al. 1992).  
 
Figure 18 Curcumin reduces microglial neurotoxicity on photoreceptors. (A) Phase contrast 
micrographs showing morphological changes of 661W photoreceptor cell cultures treated with 
conditioned media from BV-2 cells for 48 hours. The supernatant from control-stimulated, 20 µM 
Curcumin-treated, 100 ng/ml LPS-treated, or 20 µM Curcumin + 100 ng/ml LPS-treated cells was 
added to 661W photoreceptor cells, respectively. The micrographs shown are from one representative 
experiment out of three independent experiments with the same tendencies. (B) Apoptosis-related 
caspase 3/7 activation in 661W photoreceptor cells incubated with conditioned media from control-
stimulated, 20 µM Curcumin-treated, 100 ng/ml LPS-treated, or 20 µM Curcumin + 100 ng/ml  
LPS-treated BV-2 cells. Results are calculated from three independent experiments performed in 
duplicate measurements. * p ≤ 0.05 for LPS vs. control and # p ≤ 0.05 for Curcumin + LPS vs. LPS, 
respectively, Mann-Whitney Rank Sum test. RLU, relative luciferase units. 
661W cells were incubated for 48 h with culture supernatants from unstimulated, 
Curcumin-, LPS- or LPS + Curcumin-treated BV-2 cells and 661W photoreceptor cell 
morphology was assessed by phase contrast microscopy. 661W cells in their own 
medium grew in a spindle-like shape with only few rounded apoptotic cells (Fig. 18A). 
Conditioned media from control- or Curcumin-treated microglial cells did not affect 
this morphology (Fig. 18A). In contrast, 661W cells incubated with LPS-stimulated 
BV-2 supernatant appeared apoptotic, leading to larger cell-free areas in the culture 
(Fig. 18A). When conditioned media from LPS + Curcumin-stimulated BV-2 cells was 
used, a nearly normal 661W cell morphology was retained (Fig. 18A). Direct 
incubation of 661W cells with Curcumin, LPS, or both had no effects on the cell 
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cultures (data not shown), demonstrating that the observed changes in 661W cell 
characteristics stem from secreted microglial compounds. 
To corroborate these morphological findings with further functional data, we analyzed 
the influence of microglia-derived products on caspase-related apoptotic cell death. 
661W cells cultured with supernatants from LPS-stimulated BV-2 cells showed a 
significant induction of caspase 3/7 activity (Fig. 18B). When using conditioned media 
from microglial cells co-treated with LPS + Curcumin, 661W apoptosis was still 
present but was significantly diminished (Fig. 18B). These data clearly implicate that 
Curcumin may limit the production of pro-apoptotic compounds in activated microglial 
cells or even promote the release of neurotrophic factors. 
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Discussion 
Oxidative stress and neuroinflammation are major factors in the pathogenesis of 
neurodegenerative disorders (Hirsch & Hunot 2009). Therefore, antioxidant and anti-
inflammatory compounds like Curcumin may be treatment options for this group of 
diseases (Ray & Lahiri 2009). However, only few experimental data are available that 
report on Curcumin-triggered transcriptional mechanisms and direct signaling targets 
in microglia.  
Our transcriptomic analysis in BV-2 cells sheds some light on target genes and 
potential signaling mechanisms. We identified a prominent transcriptional response of 
resting as well as LPS-activated microglial cells after Curcumin treatment. Distinct 
gene clusters were detected that reflect up-regulated and suppressed transcripts in 
both microglial phenotypes. We identifed and validated six genes that were 
constistently induced in resting as well as activated BV-2 cells that have not been 
described as Curcumin targets before. Among these, four Curcumin target genes are 
related to cell migration. Netrin G1 is a lipid-anchored protein that is structurally 
related to the netrin family of axon guidance molecules (J. C. Lin et al. 2003).  
It regulates synaptic interactions between neurons by binding to transmembrane 
netrin G ligands (Woo et al. 2009). Interestingly, the related Netrin 1 molecule is a 
broad inhibitor of leukocyte chemotaxis (Ly et al. 2005) and Netrin G1 may have a 
similar function in microglia. The adhesion molecule PECAM1 is also directly involved 
in monocyte/macrophage migration (Jackson 2003). Another migration-related gene 
induced by Curcumin is Plasma cell endoplasmic reticulum protein 1. PERP 1 is a 
molecular chaperone required for proper folding and secretion of immunoglobulins in 
B-cells (Shimizu et al. 2009; van Anken et al. 2009). Related to our study, a recent 
report linked PERP 1 (alias MZB1) to calcium signaling, activation of integrins and 
cell adhesion (Flach et al. 2010). Expression of the Notch-ligand Delta-like 1 has 
been demonstrated in BV-2 cells and primary rat brain microglial cells, where Notch-1 
signaling negatively regulates TNF release (Cao et al. 2008). Our data show that 
basal Dll1 expression in resting microglial cells can be potently induced by Curcumin, 
which could potentially trigger Notch-signaling to prevent migration associated with 
pro-inflammatory priming of BV-2 cells. 
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These transcriptomic data of Curcumin-treatment promoted us to analyze its effects 
on microglial motility. Both types of assays, the wound healing assays and the 
transwell migration experiments, showed that BV-2 cell migration was significantly 
inhibited by 20 µM Curcumin over a period of 12 hours to 24 hours. These findings 
are in good agreement with papers reporting reduced migration of tumor cells, 
endothelial cells, and dendritic cells after treatment with comparable doses of 
Curcumin (Senft et al. 2010; Sameermahmood et al. 2008; Shirley et al. 2008). In the 
homeostatic state, microglia constantly scan their environment with their long 
protrusions without movement of the somata (Nimmerjahn et al. 2005). In contrast, 
migration of microglial cells is a hallmark of pro-inflammatory and chronic activation 
during early phases of neurodegeneration. Thus, Curcumin may support the 
homeostatic state of microglia and prevent their early and excessive transformation 
into migrating phagocytes. 
It is well known that Curcumin broadly inhibits pro-inflammatory gene expression by 
targeting different signal pathways and transcriptional regulators including NFkB, 
AP1, EGR1, and STAT3 (Shishodia et al. 2007). Our microarray data corroborate 
these findings especially in LPS-activated BV-2 cells by showing Curcumin-triggered 
suppression of Ptgs2, Ccl2, Il6, and Nos2, which are NFkB, AP1, and STAT3 target 
genes (Maheshwari et al. 2006). Moreover, the Curcumin-regulated transcriptomic 
profiles revealed lower gene expression of toll-like receptor 2 in resting microglia and 
complement factor 3 in activated cells. These two factors broadly support the 
conversion of microglial cells to the pro-inflammatory state (H.-Y. Lin et al. 2010;  
R. Fan et al. 2007) and hence Curcumin signaling may abrogate both pathways.  
Our data also showed diminished mRNA expression of the transcription factors Egr2 
and Stat1 following Curcumin-treatment. This indicates that Curcumin may further 
dampen microglial activation by interfering with two other key transcription factors 
expressed in activated microglial cells. In addition to its inhibitory effects on pro-
inflammatory signaling, two well known anti-inflammatory molecules, PPARα and IL4, 
were significantly induced by Curcumin. PPARα and IL4 both specifically inhibit pro-
inflammatory activation of microglial cells (J. Xu et al. 2005; Lyons et al. 2009) and 
some of the immune-dampening effects of Curcumin may be mediated via this 
signaling axis.  
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The cell culture experiments with conditioned media from BV-2 cells showed that 
Curcumin significantly reduced LPS-triggered microglial neurotoxicity on 661W 
photoreceptor cells. We hypothesize that the strong suppression of LPS-induced 
Nos2 transcription by Curcumin is a major pathway responsible for this phenomenon. 
In this context, Mandal et al. have recently demonstrated that Curcumin protects 
661W cells from hydrogen peroxide-induced cell death (Mandal et al. 2009).  
This effect is very likely mediated by the antioxidant and radical-scavenging capacity 
of Curcumin. In a model of light-induced retinal degeneration, Curcumin also 
suppressed inflammatory marker expression in vivo (Mandal et al. 2009), which could 
be potentially mediated by its attenuating effect on retinal microglia. 
Conclusions  
We have shown that Curcumin triggered global changes in the transcriptome of 
resting and LPS-activated microglial cells. In addition to its known function in blocking 
pro-inflammatory gene expression via interference with NFkB signaling, Curcumin 
induced novel anti-inflammatory targets in microglia. Curcumin also significantly 
inhibited microglial migration and cytotoxicity, which are key features of 
neuroinflammation. Our publicily available dataset provides a basis to understand the 
pleiotropic beneficial effects of Curcumin on microglia as key innate immune cells of 
the nervous system. Moreover, the results of this study also underscore the 
importance of Curcumin as a promising dietary compound for the treatment of 
various neurodegenerative disorders associated with inflammation. 
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Abstract 
Background 
Luteolin, a plant derived flavonoid, exerts a variety of pharmacological activities and 
anti-oxidant properties associated with its capacity to scavenge oxygen and nitrogen 
species. Luteolin also shows potent anti-inflammatory activities by inhibiting nuclear 
factor kappa B (NFkB) signaling in immune cells. To better understand the immuno-
modulatory effects of this important flavonoid, we performed a genome-wide 
expression analysis in pro-inflammatory challenged microglia treated with Luteolin 
and conducted a phenotypic and functional characterization. 
Methods 
Resting and LPS-activated BV-2 microglia were treated with Luteolin in various 
concentrations and mRNA levels of pro-inflammatory markers were determined. DNA 
microarray experiments and bioinformatic data mining were performed to capture 
global transcriptomic changes following Luteolin stimulation of microglia. Extensive 
qRT-PCR analyses were carried out for an independent confirmation of newly 
identified Luteolin-regulated transcripts. The activation state of Luteolin-treated 
microglia was assessed by morphological characterization. Microglia-mediated 
neurotoxicity was assessed by quantifying secreted nitric oxide levels and apoptosis 
of 661W photoreceptors cultured in microglia-conditioned medium.  
Results 
Luteolin dose-dependently suppressed pro-inflammatory marker expression in LPS-
activated microglia and triggered global changes in the microglial transcriptome with 
more than 50 differentially expressed transcripts. Pro-inflammatory and pro-apoptotic 
gene expression was effectively blocked by Luteolin. In contrast, mRNA levels of 
genes related to anti-oxidant metabolism, phagocytic uptake, ramification, and 
chemotaxis were significantly induced. Luteolin treatment had a major effect on 
microglial morphology leading to ramification of formerly amoeboid cells associated 
with the formation of long filopodia. When co-incubated with Luteolin, LPS-activated 
microglia showed strongly reduced NO secretion and significantly decreased 
neurotoxicity on 661W photoreceptor cultures. 
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Conclusions 
Our findings confirm the inhibitory effects of Luteolin on pro-inflammatory cytokine 
expression in microglia. Moreover, our transcriptomic data suggest that this flavonoid 
is a potent modulator of microglial activation and affects several signaling pathways 
leading to a unique phenotype with anti-inflammatory, anti-oxidative, and 
neuroprotective characteristics. With the identification of several novel Luteolin-
regulated genes, our findings provide a molecular basis to understand the versatile 
effects of Luteolin on microglial homeostasis. The data also suggest that Luteolin 
could be a promising candidate to develop immuno-modulatory and neuroprotective 
therapies for the treatment of neurodegenerative disorders. 
Background 
Microglia, the resident macrophages of the nervous system, have important roles in 
immune regulation (Hanisch 2002; Hanisch & Kettenmann 2007) and neuronal 
homeostasis (Streit 2002; Streit 2005). Microglia belong to the mononuclear 
phagocyte system but their special localization in the fragile neuronal environment 
and their morphological features clearly distinguish  them from other peripheral 
macrophages (Ransohoff & Perry 2009; Giulian et al. 1995). Ramified microglia 
perform a very active and continuous surveillance function with their long protrusions 
(Davalos et al. 2005; Nimmerjahn et al. 2005). They receive permanent tonic 
inhibitory inputs from neurons to prevent microglial neurotoxicity  
(Broderick et al. 2002; Cardona et al. 2006). Loss of microglia-neuron cross-talk  
(Dick 2003), local danger signals such as extracellular ATP (Haynes et al. 2006), or 
neurotransmitter gradients (Ransohoff & Perry 2009) rapidly lead to a functional 
transformation of ramified microglia with a variety of effector functions. 
Microglia activation is a protective mechanism regulating tissue repair and recovery 
in the early phase of neurodegeneration (Streit 2005). However, excessive or 
sustained activation of microglia often contributes to acute and chronic neuro-
inflammatory responses in the brain and the retina (Hanisch & Kettenmann 2007). 
Activated microglia in the vicinity of degenerating neurons have been identified in a 
broad spectrum of neurodegenerative disorders including Alzheimer’s disease 
(Khoury & Luster 2008), Parkinson’s disease (Orr et al. 2002), amyotrophic lateral 
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sclerosis (Sargsyan et al. 2005), multiple sclerosis (Raivich & Banati 2004), and 
inherited photoreceptor dystrophies (Langmann 2007; Schuetz & Thanos 2004). 
Macrophage heterogeneity and plasticity is very large and the set of marker 
combinations and sub-populations is essentially infinite (Hume 2008). To define a 
simplified conceptual framework, classification into polarized functional categories, 
called M1 and M2 macrophages has been proposed (Gordon & Taylor 2005;  
Mosser 2003). M1 or ‘classically activated’ macrophages produce high levels of 
oxidative metabolites and pro-inflammatory cytokines but also cause damage to 
healthy tissue as side effect (Martinez et al. 2008). M2 or ‘alternatively activated’ 
macrophages promote tissue remodeling and generally suppress destructive immune 
reactions. Information on microglial subsets in the nervous system are relatively 
scarce compared to other tissue macrophages. Nevertheless, recent findings from  
in vitro cultures of the murine microglial cell line MMGT12 (Michelucci et al. 2009) 
and hippocampal microglia from the PS1xAPP Alzheimer´s mouse model  
(Jimenez et al. 2008) implicate that microglia have the ability to differentiate into M1 
and M2 polarized phenotypes. A co-existence of neurotoxic M1 microglia and 
regenerative M2 microglia has been recently documented in the injured mouse spinal 
cord (Kigerl et al. 2009). Microarray-based quantitation of M1 and M2 markers as well 
as functional tests on axonal regrowth after injury demonstrated that a transient anti-
inflammatory and neuroprotective M2 response was rapidly overwhelmed by a 
neurotoxic M1 microglial response (Kigerl et al. 2009). A similar but age-dependent 
switch from alternative to classical activation was shown in PS1xAPP Alzheimer’s 
mice (Jimenez et al. 2008), indicating a common phenomenon in neurodegenerative 
disorders. Compounds that induce the switch of microglia from inflammatory M1 type 
to anti-inflammatory M2 type could therefore be a potential therapeutic agent to 
attenuate neuronal inflammation and boost neuronal recovery (Zhang et al. 2009). 
Several anti-inflammatory drugs have been shown to diminish neuroinflammation, but 
only a few direct functional effects on microglial activity have been elucidated  
(Lleo et al. 2007). Among the naturally occuring immuno-modulators, the flavonoid 
Luteolin (3´,4´,5,7-tetrahydroxyflavone), abundant in parsley, green pepper, celery, 
perilla leaf, and chamomile tea, exerts prominent anti-inflammatory and anti-oxidant 
activities (López-Lázaro 2009). Luteolin suppressed pro-inflammatory cytokine 
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production in macrophages by blocking nuclear factor kappa B (NFkB) and activator 
protein 1 (AP1) signaling pathways (C. Chen et al. 2007) and inhibited the production 
of nitric oxide (Hu & Kitts 2004) and pro-inflammatory eicosanoids  
(Harris et al. 2006). Luteolin also diminshed the release of Tnf and superoxide anions 
in LPS or Interferon-γ treated microglial cell cultures (H.-Q. Chen et al. 2008; 
Rezai-Zadeh et al. 2008) and reduced the LPS-induced IL-6 production in brain 
microglia in vivo (Jang et al. 2008).  
Although the inhibitory function of Luteolin on NFkB and a few selected cytokines is 
well documented in macrophages, a genome-wide search for further molecular 
targets in microglia has not yet been published. Furthermore, the immuno-modulatory 
effects of Luteolin related to the stimulation of distinct functional microglial 
phenotypes has not been investigated before. Therefore, this study investigated the 
global transcriptomic effects of Luteolin at near physiological concentrations  
(Shimoi et al. 1998) alone or in combination with LPS in pure BV-2 microglial 
cultures. We further validated the Luteolin-regulated expression of novel pro- and 
anti-inflammtory microglial transcripts, analyzed microglial morphology, and studied 
the consequences of microglia-conditioned media for photoreceptor viability. 
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Methods 
Reagents 
Luteolin (3´,4´,5,7-tetrahydroxyflavone) and E.coli 0111:B4 lipopolysaccharide were 
purchased from Sigma Aldrich (Steinheim, Germany). Luteolin was dissolved in 
DMSO and added in concentrations that did not exceed 0.05% of the total volume in 
any of the cell culture experiments. 
Animals 
C57BL/6 mice were purchased from Charles River Laboratories. Mice were kept in 
an air-conditioned barrier environment at constant temperature of 20-22°C on a 12h 
light-dark schedule, and had free access to food and water. The health of the animals 
was regularly monitored, and all procedures were approved by the University of 
Regensburg animal rights committee and complied with the German Law on Animal 
Protection and the Institute for Laboratory Animal Research Guide for the Care and 
Use of Laboratory Animals, 1999. 
Cell culture 
Brain microglia were isolated and cultured as described earlier (Ebert et al. 2009). 
BV-2 microglia-like cells were provided by Professor Ralph Lucius  
(Clinic of Neurology, Christian Albrechts University, Kiel, Germany). BV-2 cells were 
cultured in RPMI/5% FCS supplemented with 2mM L-Glutamine and 195 nM  
β-mercaptoethanol. Primary brain microglia or BV-2 cells were stimulated with  
10 ng/ml or 50 ng/ml LPS and various concentrations of Luteolin for 24 h. 661W 
photoreceptor-like cells were a gift from Prof. Muayyad Al-Ubaidi  
(University of Illinois, Chicago, IL) and the culture conditions have been described 
elsewhere (Ebert et al. 2008). 
Phalloidin staining 
BV-2 cells were plated overnight on coverslips, fixed with 3.7% paraformaldehyde for 
10 min at 37°C, permeabilized with 0.2% Triton X-100 for 5 min, blocked with  
5% non-fat milk, 0.2% Triton X-100, and stained with DAPI for 10 min at room 
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temperature (0.1 µg/ml in PBS, 4',6-diamidino-2-phenylindol, Molecular Probes). 
Filamentous actin was stained by addition of 1.5 µM TRITC-conjugated phalloidin 
(Sigma). The coverslips were mounted on microscopic glass slides and viewed with a 
Axioskop 2 fluorescence microscope equipped with an Eclipse digital analyzer  
(Carl Zeiss). 
NO measurement 
NO concentrations were determined by measuring the amount of nitrite secreted by 
BV-2 cells into the culture medium using the Griess reagent system (Promega). 50 µl 
cell culture supernatant was collected and an equal volume of Griess reagent was 
added to each well. After incubation for 15 min at room temperature, the absorbance 
was read at 540 nm on a BMG FluoStar Optima plate reader (Labtech, Offenburg, 
Germany). The concentration of nitrite for each sample was calculated from a sodium 
nitrite standard curve. 
Apoptosis assay 
Apoptotic cell death of 661W cells was determined with the Caspase-Glo® 3/7 Assay 
(Promega). Cells were lysed and incubated with a luminogenic caspase-3/7 
substrate, which contains the tetrapeptide sequence DEVD. Luminescence was then 
generated by addition of recombinant luciferase and was proportional to the amount 
of caspase activity present. The luminescent signal was read on a BMG FluoStar 
Optima plate reader (Labtech, Offenburg, Germany). A blank reaction was used to 
measure background luminescence associated with the cell culture system and 
Caspase-Glo® 3/7 Reagent. The value for the blank reaction was subtracted from all 
experimental values. Negative control reactions were performed to determine the 
basal caspase activity of 661W cells. 
RNA isolation and reverse transcription 
Total RNA was extracted from cultured microglia according to the manufacturer's 
instructions using the RNeasy Protect Mini Kit (Qiagen, Hilden, Germany). Purity and 
integrity of the RNA was assessed on the Agilent 2100 bioanalyzer with the RNA 
6000 Nano LabChip® reagent set (Agilent Technologies, Böblingen, Germany).  
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The RNA was quantified spectrophotometrically and then stored at −80 °C.  
First-strand cDNA synthesis was performed with RevertAid™ H Minus First Strand 
cDNA Synthesis Kit (Fermentas, St. Leon-Rot, Germany).  
DNA microarray analysis 
Triplicate microarrays were carried out with three independent RNAs from non-
stimulated BV-2 microglia or cultures treated for 24 h with 50 µM Luteolin, 50 ng/ml 
LPS, or 50 µM LPS + 50 ng/ml LPS, respectively. Generation of double-stranded 
cDNA, preparation and labeling of cRNA, hybridization to Affymetrix 430 2.0 mouse 
genome arrays, washing, and scanning were performed according to the Affymetrix 
standard protocol. Minimum information about a microarray experiment (MIAME) 
criteria were met (Brazma et al. 2001). The microarray datasets of this study are 
publicly available at the National Center for Biotechnology Information Gene 
Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) as series record GSE18740. 
Bioinformatic data analysis 
The Affymetrix Expression Console Software Version 1.0 was used to create 
summarized expression values (CHP-files) from 3’ expression array feature 
intensities (CEL-files) using the Robust Multichip Analysis (RMA) algorithm. 
Integrative analysis of genome-wide expression activities from BV-2 cells was 
performed with the Gene Expression Dynamics Inspector (GEDI), a Matlab 
(Mathworks, Natick, MA) freeware program which uses self-organizing maps (SOMs) 
to translate high-dimensional data into a 2D mosaic (Eichler et al. 2003). Each tile of 
the mosaic represents an individual SOM cluster and is color-coded to represent high 
or low expression of the cluster's genes, thus identifying the underlying pattern. 
Differentially regulated transcripts in 24 h Luteolin stimulated versus non-treated and 
Luteolin + LPS versus LPS-treated BV-2 cells, respectively, were retrieved with the 
Genomatix ChipInspector program (Genomatix Software GmbH, Munich, Germany), 
applying the Significance Analysis of Microarray (SAM) algorithm using a  
false-discovery rate of 0.1% and a minimum coverage of 3 independent probes. 
Functional annotation of transcripts was performed using the Database for 
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Annotation, Visualization, and Integrated Discovery (DAVID) (Dennis et al. 2003) and 
the Bibliosphere pathway edition (Genomatix). 
Table 4 Primer pairs and Roche library probes for real time qRT-PCR validation 
Gene F-Primer (5'-3') R-Primer (5'-3') Roche Library Probe 
AA467197 aaatggtggatcctactcaacc gttgccctccggactttt 17 
Blvrb tcctcggagttctcagcttt gcaccgtcacctcataacct 81 
C3 accttacctcggcaagtttct ttgtagagctgctggtcagg 76 
CD36 ttgaaaagtctcggacattgag tcagatccgaacacagcgta 6 
CD83 gctctcctatgcagtgtcctg ggatcgtcagggaataggc 2 
Cfb ctcgaacctgcagatccac tcaaagtcctgcggtcgt 1 
Cst7 atgtcagcaaagccctggta ggtcttcctgcatgtagttcg 67 
Cxcl10 gctgccgtcattttctgc tctcactggcccgtcatc 3 
Ddit3 ccaccacacctgaaagcag tcctcataccaggcttcca 33 
Gbp2 tgtagaccaaaagttccagacaga gataaaggcatctcgcttgg 62 
Gbp3 aagattgagctgggctacca gaaactcttgagaacctcttttgc 73 
Gclm tggagcagctgtatcagtgg caaaggcagtcaaatctggtg 18 
Gusb gtgggcattgtgctacctg atttttgtcccggcgaac 25 
Hmox1 ctgctagcctggtgcaaga ccaacaggaagctgagagtga 25 
Hp ccctgggagctgttgtca ctttgggcagctgtcatctt 15 
Hprt1 tcctcctcagaccgctttt cctggttcatcatcgctaatc 95 
Ifi44 ctgattacaaaagaagacatgacagac aggcaaaaccaaagactcca 78 
Ifitm3 aacatgcccagagaggtgtc accatcttccgatccctagac 84 
Ifitm6 ccggatcacattacctggtc catgtcgcccaccatctt 27 
IL-6 gatggatgctaccaaactggat ccaggtagctatggtactccaga 6 
iNos ctttgccacggacgagac tcattgtactctgagggctga 13 
Irf7 cttcagcactttcttccgaga tgtagtgtggtgacccttgc 25 
Kdr cagtggtactggcagctagaag acaagcatacgggcttgttt 68 
Lcn2 atgtcacctccatcctggtc cctgtgcatatttcccagagt 1 
Lpcat1 aatgtgaggcgtgtcatgg ggcagtcctcaaatgtatagtcg 81 
Marco cagagggagagcacttagcag gccccgacaattcacatt 20 
Mpeg1 cacagtgagcctgcacttaca gcgctttcccaatagcttta 69 
Nupr1-F gatggaatcctggatgaatatga gtccgacctttccgacct 64 
Rnf145 catggacttctggcttctcat aataaaaagtgttcccagaacctg 67 
Saa3 atgctcgggggaactatgat acagcctctctggcatcg 26 
Slpi gtgaatcctgttcccattcg cctgagttttgacgcacctc 69 
Srxn1 gctatgccacacagagaccata gtgggaaagctggtgtcct 33 
Trib3 gctatcgagccctgcact acatgctggtgggtaggc 98 
Quantitative real-time RT-PCR 
Amplifications of 50 ng cDNA were performed with an ABI7900HT machine  
(Applied Biosystems) in triplicates in 10 µl reaction mixtures containing 1×TaqMan 
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Universal PCR Master Mix (Applied Biosystems), 200nM of primers and 0.25 µl  
dual-labeled probe (Roche ProbeLibrary). The reaction parameters were as follows: 
2-min 50 °C hold, 30-min 60 °C hold, and 5-min 95 °C hold, followed by 45 cycles of 
20-s 94 °C melt and 1-min 60 °C anneal/extension. Measurements were performed in 
triplicate. Results were analyzed with an ABI sequence detector software version 2.3 
using the ΔΔCt method for relative quantitation. Primer sequences and Roche Library 
Probe numbers are listed in table 4. 
Statistical analysis 
Statistical analysis were performed on ΔΔCt data using analysis of variance with a 
two-sample Student's t test (P < 0.05) unless otherwise indicated. Quantitative data 
are expressed as mean ± SEM. The levels of gene expression in treated BV-2 cells 
are shown relative to control cells. 
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Results 
Effects of Luteolin on selected pro-inflammatory markers 
As a basis to study the genome-wide transcriptional effects of Luteolin on activated 
microglia and to validate our cell culture system, we initially performed a dose-
response curve for Luteolin. Four pro-inflammatory microglia markers with different 
expression levels and ranges of induction were selected as positive controls for  
qRT-PCR analyses. 
  
Figure 19 Dose-dependent suppression of LPS-induced pro-inflammatory gene expression in 
BV-2 microglia. BV-2 microglia were treated with the indicated concentrations of Luteolin for 1 h and 
then stimulated with 10 ng/ml or 50 ng/ml LPS for 24 h. Gene expression levels of (A) interleukin 6 
(Il6), (B) chemokine (C-X-C motif) ligand 10 (Cxcl10), (C) interferon-regulatory factor 7 (Irf7), and  
(D) interferon-induced gene 44 (Ifi) were analyzed with real-time qRT-PCR. Expression was 
normalized to the control gene Gusb and mRNA levels (+/- SEM) are graphed relative to mock-treated 
control cells. Results are calculated from three independent experiments performed in triplicate 
measurements. * p ≤ 0.05, ** p ≤ 0.01, and *** p ≤ 0.001 for Luteolin + LPS vs. LPS, respectively. 
Interleukin 6 (Il6) is a well known pro-inflammatory cytokine target of Luteolin  
(Jang et al. 2008), chemokine (C-X-C motif) ligand 10 (Cxcl10), interferon-regulatory 
factor 7 (Irf7), and interferon-inducible protein 44 (Ifi44) are LPS-sensitive genes in 
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microglia (Ebert et al. 2008). BV-2 microglia were pre-treated with different 
concentrations of Luteolin (0, 5, 10, 25, and 50 µM) for 1 h and then stimulated with 
LPS (10 ng/ml and 50 ng/ml) for a further 24 h period. Neither LPS nor Luteolin 
changed the proliferation rate or cell survival at the concentration levels applied to 
the cells (data not shown). mRNA levels of Il6 (Fig. 19A), Cxcl10 (Fig. 19B),  
Irf7 (Fig. 19C), and Ifi44 (Fig. 19D), which were all induced by 10 ng/ml LPS and 
further increased by 50 ng/ml LPS, were dose-dependently reduced by Luteolin  
(Fig. 19A-D). Luteolin’s effects on the four genes were most prominent at 50 µM  
(Fig. 19A-D) and therefore this concentration was used in all further experiments. 
Luteolin triggers global changes in the microglial transcriptome 
Our next goal was to capture and compare the transcriptional profile of non-activated 
and LPS-activated BV-2 microgli treated each with 50 µM Luteolin for 24 h using 
Affymetrix Mouse Genome 430 2.0 GeneChips. Twelve microarray analyses from 
three independent stimulation experiments were performed and high stringency 
criteria with a minimal signal intensity of 50 fluorescence units were used. The 
complete microarray RMA datasets and all raw data (Affymetrix CEL-files) were 
stored in the NCBI GEO repository as record GSE18740. We used the Gene 
Expression Dynamics Inspector (GEDI) to determine the global patterns of gene 
expression in the four different conditions, untreated, Luteolin-treated, LPS-treated, 
and Luteolin + LPS-treated microglia. GEDI is based on self-organizing maps to 
identify genome-wide transcriptome activity via ‘gestalt’ recognition  
(Eichler et al. 2003). GEDI is sample-oriented rather than gene-oriented, which 
facilitates the identification of genome-wide patterns. Each mosaic tile in the GEDI 
map represents a gene group or cluster that is expressed at similar levels, with blue 
color indicating a low level and red corresponding to high expression. The four GEDI 
maps clearly show a dynamic regulation of gene expression in stimulated versus 
non-stimulated microglia (Fig. 20). Especially the upper right positions in the control 
dataset and more pronounced in the LPS-treated dataset display an inverse 
regulation of the gene clusters following Luteolin stimulation (Fig. 20A, white circles).   
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Figure 20 Luteolin triggers global transcriptomic changes in non-activated and LPS-activated 
BV-2 microglia. (A) Comparative Gene Expression Dynamics Inspector (GEDI) analysis of  
DNA-microarray datasets from control BV-2 cells or cells treated with 50 µM Luteolin, 50 ng/ml LPS, or 
50 µM Luteolin + 50 ng/ml LPS. The white circle denotes the most prominent expression changes in 
several corresponding gene clusters. (B) Genomatix ChipInspector single probe analysis of 
differentially expressed transcripts in Luteolin versus control-treated cells (top) or Luteolin + LPS 
treated cells versus LPS stimulated cells. Triplicate Affymetrix Mouse 430 2.0 GeneChips were 
analyzed with a false-discovery-rate (FDR) <0.1%, 3 significant probes and log2 ratios >1. 
Differentially expressed transcrips from both comparisons were subjected to pathway analysis and 
clusters with ≥ 3 genes were defined as an independent group. Up-regulated genes are shown on the 
left side in red and down-regulated genes are displayed on the right side in blue. The total numbers of 
significantly up- or down-regulated genes from both comparions are indicated in circles placed in the 
centers of individual pie charts. All differentially expressed genes are listed in Tables 5 and 6, 
respectively.  
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These results demonstrate that stimulation with Luteolin has a major impact on the 
global pattern of gene expression notably in activated microglia and to a lower extent 
in resting cells. We have previously shown that a single probe analysis of Affymetrix 
microarrays using the Genomatix ChipInspector tool with the Significance Analysis of 
Microarray (SAM) algorithm improves detection of regulated transcripts  
(Weigelt et al. 2009). We therefore used ChipInspector to analyze our dataset 
applying a false discovery rate (FDR) of 0.1%, a minimal probe coverage of 3, and a 
minimum log2 ratio of 1 (fold change of 2.0). Thereby, 18 significantly regulated 
genes were identified in Luteolin-treated versus non-treated microglia (Table 5) and 
54 differentially expressed genes were detected in Luteolin + LPS versus  
LPS-stimulated cells (Table 6).  
Table 5 Differentially expressed transcripts after 24 h stimulation of BV-2 cells with 50 µM 
Luteolin. 
Nr ID Symbol Gene Name FC* Cov 
UP-REGULATED 
1 74315 Rnf145 Ring finger protein 145 2.87 11 
2 76650 Srxn1 Sulfiredoxin 1 homolog 2.38 5 
3 19252 Dusp1 Dual specificity phosphatase 1 2.35 10 
4 12267 C3ar1 Complement component 3a receptor 1 2.30 22 
5 12491 Cd36 CD36 antigen 2.28 10 
6 12475 Cd14 CD14 antigen 2.25 10 
7 233016 Blvrb Biliverdin reductase B 2.22 9 
8 15368 Hmox1 Heme oxygenase 1 2.17 10 
9 210992 Lpcat1 Lysophosphatidylcholine acyltransferase 1 2.13 11 
DOWN-REGULATED 
1 13198 Ddit3 DNA-damage inducible transcript 3 -5.21 11 
2 12862 Cox6a2 Cytochrome c oxidase, subunit VI a, polypeptide 2 -2.89 9 
3 228775 Trib3 Tribbles homolog 3 -2.62 22 
4 56312 Nupr1 Nuclear protein 1 -2.36 15 
5 13011 Cst7 Cystatin F -2.19 9 
6 223920 Soat2 Sterol O-acyltransferase 2 -2.16 8 
7 16149 Cd74 CD74 antigen -2.10 8 
8 17064 Cd93 CD93 antigen -2.08 11 
9 213002 Ifitm6 Interferon induced transmembrane protein 6 -2.06 8 
Significance analysis of triplicate microarrays was performed with a false discovery rate of 0.1% and a minimum probe coverage 
of 3. ID, Entrez Gene ID; FC: Fold change; Cov: probe coverage; * validated by Taqman realtime RT-PCR. 
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Table 6 Differentially expressed transcripts after 24 h stimulation with 50 µM Luteolin  
+ 50 ng/ml LPS versus 50 ng/ml LPS 
Nr ID Symbol Gene Name FC* Cov 
UP-REGULATED 
1 74315 Rnf145 Ring finger protein 145 3.27 11 
2 210992 Lpcat1 Lysophosphatidylcholine acyltransferase 1 2.55 11 
3 12522 Cd83 CD83 antigen 2.51 11 
4 14630 Gclm Glutamate-cysteine ligase , modifier subunit 2.46 10 
5 16889 Lipa Lysosomal acid lipase A 2.31 6 
6 56336 B4galt5 UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 5 2.30 8 
7 14950 H13 Histocompatibility 13 2.30 7 
8 14104 Fasn Fatty acid synthase 2.28 4 
9 12125 Bcl2l11 BCL2-like 11 2.16 14 
10 16542 Kdr Kinase insert domain protein receptor 2.16 9 
11 216345 Ccdc131 Coiled-coil domain containing 131 2.11 7 
DOWN-REGULATED 
1 66141 Ifitm3 Interferon induced transmembrane protein 3 -13.74 9 
2 433470 AA467197 Expressed sequence AA467197, miR-147 -9.32 9 
3 16819 Lcn2 Lipocalin 2 -6.87 10 
4 14469 Gbp2 Guanylate binding protein 2 -6.41 16 
5 14962 Cfb Complement factor B -5.94 8 
6 13198 Ddit3 DNA-damage inducible transcript 3 -5.58 11 
7 16181 Il1rn Interleukin 1 receptor antagonist -5.28 33 
8 55932 Gbp3 Guanylate binding protein 3 -4.72 10 
9 56312 Nupr1 Nuclear protein 1 -4.35 15 
10 75345 Slamf7 SLAM family member 7 -4.14 9 
11 20210 Saa3 Serum amyloid A 3 -3.78 7 
12 17386 Mmp13 Matrix metallopeptidase 13 -3.63 11 
13 15439 Hp Haptoglobin -3.56 11 
14 17167 Marco Macrophage receptor with collagenous structure -3.34 8 
15 12266 C3 Complement component 3 -3.29 6 
16 12870 Cp Ceruloplasmin -3.05 5 
17 13011 Cst7 Cystatin F -3.03 9 
18 23882 Gadd45g Growth arrest and DNA-damage-inducible 45 gamma -2.95 11 
19 242341 Atp6v0d2 ATPase, H+ transporting, lysosomal V0 subunit D2 -2.81 13 
20 68774 Ms4a6d Membrane-spanning 4-domains, subfamily A, member 6D -2.75 19 
21 83673 Snhg1 Small nucleolar RNA host gene 1 -2.75 24 
22 12494 Cd38 CD38 antigen -2.73 6 
23 19655 Rbmx RNA binding motif protein, X chromosome -2.73 11 
24 56405 Dusp14 Dual specificity phosphatase 14 -2.68 10 
25 213002 Ifitm6 Interferon induced transmembrane protein 6 -2.57 8 
26 12517 Cd72 CD72 antigen -2.55 9 
27 14129 Fcgr1 Fc receptor, IgG, high affinity I -2.55 11 
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Table 6 Differentially expressed transcripts after 24 h stimulation with 50 µM Luteolin  
+ 50 ng/ml LPS versus 50 ng/ml LPS 
Nr ID Symbol Gene Name FC* Cov 
DOWN-REGULATED 
28 14130 Fcgr2b Fc receptor, IgG, low affinity IIb -2.48 27 
29 231532 Arhgap24 Rho GTPase activating protein 24 -2.46 8 
30 29818 Hspb7 Heat shock protein family, member 7 (cardiovascular) -2.45 5 
31 17476 Mpeg1 Macrophage expressed gene 1 -2.43 6 
32 66222 Serpinb1a Serine peptidase inhibitor, clade B, member 1a -2.41 10 
33 78771 Mctp1 Multiple C2 domains, transmembrane 1 -2.39 8 
34 20568 Slpi Secretory leukocyte protease inhibitor -2.39 9 
35 12507 Cd5 CD5 antigen -2.35 9 
36 50778 Rgs1 Regulator of G-protein signaling 1 -2.35 11 
37 21897 Tlr1 Toll-like receptor 1 -2.20 5 
38 16149 Cd74 CD74 antigen -2.17 5 
39 73167 Arhgap8 Rho GTPase activating protein 8 -2.13 8 
40 15064 Mr1 Major histocompatibility complex, class I-related -2.06 7 
41 347722 Centg2 Centaurin, gamma 2 -2.04 11 
42 98365 Slamf9 SLAM family member 9 -2.04 8 
43 72999 Insig2 Insulin induced gene 2 -2.00 8 
Significance analysis of triplicate microarrays was performed with a false discovery rate of 0.1% and a minimum probe coverage 
of 3. ID, Entrez Gene ID; FC: Fold change; Cov: probe coverage; * validated by Taqman realtime RT-PCR. 
 
Comparison of the total number of differentially expressed genes indicated that the 
effects of Luteolin were more pronounced in LPS-activated BV-2 cells than in resting 
microglia. Also, the overall fold change range was higher in the LPS-treated microglia 
than in the resting BV-2 cells when stimulated with Luteolin. These finding correlate 
with the gene cluster patterns observed in GEDI analysis and implicate that Luteolin 
is an effective counter-player of pro-inflammatory microglial activation. 
Luteolin regulates important immune pathways and changes the microglial 
transcriptional phenotype 
Our next aim was to put the newly identified Luteolin-regulated expression patterns 
into a specific biological context. We used all differentially expressed genes to 
perform a classification into functional categories with the Database for Annotation, 
Visualization, and Integrated Discovery (DAVID). The major enriched functional 
categories in Luteolin-treated resting microglia were anti-oxidants, phagocytosis, and 
anti-inflammation for up-regulated genes and pro-inflammation and apoptosis for 
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down-regulated genes (Fig. 20B, upper part). These pathways indicate that Luteolin 
stimulated anti-oxidant and anti-inflammatory transcriptional programs which could 
potentially reflect M2 macrophage polarization. Moreover, basal pro-inflammatory 
and pro-apoptotic gene expression was blocked in non-activated BV-2 microglia.  
In Luteolin + LPS co-treated versus LPS-treated cells, 11 induced transcripts 
represented pathways of lipid metabolism, antigen presentation, and anti-oxidants 
(Fig. 20B, bottom left). Interestingly, a large number of down-regulated genes 
covered the pathway categories pro-inflammation, toll-like receptor (TLR) signaling, 
acute phase response, apoptosis, and complement factors (Fig. 20B, bottom right). 
These results implicate that Luteolin-induced transcriptomic changes promote a 
stable anti-inflammatory, anti-oxidant, and anti-apoptotic microglial phenotype 
reminescent of M2 macrophages. Our microarray data also identified a significant 
number of genes that could not be grouped into larger immune-related pathways and 
that have not been previously connected to microglial activation or flavonoid 
stimulation (Tables 5 and 6). 
Microarray validation by qRT-PCR confirms novel Luteolin-regulated target genes 
To validate a significant portion of the DNA microarray results, real-time qRT-PCR 
analyses were carried out with RNA samples from three independent BV-2 replicate 
experiments. We focused on representative candidates from different biological 
pathways which have not been previously described as flavonoid targets. 22 genes 
fulfilled these criteria and were analyzed with qRT-PCR. In the first set of 
experiments, mRNA levels of genes up-regulated by Luteolin treatment were 
assessed (Fig. 21). Transcripts of Sulfirexodin 1 (Srxn1), Biliverdin reductase B 
(Blvrb), Heme oxigenase 1 (Hmox1), and Glutamate-cysteine ligase (Gclm) are 
components of the cellular anti-oxidant response (Wegiel et al. 2009; Doi et al. 2009; 
Bea et al. 2003) and were all induced by Luteolin treatment (Fig. 21A-D). We could 
further validate increased levels of Lysophosphatidylcholine acyltransferase (Lpcat1), 
Ring finger protein 145 (Rnf145), Cd36 antigen, Kinase insert domain receptor (Kdr, 
alias Vegfr2), and Cd83 antigen. Lpcat1 catalyzes the inactivation of inflammatory 
lipids (Cheng et al. 2009), whereas Cd36 and Kdr are surface receptors required for 
phagocytic uptake and chemotactic migration, respectively (Koenigsknecht & 
Landreth 2004; Ryu et al. 2009). The function of Rnf145 is currently unknown. 
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Figure 21 Luteolin induces anti-oxidant, anti-inflammtory, and survival pathways. Real-time 
qRT-PCR validation of transcripts in BV-2 microglia stimulated with 50 µM Luteolin, 50 ng/ml LPS, or 
50 µM Luteolin + 50 ng/ml LPS. Relative mRNA levels were quantified for (A) Sulfiredoxin 1 (Srxn1), 
(B) Biliverdin reductase b (Blvrb), (C) Heme oxigenase 1 (Hmox1), (D) Glutamate-cysteine ligase 
modifier subunit (Gclm), (E) Lysophosphatidylcholine acyltransferase 1 (Lpcat1), (F) Ring finger 
protein 145 (Rnf145), (G) Cd36 antigen (Cd36), (H) Kinase insert domain protein receptor (Kdr), and 
(I) Cd83 antigen (Cd83). Expression was normalized to the control gene Gusb and mRNA levels  
(+/- SEM) are graphed relative to mock-treated control cells. Results are calculated from three 
independent experiments performed in triplicate measurements. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 
for Luteolin vs. control and Luteolin + LPS vs. LPS, respectively.  
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Figure 22 Luteolin inhibits pro-inflammatory and stress-related pathways. Real-time qRT-PCR 
validation of transcripts in BV-2 microglia stimulated with 50 µM Luteolin, 50 ng/ml LPS, or 50 µM 
Luteolin + 50 ng/ml LPS. Relative mRNA levels were quantified for (A) Complement component 3 
(C3), (B) Complement factor B (Cfb), (C) Serine leukocyte peptidase inhibitor (Spli), (D) Guanylate 
binding protein 2 (Gnbp2), (E) Guanylate binding protein 3 (Gnbp3), (F) micro RNA 147 (miR-147),  
(G) Haptoglobin (Hp), (H) Nuclear protein 1 (Nupr1), and (I) Cystatin F (Cst7). Expression was 
normalized to the control gene Gusb and mRNA levels (+/- SEM) are graphed relative to mock-treated 
control cells. Results are calculated from three independent experiments performed in triplicate 
measurements. * p ≤ 0.05, ** p ≤ 0.01 for Luteolin vs. control and Luteolin + LPS vs. LPS, respectively.  
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In the next set of qRT-PCR experiments, down-regulated transcripts involved in pro-
inflammatory activation and acute phase response were analyzed. Complement 
factor C3 (C3), Complement factor b (Cfb), Secretory leukocyte protease inhibitor 
(Slpi), and the pro-inflammatory Guanylate binding proteins 2 (Gbp2) and Gbp3 
(Shenoy et al. 2007) showed diminished mRNA levels in Luteolin-treated samples 
(Fig. 22A-D). The same tendency was seen in the newly identified microRNA  
miR-147, which is involved in toll-like receptor signaling (Liu et al. 2009), the acute 
phase gene Haptoglobin (Hp), the stress-related gene Nuclear protein 1  
(Nupr1, alias p8) (Plant et al. 2006), and Cystatin 7 (Cst7) (Fig. 22F-I). 
 
Figure 23 Luteolin inhibits apoptosis-related pathways and reduces de-ramification genes. 
Real-time qRT-PCR validation of transcripts in BV-2 microglia stimulated with 50 µM Luteolin,  
50 ng/ml LPS, or 50 µM Luteolin + 50 ng/ml LPS. Relative mRNA levels were quantified for (A) DNA-
damage inducible transcript 3 (Ddit3), (B) Tribbles homolog 3 (Trib3), (C) Macrophage receptor with 
collagenous structure (Marco), and (D) lipocalin 2 (Lcn2). Expression was normalized to the control 
gene Gusb and mRNA levels (+/- SEM) are graphed relative to mock-treated control cells. Results are 
calculated from three independent experiments performed in triplicate measurements. * p ≤ 0.05 for 
Luteolin vs. control and Luteolin + LPS vs. LPS, respectively. 
 
Results 
 
91 
As third group of genes validated by qRT-PCR, four Luteolin-repressed genes related 
to apoptosis and microglial shape formation were studied (Fig. 23A-D). The apoptotic 
mediators DNA-damage inducible transcript 3 (Ddit3, alias Chop, Gadd153) and 
Tribbles homolog 3 (Gotoh et al. 2002; Shang et al. 2009) were down-regulated by 
Luteolin in non-activated as well as LPS-activated microglia (Fig. 23A, B), indicating 
anti-apoptotic protection mechanisms elicited by Luteolin. In line with these findings, 
we also observed reduced expression of the Macrophage receptor with collagenous 
structure (Marco) and Lipocalin 2 (Lcn2), two molecules with dual roles in apoptosis 
and de-ramification of activated microglia (S. Lee et al. 2007; Granucci et al. 2003). 
Luteolin changes microglial morphology and inhibits NO secretion 
To assess whether the particular gene expression profiles measured in Luteolin-
stimulated microglia translate into detectable functional properties, phenotypic 
characterization was performed. The general activation state and morphological 
phenotype of microglia is particularly reflected by their cell shape and cytoskeletal 
organization. To detected morphological changes and for visualization of filopodia we 
performed phalloidin staining. Conventional BV-2 microglia cultures were low level 
activated cells with a flat shape and some filopodia (Fig. 24A). Culture of BV-2 cells 
in the presence of Luteolin lead to considerable ramification and formation of long 
protrusions (Fig. 24B), indicating induction of a surveillance state. LPS-activation of 
BV-2 cells caused formation of a round cell shape with retracted filopodia (Fig. 24C). 
In contrast, co-incubation of LPS-treated cells with Luteolin sustained the ramified 
microglial morphology (Fig. 24D). A similar effect was seen in primary mouse 
microglia, where Luteolin increased the length of filopodia in non-activated cells  
(Fig. 24E, F) and caused flattening and ramification of LPS-treated cells (Fig. 24G, 
H). To test the direct effect of Luteolin on microglial secretion of toxic metabolites, NO 
levels were determined in the supernatant of BV-2 cells. Treatment of BV-2 cells with 
Luteolin alone did not result in increased NO concentrations (Fig. 24I), whereas 
stimulation with LPS markedly increased secreted NO levels. Co-incubation of  
LPS-activated cells with Luteolin nearly completely abolished NO secretion (Fig. 24I).   
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Figure 24 Luteolin promotes ramification of microglia and inhibits NO-synthesis. Effects of 
Luteolin, LPS and Luteolin + LPS on BV-2 (A-D) and primary brain microglia (E-H) cell morphology 
and actin cytoskeleton. Phallodin-TRITC-staining of F-actin bundles and DAPI co-staining reveals that 
24 h treatment with 50 µM Luteolin in non-activated (B, F) or LPS-activated microglia (D, H) supports 
ramification. (I) NO release from BV-2 cells treated for 24 h with 50 µM Luteolin, 50 ng/ml LPS, or LPS 
+ Luteolin. The micrographs and data shown are from one representative experiment out of three 
independent experiments with the same tendencies. Scale bar, 50 µM. (J) Real-time qRT-PCR 
analysis of iNos transcripts in BV-2 microglia stimulated with 50 µM Luteolin, 50 ng/ml LPS, or 50 µM 
Luteolin + 50 ng/ml LPS. Expression was normalized to the control gene Gusb and mRNA levels  
(+/- SEM) are graphed relative to mock-treated control cells. Results are calculated from two 
independent experiments performed in triplicate measurements. *** p ≤ 0.001, ** p ≤ 0.01 for LPS vs. 
control and Luteolin + LPS vs. LPS, respectively. 
These data indicate that Luteolin favors the ramified surveillance state of microglia 
and effectively inhibits cytotoxic NO formation. Kim et al. previously reported that 
Luteolin triggered a blockade of NO secretion in LPS-stimulated BV-2 microglia, 
which was mediated by inhibition of inducible NO synthase (iNos) protein expression 
(J. Kim et al. 2006). To independently verify these data by qRT-PCR, we analyzed 
iNos mRNA levels in BV-2 cells treated with Luteolin, LPS, or both simultaneously. 
LPS caused a more than 40-fold increase in iNos transcripts and Luteolin  
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co-treatment significantly reduced iNos levels more than 2-fold. Thus, our expression 
data corroborate the findings by Kim et al. and provide a reasonable explanation for 
reduced NO secretion levels (J. Kim et al. 2006). 
To test the hypothesis that Luteolin leads to decreased microglial neurotoxicity, a 
culture system of 661W photoreceptor cells with conditioned medium (CM) from BV-2 
cells or primary microglia was established. 661W, a retina-derived cell line  
(al-Ubaidi et al. 1992), represents a valuable model to study microglial neurotoxicity 
in the special context of retinal degeneration (Ebert et al. 2008).  
 
Figure 25 Luteolin inhibits microglial neurotoxicity on photoreceptors. Phase contrast 
micrographs showing morphological changes of 661W photoreceptor cultures treated with conditioned 
media from BV-2 cells (A-D) or primary brain microglia (E-H). The supernatant from control-stimulated 
(A, E), 50 µM Luteolin-treated (B, F), 50 ng/ml LPS-treated (C, G), or 50 µM Luteolin + 50 ng/ml LPS-
treated cells (D, H) was added to 661W photoreceptor cells, respectively. The micrographs shown are 
from one representative experiment out of three independent experiments with the same tendencies. 
Scale bar, 50 µM. (I) Apoptosis-related caspase 3/7 activation in 661W photoreceptor cells incubated 
with conditioned media from control-stimulated, 50 µM Luteolin-treated, 50 ng/ml LPS-treated, or  
50 µM Luteolin + 50 ng/ml LPS-treated BV-2 cells. Results are calculated from two independent 
experiments performed in triplicate measurements. ** p ≤ 0.01, * p ≤ 0.05 for LPS vs. control and 
Luteolin + LPS vs. LPS, respectively. 
661W cells were incubated for 24 h with culture supernatants from unstimulated, 
Luteolin-, LPS- or LPS + Luteolin-treated cells and 661W photoreceptor cell 
morphology was assessed by phase contrast microscopy. 661W cells in their own 
medium grew confluent after 24 h and the presence of CM from control- or Luteolin-
treated BV-2 cells did not affect cell morphology (Fig. 25A, B). As described 
previously (Tan et al. 2004), confluent 661W cells flattened out and often multiple 
cells were connected to each other through their projected extensions (Fig. 25A, B). 
In contrast, 661W cells co-incubated with LPS-stimulated BV-2 supernatant appeared 
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elongated and smaller, leading to prominent cell-free areas present in the culture 
(Fig. 25C). When adding CM from LPS + Luteolin-stimulated BV-2 cells, nearly 
normal cell characteristics were retained (Fig. 25D). Similar morphological changes 
of 661W cells were observed when cultured in the presence of primary microglia CM 
(Fig. 25E-H). Direct incubation of photoreceptor cells with LPS, Luteolin, or both had 
no effects on cell morphology (data not shown), indicating that the observed changes 
in 661W cell growth arise from secreted microglial compounds.  
To correlate the microscopic findings with functional data, we next studied the 
influence of microglia-secreted products on caspase-related apoptotic signaling in the 
neuronal cell model. 661W cells cultured in the presence of CM from LPS-stimulated 
BV-2 cells displayed a strong induction of caspase 3/7 activity (Fig. 25I). When CM 
from microglia co-treated with LPS + Luteolin was used, 661W apoptosis was still 
present but was significantly diminished (Fig. 25I). Culture media from BV-2 cells 
kept in the presence of Luteolin alone had no effect on 661W apoptosis. These 
findings implicate that Luteolin either stimulates microglia to produce less  
pro-apoptotic substances or actively promotes the release of survival signals. 
  
Results 
 
95 
Discussion  
Like other plant-derived flavonoids, Luteolin has a variety of biological activi- 
ties including well-known anti-mutagenic and anti-tumorigenic properties  
(Ross & Kasum 2002). Moreover, this flavone possesses direct anti-oxidant activity, 
which is attributed to structural features of all flavonoids, which favor scavenging of 
reactive oxygen and nitrogen species (Rice-Evans et al. 1996). Although the anti-
oxidant and anti-inflammatory activities of Luteolin may be also useful in the 
treatment of many chronic inflammatory diseases including neurodegeneration, only 
little information is available about Luteolin-mediated transcriptional mechanisms or 
molecular targets in microglia (Seelinger et al. 2008). 
We have therefore performed the first genome-wide study of Luteolin-mediated 
transcriptional effects in microglia. To our surprise, Luteolin treatment did not only 
change expression levels of a few transcripts but had a broad and strong impact on 
the transcriptome of resting and particularly of LPS-activated microglia. The 
microarray dataset and the qRT-PCR validations revealed several Luteolin-regulated 
pathways. Luteolin caused simultaneous up-regulation of four important anti-oxidant 
enzymes Srxn1, Blvrb, Gclm, and Hmox1. These data are consistent with earlier 
findings demonstrating increased Hmox1 transcription in RAW264.7 macrophages 
after Luteolin treatment (Li et al. 2000). Stimulation with the flavonoid induced binding 
of the transcription factor NF-E2-related factor 2 (Nrf2) to anti-oxidant response 
elements (ARE) in the Hmox1 promoter region (Li et al. 2000). Luteolin is a potent 
activator of Nrf2 (Lim et al. 2007) and the majority of anti-oxidant enzymes contain 
ARE in their regulatory regions, including Srxn1 (Singh et al. 2009). Moreover, mouse 
embryonic fibroblasts derived from Nrf2−/− mice showed significantly lower Blvrb and 
Gclm mRNA levels upon Diquat induction (Osburn et al. 2006). Therefore, we 
speculate that increased microglial expression of Srxn1, Blvrb, and Gclm is also 
mediated by activation of Nrf2. This hypothesis is further corroborated by the 
protective functions of Nrf2 in several microglia-related neurodegenerative disorders 
(de Vries et al. 2008).  
Luteolin significantly enhanced mRNA synthesis of five other genes involved in 
different biological pathways. Lpcat1 is a lysophospholipid acyltransferase implicated 
in anti-inflammatory responses by converting lyso-platelet activation factor (lyso-PAF) 
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to PAF and lyso-phosphatidylcholine (lyso-PC) to PC (Harayama et al. 2008). LPC 
exerts considerable neuroinflammatory reactivity in the brain and inhibition of LPC 
signaling in astrocytes and microglia confers neuroprotection (Harayama et al. 2008). 
Lpcat1 is also highly expressed in the retina (Cheng et al. 2009), indicating that 
Luteolin-induced Lpcat1 levels could lead to diminished LPC levels in retinal 
microglia. Rnf145 was also up-regulated by Luteolin but the function of this protein 
remains to be determined. Cd36 and Kdr (alias Vegfr2) were also significantly 
induced by Luteolin in non-activated as well as activated microglia. The pattern 
recognition receptor Cd36 signals to the actin cytoskeleton and regulates microglial 
migration and phagocytosis (Stuart et al. 2007), whereas Kdr is involved in the 
chemotactic response of microglia (Ryu et al. 2009). We thus speculate that Luteolin-
mediated expression of both genes could result in increased phagocytic responses of 
microglia without inducing inflammation. 
Several reports have demonstrated that Luteolin inhibits pro-inflammatory cytokine 
expression in various cell types by blocking NFkB (reviewed in López-Lázaro 2009). 
Our microarray data confirmed these findings and revealed further NFkB target 
genes including the recently discovered microRNA miR-147 (Liu et al. 2009). 
Recently, Jang et al. showed that Luteolin reduced Il6 production mainly by inhibiting 
JNK signaling and AP1 activation (Jang et al. 2008). Luteolin did not affect IkB-α 
degradation or NFkB DNA binding in brain microglia, implicating that Luteolin-
mediated effects in microglia are not solely dependent on NFkB blockade  
(Jang et al. 2008). In line with this notion, our Luteolin-regulated expression profiles 
identified several genes with NFkB-independent promoter control. Likewise, Luteolin 
down-regulated complement factor 3, which is regulated by AP1 (Martin et al. 2007) 
and blocked expression of Slpi, which is a target of interferon regulatory factor 1 
(IRF1) (Nguyen et al. 1999). Luteolin also diminished mRNA levels of the  
pro-inflammatory GTPase Gbp2 and the acute phase protein Haptoglobin, which are 
both regulated by signal transducers and activators of transcription (STATs) 
(Ramsauer et al. 2007; Zauberman et al. 2001). These data clearly show that 
Luteolin dampens microglia activation by interfering with several divergent signaling 
pathways. 
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The Luteolin-regulated differential expression patterns also revealed genes involved 
in microglial apoptosis and ramification. Microglia are more susceptible than 
macrophages to apoptosis (White et al. 1998) and recent evidence indicates that 
microglial apoptosis and senescence may precede neurodegeneration  
(Streit et al. 2009). Ddit 3 and Trib3, which were both induced by LPS and 
suppressed by Luteolin, support stress and NO-mediated apoptosis  
(Gotoh et al. 2002; Shang et al. 2009). We therefore hypothesize that Luteolin could 
promote the survival of activated and stressed microglia in an environment of early 
neurodegeneration. Our expression data also revealed the unexpected finding that 
Luteolin down-regulated Lcn2 and Marco, two molecules involved in microglial 
ramification and formation of filopodia. Lee et al. demonstrated that stable expression 
of Lcn in BV-2 microglia, the same cell line we used in our experiments, induced a 
round cell shape with a loss of processes (S. Lee et al. 2007). In line with this, over-
expression of the scavenger receptor Marco in dendritic cells caused rounding of 
cells and down-regulated antigen uptake (Granucci et al. 2003). Thus, we 
hypothesized that the observed changes in mRNA levels of both genes might also 
translate into different morphological characters.  
The morphological and functional assays fully supported the implications from gene 
expression profiles and revealed a direct effect of Luteolin on the microglial 
phenotype. Luteolin stimulated the formation of filopodia and caused ramification of 
BV-2 cells and primary microglia even in the setting of strong LPS activation. 
Moreover, NO secretion was completely blocked in LPS-activated microglia upon co-
incubation with Luteolin. We studied the effects of conditioned media from microglia 
on cultured photoreceptor-like 661W cells and demonstrated that Luteolin-treatment 
effectively protected 661W cells from LPS-induced microglial toxicity. Since NO and 
other reactive oxygen species are the major radicals secreted from microglia, we 
speculate that Luteolin directly inhibits the secretion of these cytotoxic radicals. Our 
hypothesis is corroborated by recent data demonstrating that Luteolin concentration-
dependently attenuated LPS-induced dopaminergic neuron loss by blocking NO 
secretion from cultured rat microglia (H.-Q. Chen et al. 2008). 
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Conclusions  
We have shown that the flavonoid Luteolin is a potent modulator of microglial 
activation, cell shape, and effector functions. Luteolin induced global changes in the 
transcriptome of resting or LPS-activated microglia leading to a polarized M2-like 
phenotype with anti-inflammatory and neuroprotective characteristics. Luteolin’s 
mechanisms of action appear to target several independent pathways independent of 
NFkB. Our results provide a basis to develop immuno-modulatory and neuropro-
tective therapies for the treatment of neurodegenerative disorders. 
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3 Discussion 
Microgliosis is a common response to injury and accompanies various pathological 
conditions of the CNS. Therefore, microglial cells represent a broad target for therapy 
options. Modulation of microglia towards a neuroprotective phenotype represents a 
promising approach, yet the interpretation of the altered phenotype and the benefits 
of such a cellular therapy are difficult to evaluate. As one aspect of the complexity of 
microglial biology, there is still little knowledge about microglial subpopulations. The 
results shown and discussed in this work, describe the application of novel 
experimental strategies with the aim to characterize microglial subpopulations 
occuring in retinal degeneration. This concept includes the identification of selective 
marker genes and the elucidation of the phenotypic functional diversity of microglial 
populations to develop and interpret therapeutic strategies. 
3.1 The concept of microglial subpopulations 
The phenotypic diversity of microglia is a local specific response to a multitude of 
microenvironmental conditions. Several reports observed profound and persistent 
retinal microgliosis under dystrophic conditions, suggesting a predominant 
participation of classically (M1) activated microglia. However, identification of  
M2-marker transcripts during acute neuronal injury and retinal degeneration, 
indicates the co-existence of regulatory, alternatively (M2) activated microglia even in 
severe phases of neuroinflammation (Gehrig et al. 2007; Eter et al. 2008). The local 
distribution of alternatively and classically activated microglia in the degenerating 
tissue, seems to be a critical determinant of tissue integrity. Alternatively activated 
microglial cells exhibit functions mainly beneficial for neuronal tissue regeneration 
(Kigerl et al. 2009). However, neuroprotective features have also been described for 
moderately M1-activated microglia (Li et al. 2007), which reflects the situation during 
onset of retinal degeneration. Ongoing retinal degeneration is accompanied by 
consecutive release of pro-inflammatory triggers from apoptotic cells, leading to a 
stepwise increment of classically activated microglial cells. In cell culture 
experiments, time-delayed challenge of microglia with different pro-inflammatory 
stimuli, induces stronger activation than co-application of stimuli simultaneously 
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(Hausler et al. 2002). This suggests a stepwise ‘priming’ of alternatively activated 
microglia during early phases of degeneration, which could explain the rapid switch 
to an overwhelming presence of classicaly activated microglia at later stages. 
Activated microglia can actively induce apoptosis in photoreceptors, which further 
exacerbates retinal degeneration (Roque et al. 1999). Therefore, microglia may 
reside in a chronically overactivated state during the resolution phase and may 
overwhelm the regulatory capacity of the alternatively activated microglia fraction  
(Langmann 2007). While signaling pathways leading to the final commitment of 
chronic neurotoxic activation are still poorly understood, therapeutic prevention or 
rescue from this stage could possibly inhibit degeneration processes. It is obvious 
that microglial activation involves multiple transient states/phenotypes, including 
naïve, ‘primed’, activated and overactivated microglia and this concept should be 
considered, when developing new therapeutic strategies.  
Apart from the above described microglial subpopulations, an age-related microglial 
type was recently described. Senescent microglia from old healthy mice, exhibit 
shorter, less branched processes and slower process motility. In addition, senescent 
microglia had a slower migratory potential towards an injury spot and impaired 
disaggregation in the resolution phase (Damani et al. 2011). These results are in line 
with earlier observations in brain tissue from AD patients, indicating a significant  
co-localization of senescent microglia with degenerating neuronal structures  
(Streit et al. 2009). In contrast to chronically activated microglia, less toxic senescent 
microglia may sustain a permanent low-grade inflammation which is relevant in the 
pathogenesis of age-related disorders like AMD. The impact of prolonged microglial 
dysfunction has been studied recently, describing autosomal-dominant mutations in 
the macrophage colony stimulating factor 1 receptor (CSFR1) gene as the ge- 
netic cause for hereditary diffuse leukoencephalopathy with spheroids (HDLS) 
(Rademakers et al. 2011). HDLS patients suffer from behavioral changes, dementia, 
depression and parkinsonism at ages 40-50 years and die within 6 years of onset. 
Interestingly, microglia are exclusively expressing CSFR1 in the CNS and CSFR1 
downstream signaling is crucially involved in microglial proliferation and differentiation 
(Rademakers et al. 2011). The molecular characterization for this phenotype may 
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elucidate how disruption of CSFR1 signaling leads to microglial dysfunction, which in 
this case is highly associated with a severe and sustained CNS pathology. 
3.2 Identification and characterization of microglial subpopulations 
Discrimination of heterogeneous microglial types during various pathological 
conditions requires the application of novel experimental strategies and techniques 
to allow an individual molecular characterization. Identification of specific 
neuroprotective mechanisms in alternatively activated microglia could deliver tools for 
altering pro-inflammatory microglial activation. Mouse models with microglia-specific 
reporter transgenes offered a detailed insight into the morphological transformation 
and migration of microglia in dystrophic retinas (Ebert et al. 2009). Morphological 
observations enable gross discrimination of microglial phenotypes (e.g. ramified 
versus amoeboid). However, these studies hardly allow an estimation of the relative 
M1/M2 phenotype distribution. In order to discriminate and quantify microglia subsets 
during retinal degeneration, reporter transgenes controlled by M1- and M2-specific 
markers would represent a valuable tool for refined molecular characterization of 
distinct cell populations in situ. 
Single markers adopted from macrophage classification are currently used to 
describe polarized activation phenotypes of microglia. However, it is generally 
questionable, whether single markers are sufficient to discriminate the fine tuned 
variety of microglial subsets. In contrast, genome-wide transcription profiling provides 
a comprehensive view and offers the possibility to discriminate distinct microglial cell 
types, by unique gene expression signatures. Transcriptomic profiling also allows 
identification of common activation/attenuation gene clusters as ‘fingerprints’ for 
microglial phenotypes. Data presented in this work, led to the identification of various 
novel M2-related gene clusters by genome-wide transcript analysis of cultured 
microglia. These datasets include transcriptomic profiles modulated with the plant-
derived polyphenols Curcumin and Luteolin (Dirscherl et al. 2010;  
Karlstetter et al. 2011). An earlier transcript profiling approach provided evidence of a 
regulatory network under the control of the transcription factor PU.1 in a microglial 
population, isolated from dystrophic retinas (Weigelt et al. 2007). The subsequent 
functional characterization of selected PU.1 target genes has then led to the 
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identification of novel microglial markers and activation mechanisms, which will be 
discussed later (Karlstetter et al. 2010a; Stoecker et al. 2009). In the future, cross-
comparison of many global expression datasets may help to dissect common 
mechanisms and novel specific markers of microglial activation.  
3.3 Microglial phenotype modulation as therapeutic option for retinal 
dystrophies 
Chronic microglial activation is a frequently observed phenomenon in severe stages 
of retinal dystrophies, preceded by sequential steps of activation. Bioactive 
compounds and endogenous factors, preventing or reprogramming neurotoxic over-
activation of microglia, may be a promising tool to slow down the progression of 
retinal degeneration.  
3.3.1 AMWAP, a counter-regulator of neuroinflammation  
To identify mechanisms involved in microglial activation, the novel transcript AMWAP 
was selected from our retinal microglia gene expression dataset for detailed 
functional analysis (Weigelt et al. 2007). Like other whey acidic proteins, AMWAP 
expression was activated during pro-inflammatory microglial activation and showed 
anti-microbial, protease-inhibitory and anti-inflammatory potential. This suggests that 
AMWAP may be a feed-back regulator of pro-inflammatory microglial activation. In 
our experiments, AMWAP expression induced alternative activation markers Arg1 
and Cd206 (Karlstetter et al. 2010a) (Chapter 1). Based on these findings we 
assumed, that AMWAP is a secreted factor for neuroprotective microglial modulation 
in vivo. This hypothesis is currently being tested in our lab by virus-mediated  
over-expression of AMWAP in the laser-damaged mouse retina. We assume a 
paracrine effect of secreted AMWAP on all retinal microglia, as it has been described 
for the whey acidic protein SLPI in brain injury after ischemic stroke  
(Wang et al. 2003). Thus, paracrine action would allow a broad local application of 
recombinant AMWAP protein to the diseased retina and circumvents many problems 
associated with a cell specific gene therapeutic approach. Attenuation of microglial 
activation by AMWAP in vivo would be a proof of concept that the identification of 
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further microglial factors by genome-wide expression profiling can highlight novel 
treatment concepts. 
3.3.2 Curcumin and Luteolin induce neuroprotective phenotypes in 
microglia 
Plant-derived polyphenols show pleiotropic biological activities including anti-allergic, 
anti-carcinogenic, anti-oxidant and anti-septic capacities (Maheshwari et al. 2006; 
Seelinger et al. 2008). Apart from studies investigating only single hallmarks of 
inflammation (Seelinger et al. 2008; Jagetia & Aggarwal 2007), our work described 
the modulatory effect of these substances on the global inflammatory transcriptome 
(Karlstetter et al. 2011; Dirscherl et al. 2010) (Chapter 2 & 3). In particular, Curcumin 
and Luteolin potently attenuated pro-inflammatory gene expression via multiple 
signaling pathways. In line with these findings, earlier studies indicated that Curcumin 
interacts with pro-inflammatory transcription factors and chromatin factors, which 
would explain the broad impact on gene expression (Shishodia et al. 2007;  
Reuter et al. 2011). Luteolin exhibits a related mode of action (Jang et al. 2008). 
Both, Luteolin and Curcumin induced the expression of distinct anti-inflammatory 
gene clusters. A gene cluster associated with M2-functions like phagocytic uptake, 
ramification and chemotaxis was characteristic for the Luteolin-stimulated phenotype. 
In contrast, Curcumin induced a gene set involving different anti-inflammatory genes 
and transcripts related to adhesion and migration, which led to decreased microglial 
migration capacity. Despite general neuroprotective effects, each substance had a 
unique gene expression signature. Based on these findings, Luteolin and Curcumin 
may present valuable therapeutic agents to prevent chronic microglial activation and 
slow down progression of neurodegeneration. Furthermore, the beneficial effects of 
Luteolin on ramification and chemotaxis could be relevant for the ‘rejuvenation’ of 
dysfunctional senescent microglia. For both compounds, it has to be considered 
whether they can be administered via dietary supplementation, which depends on the 
ability to cross the BBB/BRB for enrichment in the CNS/retina. There is good 
evidence that the flavonoids Naringenin and Quercetin can well penetrate into the 
brain (Youdim et al. 2004), but this still needs to be determined for Luteolin. 
Curcumin has been detected in the forebrain of mice after systemic injection,  
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which led to downregulation of pro-inflammatory markers after light-induced retinal 
degeneration (Purkayastha et al. 2009). Experiments by Mandal et al. also indicate 
that Curcumin enrichment reaches bioactive levels in the retina after dietary 
supplementation, however Curcumin accumulation has not been experimentally 
proven in the retina (Mandal et al. 2009). The fact that certain bioactive substances 
can not penetrate the brain, could be potentially circumvented by chemical 
modification or packaging. Curcumin loaded nanoparticles for instance, can enhance 
half-life of Curcumin in neuronal tissue and improve the efficacy of BBB penetration 
(Tsai et al. 2011).  
3.4 Perspectives 
Although valuable insight into microglia biology has been gained from mouse models, 
the functions of human microglia have been hardly elucidated. This is due to the fact, 
that human tissue is hard to obtain and microglia from postmortem retinas are difficult 
to isolate. It is obvious that investigations of human microglia are required to validate 
the findings from animal studies in a clinical context. Recently, the establishment of a 
protocol for generation of human microglia derived from induced pluripotent stem 
cells (iPS) has been reported (pending European patent EP2010_055731). These 
iPS-derived human microglia open a broad field of study and will help to gain 
profound data for human therapy. Primary human microglia from iPS cells are 
available in high numbers, which allows wide-range screening of pharmacological 
substances, transcriptional phenotyping and functional characterization, as described 
in this work for mouse cells. Moreover, primary microglia from patients carrying 
mutations that cause microglial dysfunction would allow particular determination of 
the functional consequences of the respective dysfunction and the development of 
individualized therapeutic strategies. Detailed knowledge about the mode of action of 
bioactive compounds on microglia (e.g. induction of phagocytosis or process 
movement) may also allow a rescue from the individual underlying ‘microgliopathy’.  
Clinical studies represent a further important step to test microglia-modulating 
substances in retinal dystrophies. At the moment, the effect of Curcumin is being 
investigated in clinical studies with general neurodegenerative disorders like AD 
(clinicaltrials.gov), but studies for retinal disorders have not been initiatied yet. In this 
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regard, the immuno-modulatory effect on microglia can be only assessed by clinical 
parameters like visual function, providing rather indirect evidence. To directly monitor 
microglial activation in human subjects, radio-labeled ligands for the mitochondrial 
protein TSPO represent a feasible tool to visualize microglial activation via positron 
emission tomography (PET). Several studies have shown that TSPO radioligands 
selectively bind to activated microglia and profound microglial activation was 
detected in disease conditions in humans (Banati 2002). Microglial activation along 
the optic nerve and the retina have been also observed by PET scan in patients 
suffering from intranuclear ophtalmoplegia, underscoring that this technique is 
adequate of visualizing microglial activation in the retina (Cagnin et al. 2007;  
Banati et al. 2000). This technology would allow the imaging of microglial activation in 
human subjects, in order to track microglial activation after application of therapeutic 
compounds.  
In conclusion, the recent association of microglial dysfunction with human disease 
and microglial activation as common phenomenon of CNS pathology, necessitates 
the clinical translation of therapeutic strategies developed in animal models to 
alleviate human degenerative diseases. 
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4 Summary 
Microglia are the sentinel cells of the retina, where they are involved in surveillance of 
tissue integrity and clearance of cellular debris. The innate immune functions of 
microglia are tightly controlled by retinal neurons via the secretion of suppressing 
factors to prevent harmful pro-inflammatory activation. Progressive retinal cell death 
is a common sink of all inherited retinal diseases, causing perturbance of the retinal 
tissue homeostasis. This leads to pro-inflammatory microglial activation, a mutual 
event of all retinal dystrophies. Sustained microglial activation is considered to 
exacerbate the progression of retinal disease. Gene therapy is a current strategy 
aiming to cure inherited retinal degenerative diseases. In contrast to this 
individualized approach, modulation of microglial activity is independent of the 
causative genetic defect and therefore provides a broad therapeutic range. Local 
application of microglia-regulating proteins or the supplementation of anti-
inflammatory plant-derived compounds could be envisioned for the treatment of 
degenerative retinal diseases. 
Transcriptional profiling of retinal microglia led to the identification of the novel whey 
acidic protein AMWAP. Based on the known properties of other myeloid-derived 
whey acidic proteins, we assumed that AMWAP could modulate microglial activity. 
Functional analyses then revealed that AMWAP has several immuno-regulatory 
effects. AMWAP effectively inhibts serine-proteases, has broad anti-microbial 
potential and dampens transcript levels of pro-inflammatory marker genes. AMWAP 
also induces expression of alternative marker genes associated with neurotrophic 
functions. The results presented in this work propose that AMWAP could be a 
potential therapeutic tool to dampen microglial activation and attenuate retinal 
degeneration. 
Compounds from plant extracts like Curcumin and Luteolin have been widely used in 
traditional chinese medicine, because they have well known anti-inflammatory and 
radical scavenging activities. As part of this work, we analyzed the modulatory effects 
of Curcumin and Luteolin on pro-inflammatory activated microglial cells by 
transcriptomic profiling. The assessment of global gene expression showed 
indications for reprogramming of the pro-inflammatory activated microglia phenotype. 
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Curcumin and Luteolin attenuated pro-inflammatory activation of microglia and 
concurrently induced the expression of neuroprotective markers with substance-
specific gene signatures. Subsequent functional analysis of microglia treated with 
both compounds in vitro revealed profound neuroprotective features. In conclusion, 
both plant-derived polyphenolic compounds may be promising tools to counter-act 
neurotoxic microglial activation in retinal disease.  
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5 Zusammenfassung 
Mikrogliazellen erfüllen wichtige Überwachungsfunktionen in der gesunden Netzhaut 
und tragen wesentlich zur Aufrechterhaltung der Gewebshomöostase bei. Mikrogliale 
Immunmechanismen werden aktiv durch die Präsentation und Sekretion 
suppressiver Faktoren von retinalen Neuronen kontrolliert, um eine überschießende 
Mikrogliaaktivierung zu verhindern. Fortschreitender Zelltod stellt einen 
gemeinsamen Endpunkt aller retinalen Degenerationskrankheiten dar, wodurch eine 
Störung der Gewebshomöostase ausgelöst wird. Die einhergehende pro-
inflammatorische Mikrogliaaktivierung gilt somit als gemeinsames Merkmal retinaler 
Dystrophien. Es wird angenommen, dass eine chronische Mikrogliaaktivierung zu 
einem schnelleren Fortschreiten von Degenerationsprozessen beiträgt. Als 
Therapiemöglichkeiten wurden bisher hauptsächlich gentherapeutische Ansätze 
erforscht, die darauf abzielen den jeweils kausalen genetischen Defekt zu beheben. 
Unabhängig von der genetischen Ursache, stellt die Modulation der Mikro-
gliaaktivierung einen breiten symptomatischen Behandlungsansatz dar. Die 
Beeinflussung entzündlicher Mikrogliazellen könnte das Fortschreiten der 
Degenerationserkrankung verlangsamen. Lokale Applikation von entzündungs-
dämpfenden Proteinen oder die orale Verabreichung von anti-entzündlichen 
sekundären Pflanzenstoffen stellen sehr vielversprechende Therapieansätze dar. 
Das neuartige whey acidic protein AMWAP wurde basierend auf Daten eines 
genomweiten Genexpressionsprofils aus aktivierten retinalen Mikrogliazellen, zur 
weiteren funktionellen Charakterisierung ausgewählt. Aufgrund der entzündungs-
hemmenden Eigenschaften von Peptiden der whey acidc protein Familie, wurde die 
Hypothese aufgestellt, dass auch AMWAP ähnliche Eigenschaften aufweist. Die in 
dieser Arbeit vorgestellten Ergebnisse der funktionellen Analyse von AMWAP haben 
gezeigt, dass AMWAP Entzündungsmechanismen auf verschiedene Weise beein-
flusst und somit die inflammatorische Mikgrogliaaktivierung abschwächt. Im Detail 
wirkte AMWAP Protease-hemmend, anti-mikrobiell und verminderte die Expression 
pro-inflammatorischer Gene. Zusätzlich erhöhte AMWAP die Produktion von Markern 
der alternativen Aktivierung, was auf eine Induktion neuroprotektiver Mechanismen 
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hindeutet. Aufgrund dieser Befunde könnte AMWAP einen Kandidaten zur 
Modulation der Mikrogliaaktivierung bei Netzhautdegeneration darstellen. 
Bioaktive sekundäre Pflanzenstoffe wie Curcumin oder Luteolin finden aufgrund ihrer 
entzündungshemmenden und anti-oxidativen Eigenschaften breite Anwendung in der 
traditionellen chinesischen Medizin. In dieser Arbeit sollte der immunregulatorische 
Einfluss der Pflanzenstoffe Curcumin und Luteolin auf aktivierte Mikrogliazellen durch 
genomweite Transkriptprofilierung untersucht werden. Die ganzheitliche Erfassung 
des Transkriptoms der modulierten Mikrogliazellen zeigte eine globale Beeinflussung 
des aktivierten Zellstatus. Behandlung der Mikrogliazellen mit Curcumin und Luteolin 
führten zur potenten Suppression der pro-inflammatorischen Aktivierung und 
zugleich zur Induktion von Genclustern mit neuroprotektiven Markern. Vergleichend 
zeigten Curcumin und Luteolin die Induktion unterschiedlicher neuroprotektiver 
Gene. Durch funktionelle Analyse wurden für beide Substanzen eindeutige 
neuroprotektive Eigenschaften in Zellkulturexperimenten mit Photorezeptorzellen 
nachgewiesen. Zusammenfassend kann gefolgert werden, dass Curcumin und 
Luteolin das Expressionsmuster aktivierter Mikrogliazellen merklich beeinflussen und 
beide Substanzen durch ein breites Wirkungsspektrum mögliche experimentelle 
Therapieansätze für retinale Degenerationserkrankungen darstellen könnten. 
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7 Appendix 
Appendix 1 
Supplementary data for chapter 1 (Karlstetter et al. 2010): 
 
Figure S1 Comparison of the mouse AMWAP open reading frame (top) and the codon optimized 
version (bottom) used for inducible expression in E. coli BL21 cells. The codon adaption index was 
increased from 0.70 before optimization to 0.91 after optimization. 
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Figure S2 (A) Comprehensive expression profile of the AMWAP-specific Affymetrix probe set 
1436530_at in various mouse tissues and cell types. Significant AMWAP transcript levels were 
specifically and exclusively detected in different macrophage populations and microglia. Data were 
obtained from the BioGPS database data (BioGPS, http://biogps.gnf.org and 
http://macrophages.com). (B) cDNA sequences of mouse AMWAP (top) and Expi (bottom) with 
underlined Affymetrix microarray probes. The probes used to detect AMWAP transcripts in isolated 
retinal microglia from wild-type and retinoschisin-deficient mice were highly specific for AMWAP and 
showed multiple gaps in the corresponding Expi cDNA sequence regions (indicated by gray shading). 
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Supplementary Table 1  
Primer sequences and Roche Probe library IDs used for real-time qRT-PCR analysis 
Gene Accession No. F-Primer (5'-3') R-Primer (5'-3') Probe ID 
AMWAP NM_001081957 TTTGATCACTGTGGGGATG ACACTTTCTGGTGAAGGCTTG 1 
CCL2 NM_011333 CATCCACGTGTTGGCTCA GATCATCTTGCTGGTGAATGAGT 61 
IL-1β NM_008361 TGTAATGAAAGACGGCACACC TCTTCTTTGGGTATTGCTTGG 78 
IL-6 NM_031168 GATGGATGCTACCAAACTGGAT CCAGGTAGCTATGGTACTCCAGA 6 
CD206 NM_008625 GGACGAGCAGGTGCAGTT CAACACATCCCGCCTTTC 47 
Arginase 1 NM_007482.3 CCTGAAGGAACTGAAAGGAAAG TTGGCAGATATGCAGGGAGT 2 
PU.1 NM_32370 GGAGAAGCTGATGGCTTGG CAGGCGAATCTTTTTCTTGC 94 
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Appendix 2 
Abbreviations: 
AcH3 Acetyl-histone H3 
AD Alzheimer's disease 
AMD Age-related macular degeneration 
AMWAP Activated Microglia/Macrophage WAP domain protein 
Ap-1 Activator protein 1 
Arg1 Arginase 1 
ATP Adenosin Triphosphate 
B. subtilis Bacillus subtilis 
BBB Blood brain barrier 
Blvrb Biliverdin reductase B 
BM Bone marrow 
BRB Blood retinal barrier 
C3 Complement component 3 
CAPE Caffeic acid phenethyl ester 
Casp Caspase 
Cbp CREB-binding protein 
Ccl2 Chemokine (C-C motif) ligand 2 
Ccl3 Chemokine (C-C motif) ligand 3 
Ccl4 Chemokine (C-C motif) ligand 4 
Ccl5 Chemokine (C-C motif) ligand 5 
Ccl6  Chemokine (C-C motif) ligand 6 
Ccl9 Chemokine (C-C motif) ligand 9 
Cd200 Cluster of differentiation 200 
Cd200r Cluster of differentiation 200 receptor 
Cd206 Cluster of differentiation 206 
Cd36 Cluster of differentiation 36 
Cd83 Cluster of differentiation 83 
Cfb Complement factor b 
ChIP Chromatin Immunoprecipitation 
Chop C/EBP homologous protein 
CHX Cycloheximide 
CM Conditioned medium 
cm2 Square centimeters 
CNS Central nervous system 
Cox2 Cyclooxygenase 2 
CpG CG-rich sequence 
cRNA Copy RNA 
Csfr1 Colony stimulating factor receptor 1 
CSPG-DS Chondroitin sulfate disaccharide 
Ct Cycle threshold 
CX3CL1 Chemokine (C-X3-C motif) ligand 1 
CX3CR1 CX3C chemokine receptor 1 
Cxcl10 C-X-C motif chemokine 10 
Cy3 Cyanine 3 
DAMP Damage associated molecular patterns 
DAPI 4',6-Diamidin-2-phenylindol 
DAVID Database for annotation, visualization and integrated genome discovery 
Ddit DNA damage-inducible transcript 
ΔΔCt Delta delta Cycle threshold 
DHA Docosahexaenoic acid 
DISC Death-inducing signaling complex 
Dll1 Delta-like protein 1 
DMEM Dulbecco's modified eagle medium 
DMSO Dimethylsulfoxide 
DNA Deoxyribonucleic acid 
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E. coli Escherichia coli 
EGFP Enhanced green fluorescent protein 
Egr2 Early growth response protein 2 
Expi Extracellular proteinase inhibitor precursor 
FAS Tumor necrosis factor receptor superfamily, member 6 
FCS Fetal calf serum 
FDR False discovery rate 
Fig Figure 
g relative centrifuge force 
Gadd153 Growth arrest and DNA damage induced-153 
Gbp2 Guanylate binding protein 2 
Gbp3 Guanylate binding protein 3 
GCL Glutamate cystein ligase 
Gclm Glutamate cystein ligase, modifier subunit 
GEDI Gene expression dynamics inspector 
GEO Gene expression omnibus 
GFP Green fluorescent protein 
h Hours 
HDLS Hereditary diffuse leukoencephalopathy with spheroids 
HMGB1 High-mobility-group-protein b1 
Hmox1 heme oxygenase-1 
Hp Haptoglobin 
Ifi44 Interferon-induced protein 44 
IFNAR Interferon-α/β receptor 
IFNβ Interferon-β 
IkBα Nuclear factor of ‚kappa light polypeptide gene enhancer’ in B-cells inhibitor, alpha 
IL-1β Interleukine-1β 
IL-4 Interleukine-4 
IL-6 Interleukine-6 
IL-10 Interleukine-10 
Inf-γ Interferon-γ 
INL Inner nuclear layer 
iNOS Inducible nitric oxide synthase 
IPL Inner plexiform layer 
iPS Induced pluripotent stem cell 
Irf7 Interferon regulatory factor 7 
Kdr Kinase insert domain receptor 
LB medium Luria broth medium 
Lcn2 Lipocalin-2 
LPC Lysophosphatidylcholine 
Lpcat Lysophosphatidylcholine Acyltransferase 
LPS Lipopolysaccharide 
Lyso-paf Lyso-platelet activation factor  
Lyso-pc Lyso-phosphatid 
Lyzs Lysozyme 
M-CSF Macrophage colony-stimulating factor 
Marco Macrophage receptor with collagenous structure 
mg Milligram 
min Minute 
miRNA MicroRNA 
ml Milliliter 
mm2 Square millimeter 
MMGT12 Murine cell line 
mRNA Messenger RNA 
MS Multiple Sclerosis 
MTT Methylthiazoletetrazolium 
MZB1 Marginal zone B and B1 cell-specific protein 
NFkB Nuclear factor 'kappa-light-chain-enhancer' of activated B-cells 
ng Nanogram 
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nm Nanometer 
NO Nitric oxide 
Nos2 Nitric oxide synthase-2 
Nrf2 NF-E2-related factor 2 
Ntng1 Netrin-G1 
Nupr1 Nuclear protein transcriptional regulator 1 
OD Optical density 
OHT Hydroxytamoxifen 
ONL Outer nuclear layer 
OPL Outer plexiform layer 
OS Outer segments 
P. aeruginosa Pseudomonas aeruginosa 
P2Y12 Purinergic receptor P2Y, G-protein coupled, 12 
PAM3CSK Tripalmitoylated lipopetide Cysteine, Serine, Lysine 4 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
Pecam1 Platelet endothelial cell adhesion molecule 1 
Perp1 Plasma cell-induced resident ER protein 
PET Positron emission tomography 
PMSF Phenylmethylsulfonylfluorid 
PPARa Peroxisome proliferator-activated receptor alpha 
PS1 Presenilin 1 
Ptgs Prostaglandin-endoperoxide synthase 2 
PU.1 Purine-rich box-1 
qRT-PCR Quantitative real-time PCR 
Rd Retinal degeneration 
Rds Retinal degeneration slow 
Rho Rhodopsin 
RLM-RACE RNA-ligase mediated rapid amplification of cDNA-ends 
RMA Robust multichip average 
RNA Ribonucleic acid 
Rnf145 Ring finger protein 145 
ROS Reactive oxgen species 
RP Retinitis pigmentosa 
RPE Retinal pigment epithelium 
Rpm Rotations per minute 
RPMI Roswell park memorial institute 
Rs1h Retinoschisin murine homolog 
SAM Significance analysis of microarrays 
SD Standard deviation 
SDS Sodium dodecyl sulfate 
siRNA Small interfering RNA 
SLPI Secretory leukocyte protease inhibitor 
SOM Self-organizing maps 
SPP1 Secreted phosphoprotein 1 
Srxn1 Sulfiredoxin 
STAP-1 Signal-transducing adaptor protein 1 
STAT Signal transducers and activators of transcription protein 
SWAM1 Single WAP motif protein 1 
TIFF Tagged image file format 
TLR Toll-like receptor 
TLR4 Toll-like receptor 4 
TLR9 Toll-like receptor 9 
TNF Tumor necrosis factor 
TNFR1 Tumor necrosis factor receptor-1 
TREM2 Triggering receptor expressed on myeloid cells 2 
TRITC Tetramethylrhodamine-5-(and 6)-isothiocyanate 
TSPO Translocator protein 
TUNEL TdT-mediated dUTP-biotin nick end labeling 
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U Unit 
µm Micrometer 
Vegfr2 Vascular Endothelial Growth Factor Receptor 2 
WAP Whey acidic protein 
wt Wild-type 
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Appendix 3 
Publications: 
Karlstetter M, Lippe E, Walczak Y, Moehle C, Aslanidis A, Mirza M, Langmann 
T.Curcumin is a potent modulator of microglial gene expression and migration. J 
Neuroinflammation. 2011 Sep 29;8:125.  
 
Kraus D, Karlstetter M, Walczak Y, Hilfinger D, Langmann T, Weber BH. Retinal 
expression of the X-linked juvenile retinoschisis (RS1) gene is controlled by an 
upstream CpG island and two opposing CRX-bound regions. Biochim Biophys 
Acta. 2011 Apr-Jun;1809(4-6):245-54.  
 
Karlstetter M, Walczak Y, Weigelt K, Ebert S, Van den Brulle J, Schwer H, 
Fuchshofer R, Langmann T. The novel activated microglia/macrophage WAP 
domain protein, AMWAP, acts as a counter-regulator of proinflammatory 
response. J Immunol. 2010 Sep 15;185(6):3379-90.  
 
Langmann T, Di Gioia SA, Rau I, Stöhr H, Maksimovic NS, Corbo JC, Renner AB, 
Zrenner E, Kumaramanickavel G, Karlstetter M, Arsenijevic Y, Weber BH, Gal 
A, Rivolta C. Nonsense mutations in FAM161A cause RP28-associated 
recessive retinitis pigmentosa. Am J Hum Genet. 2010 Sep 10;87(3):376-81.  
 
Corbo JC, Lawrence KA, Karlstetter M, Myers CA, Abdelaziz M, Dirkes W, Weigelt 
K, Seifert M, Benes V, Fritsche LG, Weber BH, Langmann T. CRX ChIP-seq 
reveals the cis-regulatory architecture of mouse photoreceptors. Genome Res. 
2010 Nov;20(11):1512-25. 
 
Karlstetter M, Ebert S, Langmann T. Microglia in the healthy and degenerating 
retina: insights from novel mouse models. Immunobiology. 2010 Sep-Oct;215(9-
10):685-91. Review. 
 
Dirscherl K, Karlstetter M, Ebert S, Kraus D, Hlawatsch J, Walczak Y, Moehle C, 
Fuchshofer R, Langmann T. Luteolin triggers global changes in the microglial 
transcriptome leading to a unique anti-inflammatory and neuroprotective 
phenotype. J Neuroinflammation. 2010 Jan 14;7:3.  
 
Stoecker K, Weigelt K, Ebert S, Karlstetter M, Walczak Y, Langmann T.Induction of 
STAP-1 promotes neurotoxic activation of microglia. Biochem Biophys Res 
Commun. 2009 Jan 30;379(1):121-6.  
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Appendix 4 
Conference contributions: 
2009 
Pro Retina Research-Colloquium 
Potsdam, Germany 
The novel activated microglia WAP domain protein, AMWAP, is induced during 
microglia activation and acts as a negative regulator of the pro-inflammatory 
response (Poster) 
 
Annual Meeting of the European Macrophage and Dendritic Cell Society (EMDS) 
Regensburg, Germany 
The novel activated microglia WAP domain protein, AMWAP, is induced during 
microglia activation and acts as a negative regulator of the pro-inflammatory 
response (Poster) 
 
2010 
Pro Retina Research-Colloquium 
Potsdam, Germany 
The novel activated microglia WAP domain protein, AMWAP, is induced during 
microglia activation and acts as a negative regulator of the pro-inflammatory 
response (Poster) 
 
XIVth International Symposium on Retinal Degeneration 
Mont Tremblant, Canada 
The novel activated microglia WAP domain protein, AMWAP, is induced during 
microglia activation and acts as a negative regulator of the pro-inflammatory 
response (Poster) 
 
Annual Meeting of the European Macrophage and Dendritic Cell Society (EMDS) 
Edinburgh, UK 
The novel activated microglia WAP domain protein, AMWAP, is induced during 
microglia activation and acts as a negative regulator of the pro-inflammatory 
response (Poster) 
 
22nd Meeting of the German Society of Human Genetics 
Regensburg, Germany 
Transcriptional Regulation and retinal knock-down of Fam161a, the mouse ortholog 
of the human RP28 gene (Poster) 
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2011 
Pro Retina Research-Colloquium 
Potsdam, Germany 
PU.1 and NFkB control Activated Macrophage/Microglia WAP domain protein 
(AMWAP) expression during microglial activation (Poster) 
 
Gordon Research Conference Mammary Gland Biology 
Newport, Rhode Island, USA 
The novel whey acidic protein AMWAP acts as a negative regulator of the pro-
inflammatory response (Poster) 
 
10th European meeting on Glial Cells in Health and Disease 
Prague, Czech Republic 
The novel Activated Microglia/Macrophage WAP Domain Protein, AMWAP, is 
induced during microglial activation and acts as a negative regulator of the 
pro-inflammatory response (Poster) 
 
Further projects associated with this thesis: 
Medical thesis Konstantin Dirscherl 
Medical thesis Elena Lippe 
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